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Abstract
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and
Allergies (NDA) was asked to revise the tolerable upper intake level (UL) for vitamin D for infants
(≤ 1 year) set in 2012. From its literature review, the Panel concluded that the available evidence on daily
vitamin D intake and the risk of adverse health outcomes (hypercalciuria, hypercalcaemia,
nephrocalcinosis and abnormal growth patterns) cannot be used alone for deriving the UL for infants. The
Panel conducted a meta-regression analysis of collected data, to derive a dose–response relationship
between daily supplemental intake of vitamin D and mean achieved serum 25(OH)D concentrations.
Considering that a serum 25(OH)D concentration of 200 nmol/L or below is unlikely to pose a risk of
adverse health outcomes in infants, the Panel estimated the percentage of infants reaching a
concentration above this value at different intakes of vitamin D. Based on the overall evidence, the
Panel kept the UL of 25 lg/day for infants aged up to 6 months and set a UL of 35 lg/day for infants
6–12 months. The Panel was also asked to advise on the safety of the consumption of infant formulae
with an increased maximum vitamin D content of 3 lg/100 kcal (Commission Delegated Regulation (EU)
2016/127 repealing Directive 2006/141/EC in 2020). For infants aged up to 4 months, the intake
assessment showed that the use of infant formulae containing vitamin D at 3 lg/100 kcal may lead some
infants to receive an intake above the UL of 25 lg/day from formulae alone without considering vitamin D
supplemental intake. For infants aged 4–12 months, the 95th percentile of vitamin D intake (high
consumers) estimated from formulae and foods fortiﬁed or not with vitamin D does not exceed the ULs,
without considering vitamin D supplemental intake.
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Summary
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and
Allergies (NDA) revised its Opinion of 2012 on the tolerable upper intake level (UL) for vitamin D,
regarding the UL set for infants, i.e. aged less than 1 year.1 The UL is the maximum level of total
chronic daily intake of a nutrient from all sources (i.e. foods, including supplements2) judged to be
unlikely to pose a risk of adverse health effects in humans.
This request arises in the context of Commission Delegated Regulation (EU) 2016/1273, which will
repeal Directive 2006/141/EC4 from 2020, and increases the maximum allowed vitamin D content from
2.5 to 3 lg/100 kcal for infant formulae (IF), i.e. to reach the same content as for follow-on formulae
(FoF). In order to ensure the highest level of protection of infants consuming formulae, the European
Commission seeks European Food Safety Authority (EFSA)’s advice on the safety of the consumption of
IF and FoF containing 3 lg/100 kcal of vitamin D by infants.
The previous EFSA Opinion of 2012 on the revision of the ULs for vitamin D set by the Scientiﬁc
Committee on Food (SCF) in 2003 concluded that there was a paucity of data on infants on which to base
a no- or a lowest observed adverse effect level (NOAEL or LOAEL). Having considered in particular
available evidence on ‘high’ vitamin D intake and the absence of retarded growth or hypercalcaemia in
infants, and as newer data from intervention studies in healthy infants had not become available since the
previous risk assessment (SCF, 2003), the Panel decided in 2012 to retain the UL of 25 lg vitamin D/day
previously derived for infants.5
Vitamin D is the generic term for ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3), which
are present in foods. Vitamin D3 is also synthesised endogenously in the skin following exposure to
ultraviolet (UV)-B irradiation. While for other age groups beyond infancy, the synthesis of vitamin D3 in
the skin during the summer months may be the main source of vitamin D and may fulﬁl the
requirement, the Panel considers that this may not be the case for infants, who therefore have greater
reliance on dietary intake. In the body, vitamin D is hydroxylated in the liver to 25-hydroxyvitamin D
(25(OH)D), which is then hydroxylated primarily in the kidneys to the biologically active metabolite
1,25-hydroxyvitamin D (1,25(OH)2D), whose concentration in blood is tightly regulated. Vitamin D, 25
(OH)D and 1,25(OH)2D are transported in the blood mainly by the vitamin D-binding protein (DBP).
The principal function of 1,25(OH)2D is to maintain calcium and phosphorus homoeostasis.
Serum 25(OH)D concentration is used as a biomarker of vitamin D intake in populations with low
exposure to UV-B irradiation and of vitamin D status. All analytical methods available for its measurement
have uncertainties, which could lead to over- or underestimation. Speciﬁcally in infants, some analytical
methods may overestimate serum concentration of 25(OH)D, due to the fact that they also detect the
C3-epimer of 25(OH)D, which may contribute up to about 40% of total 25(OH)D during the ﬁrst
3 months of life (contrary to older children and adults). However, the metabolic role of the C3-epimer is
unclear. Serum 25(OH)D concentration in infants can be inﬂuenced by vitamin D intake level, form and
frequency of consumption, baseline serum 25(OH)D concentration, sun exposure, season, body mass (or
age) and body fat and maternal characteristics during pregnancy and lactation (e.g. maternal
supplementation with vitamin D).
Vitamin D toxicity resulting from ‘long-term’ ingestion of ‘large’ doses of vitamin D is associated with
an increase in the serum concentration of 25(OH)D and some other vitamin D metabolites but usually not
of the active metabolite 1,25(OH)2D. Some hypotheses for mechanisms of toxicity have been proposed.
The presence of elevated serum-free 1,25(OH)2D concentration despite normal total 1,25(OH)2D
suggests that, in states of vitamin D toxicity, 1,25(OH)2D is displaced from DBP by 25(OH)D or other
metabolites, and that this could promote entry of free 1,25(OH)2D into target cells where it could
stimulate gene transcription.
1 The deﬁnition of vitamin D supplementation policies for infants or of public health actions in favour of breastfeeding is outside
the scope of this opinion.
2 Prophylactic administration of vitamin D in some countries may be considered as medication.
3 Commission Delegated Regulation (EU) 2016/127 of 25 September 2015 supplementing Regulation (EU) No 609/2013 of the
European Parliament and of the Council as regards the speciﬁc compositional and information requirements for infant formula
and follow-on formula and as regards requirements on information relating to infant and young child feeding, OJ L 25,
2.2.2016, p. 1.
4 Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending Directive
1999/21/EC, OJ L 401, 30.12.2006, p. 1.
5 ULs set in the previous EFSA Opinion of 2012 for other population groups were outside the scope of this opinion, thus remain
unchanged, i.e. 50 µg/day for children aged 1–10 years, and 100 µg/day for children aged 11–17 years and all adults.
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Based on this proposed mechanism of toxicity and in line with previous assessments by EFSA and
other bodies, the Panel focussed on the following four adverse health outcomes: hypercalciuria,
hypercalcaemia, ectopic calciﬁcation, e.g. nephrocalcinosis, and abnormal growth patterns.
The Panel collected data on serum 25(OH)D concentration in relation to vitamin D intake or adverse
health outcomes, recognising that a ‘high’ concentration is not an adverse health outcome per se, but
can be considered as a surrogate endpoint.
The Panel deﬁned upfront the strategy and methodology to evaluate possible relationships between
daily intake of vitamin D, i.e. D2 or D3 from all dietary sources including fortiﬁed foods and
supplements, and adverse health outcomes or endpoints in infants. In June 2017, the Panel undertook
a systematic literature search of trials and observational studies on full-term healthy infants, either
breastfed or fed with a standard IF or FoF, possibly receiving complementary foods, and appraised the
risk of bias (RoB) of the studies.
The Panel discussed the available evidence from trials and observational studies on the four adverse
health outcomes (hypercalciuria, hypercalcaemia, nephrocalcinosis and abnormal growth patterns).
Although more data in infants are available since 2012, the Panel concludes that these data on daily
vitamin D intake and adverse health outcomes cannot be used alone for deriving the UL of vitamin D for
infants. This is because of methodological limitations of the studies, including the use of unclear
reference values for serum or urinary calcium in infants, and of single measurements that may not
provide an indication of the risk of sustained elevated concentrations. Moreover, the studies showed
inconsistent results, or the absence of a dose–response relationship between vitamin D intake (or serum
25(OH)D concentration) and adverse health outcomes. The Panel notes the absence of data on the
systematic administration of deﬁned vitamin D doses above 50 lg/day to healthy infants for ethical
reasons.
The level of daily vitamin D intake or serum 25(OH)D concentration that is associated with the
occurrence of adverse health outcomes could not be determined on the basis of the available data and
the Panel could not deﬁne a NOAEL for vitamin D intake. However, having considered previous
assessments of EFSA and of other bodies that discussed ‘high’ serum 25(OH)D concentration (not
speciﬁcally for infants), as well as available data collected through the dedicated literature search on
infants, the Panel concludes that a serum 25(OH)D concentration of 200 nmol/L or below is unlikely to
pose a risk of adverse health outcomes in healthy infants. This should not be regarded as a cut-off for
toxicity but as a conservative value from which a UL could be derived.
Case reports described adverse health outcomes in infants associated with chronic daily
administration of vitamin D doses of about 4.5–20 times the adequate intake (AI) of 10 lg/day set by
EFSA in 2016 for this age group; these outcomes were associated with elevated serum 25(OH)D
concentrations. However, as these reports are based on incidental ﬁndings, they are not suitable to
deﬁne a LOAEL for vitamin D in infants.
The Panel conducted a meta-regression analysis of collected data to derive a dose–response
relationship between daily supplemental intake of vitamin D and mean achieved serum 25(OH)D
concentrations from data collected per arm of the trials selected through the literature search,
adjusted for baseline serum 25(OH)D concentrations, age and duration of supplementation. This
analysis was based on aggregated data from six trials with limited RoB, corresponding to 17 arms and
58 time points, which used vitamin D from supplements and generally did not assess the intake of
vitamin D from the diet. From this model, an empirical distribution of mean achieved serum 25(OH)D
concentrations was generated from a large number of simulations. From this, a distribution of serum
25(OH)D concentrations that may be achieved by individuals was then simulated, and the percentage
of infants reaching a concentration above 200 nmol/L was estimated for different vitamin D intakes.
For infants aged up to 6 months, the Panel concludes that the available body of evidence supports
keeping the previous UL of 25 lg/day. The Panel notes that predictions from the model support this
conclusion. These predictions also show that, at a given intake of vitamin D, infants older than
6 months achieve lower serum 25(OH)D concentration than infants younger than 6 months, which
may be explained by the increase in body mass. Thus, for infants aged 6 to less than 12 months, the
Panel considers that evidence from the predictions supports a UL of 35 lg/day.
The Panel draws its conclusions on the UL for vitamin D from data mainly on vitamin D3, as the
dose–response analysis to predict the percentage of individuals that would have serum 25(OH)D
concentrations above 200 nmol/L included studies that used supplementation with vitamin D3.
However, the updated UL of 25 and 35 lg/day applies both to vitamin D2 and D3.
In order to characterise the risk of infants having an intake above the UL for vitamin D, the
Panel assessed the daily vitamin D intake in Europe, considering in particular the consumption of IF
UL of vitamin D for infants
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and FoF containing 3 lg/100 kcal of vitamin D. The intake assessment was conducted separately for
infants aged up to 4 months, and for those aged 4 to less than 12 months, to account for the
additional vitamin D intake in relation to the introduction of complementary feeding.6
The Panel notes that there are different national supplementation policies for vitamin D in infants in
the European Union (EU) and compliance with these policies may vary between countries. In addition,
limited information was available to the Panel from surveys on infants in Europe on the percentage of
consumers of vitamin D-containing supplements without information on their vitamin D content.
Furthermore, limited information was available on possible disparities between the labelled and the
actual vitamin D content of a product (fortiﬁed foods or supplements). Thus, the Panel did not make any
assumption regarding such disparities or regarding vitamin D supplementation in its intake assessment.
With the objective of comparing the outcome of the intake assessment undertaken by EFSA with
other available data, data were collected either from published studies or reports from national
authorities or through a consultation of Member States undertaken by the European Commission.
For infants aged up to 4 months, according to calculations based on the maximal regulated vitamin
D content in IF and the default ‘high’ IF consumptions set by the EFSA Scientiﬁc Committee in 2017,
the Panel concludes that, depending on the reference body weight, age of the infants and energy
content of IF (without considering additional intake due to supplementation or possible disparities
between the labelled and the actual composition of IF):
 the use of a maximum vitamin D content of 3 lg/100 kcal in IF (as per Delegated Regulation
(EU) 2016/127) may lead some infants to consume amounts of vitamin D above the UL of
25 lg/day from formulae alone. The precise percentage of such infants could not be
determined from the available data.
 the use of a maximum vitamin D content of 2.5 lg/100 kcal in IF (as per Directive 2006/141/EC)
does not result in intakes of vitamin D above the UL of 25 lg/day from formulae alone. The
margin between the calculated intakes via formulae and the UL varies between 1 and 9 lg/day.
For infants aged from 4 to 12 months, the intake assessment was conducted separately for
consumers and non-consumers of IF and FoF. The intake assessment was done:
 using individual data available to EFSA in 2017 of food consumption of infants from six
surveys, conducted between 2001 and 2011 and most of them nationally representative of
their respective EU countries;
 and considering eight intake scenarios, based on the minimum or maximum amount of
vitamin D in IF and FoF according to the two regulatory texts (Directive 2006/141/EC and
Commission Delegated Regulation (EU) 2016/127) and based on the composition of foods
fortiﬁed or not with vitamin D (without considering possible disparities between the labelled
and the actual composition of foods), coming from the EFSA Nutrient Composition Database,
and from the Mintel Global New Products Database.
These eight scenarios were assumed to describe situations that may occur on the EU market taking
into account voluntarily fortiﬁed foods, different possible food patterns in infants but excluding the
contribution from supplements and considering the two extremes in the range of the vitamin D content
in mandatorily fortiﬁed foods. They were not meant to reﬂect the fortiﬁcation practices of the six EU
countries that provided food consumption data. Means and 95th percentiles (P95) of estimated vitamin
D intake were used to characterise the risk of exceeding the UL (without considering additional intake
due to supplementation) for infants aged from 4 to 12 months:
 For infants consuming neither formulae nor fortiﬁed foods and for those not consuming
formulae but consuming fortiﬁed foods, the estimated means and P95 of vitamin D intake are
below or at the AI of 10 lg/day.
 For infants consuming IF or FoF containing the maximum amount of vitamin D of 3 lg/100 kcal,
but not consuming fortiﬁed foods, the estimated means and P95 of vitamin D intake are higher
than in the above situation, but do not exceed the UL of 35 lg/day (i.e. for infants
6–12 months). The margin between the estimated P95 of vitamin D intake in formula consumers
6 In its scientiﬁc opinion of 2009 on the appropriate age for introduction of complementary feeding of infants, ‘the
Panel concludes that the introduction of complementary food into the diet of healthy term infants in the EU between the age of
4 and 6 months is safe and does not pose a risk for adverse health effects’. At the time the present scientiﬁc opinion was
drafted, this opinion on appropriate age for introduction of complementary feeding was under revision (EFSA-Q-2016-00482).
UL of vitamin D for infants
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and the UL of 35 lg/day varies between about 15 and 22 lg/day. The margin calculated with
the UL of 25 lg/day (i.e. for infants 4–6 months), varies between about 5 and 12 lg/day.
 With the additional intake of fortiﬁed foods, the estimated means and P95 of vitamin D intake
are higher than in the above situation, but do not exceed the UL of 35 lg/day (i.e. for infants
6–12 months). The margin between the estimated P95 of vitamin D intake in formula
consumers and the UL of 35 lg/day varies between about 10 and 18 lg/day. The margin
calculated with the UL of 25 lg/day (i.e. for infants 4–6 months), varies between about
0.4 and 8 lg/day.
Observed food patterns were not available for infants in nationally representative surveys from all
EU Member States and food fortiﬁcation practices vary substantially from one country to the other. The
Panel notes that this should be born in mind when discussing estimated intakes of vitamin D in
different scenarios. The margin between the estimated P95 of vitamin D intake in formula consumers
and the UL in the various deﬁned scenarios of food consumption could be considered as an indication
of the possible additional impact of supplementation. This indication should be considered bearing in
mind the regulatory compositional requirements of formulae and in the speciﬁc context of national
supplementation policies and compliance with these policies.
As supporting documents, Annex A contains the full details of the statistical approach of the
analysis of the response in infants of a vitamin D biomarker to daily intake of this vitamin, and Annex
B (Excel® ﬁle) contains the full details (P5, P95, median and mean) of the calculations for the intake
assessment for age from 4 months to < 1 year. Both results are summarised in the following sections.
The NDA Panel endorsed a draft of this scientiﬁc opinion for public consultation on 9 April 2018.
The draft document has been revised and updated according to the comments received, where
appropriate, and the comments received were addressed and published in a technical report.
UL of vitamin D for infants
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1. Introduction
1.1. Background as provided by the European Commission
Commission Directive 2006/141/EC4 lays down requirements for infant formulae and follow-on
formulae placed on the market in the EU. Commission Delegated Regulation (EU) 2016/1273 repeals
Directive 2006/141/EC from 2020 and revises the rules applicable to infant formulae and follow-on
formulae, taking account of the opinion of the European Food Safety Authority (EFSA) of 2014.7
Directive 2006/141/EC requires infant formula to contain vitamin D at amounts in the range
1–2.5 lg/100 kcal and follow-on formula in the range 1–3 lg/100 kcal. In Delegated Regulation (EU)
2016/127, the Commission has set vitamin D levels for infant formula and follow-on formula in the
range 2–3 lg/100 kcal. The minimum amount of 2 lg/100 kcal was recommended by EFSA in its
Scientiﬁc Opinion of 2014 and the maximum amount of 3 lg was extended also to infant formula
based on its history of safe use in follow-on formula and taking into account technological
considerations brought forward by manufacturers.
Concerns have been raised that high consumption of formula containing 3 lg/100 kcal of vitamin D,
combined with vitamin D intake via national supplementation policies (e.g. supplemental 10 lg per day
recommended in Finland) could lead some infants to consume vitamin D at amounts that could pose
safety risks. These concerns derive from calculations showing that the total daily intake of vitamin D
resulting from the consumption of high amounts of formula containing 3 lg/100 kcal of vitamin D
together with the amounts consumed according to national supplementation policies could be, for some
infants, higher than the Tolerable Upper Intake Level set by EFSA for vitamin D in 2012 (25 lg/d for
infants).8 Furthermore, the issue was brought up that the present Tolerable Upper Intake Level for vitamin
D for infants was derived from experiments with a form of vitamin D (vitamin D2), which may be less
efﬁcient than the form of vitamin D currently preferred for fortiﬁcation and supplementation (vitamin D3).
In order to ensure the highest level of protection of infants consuming formulae, the Commission
would like to seek EFSA’s advice on the matter. More speciﬁcally, the Commission would like EFSA to
assess whether consumption of formula containing 3 lg/100 kcal of vitamin D, assuming additional
vitamin D intakes through supplementation, is safe for infants and under what conditions.
In order to best address this question, EFSA should look into the latest scientiﬁc evidence and
revise, if necessary, its opinion of 2012 on the Tolerable Upper Intake Level of vitamin D as regards
infants. As the EFSA opinion is relatively recent, EFSA should focus only on infants and not address the
matter for other population groups covered by the 2012 opinion.
1.2. Terms of reference as provided by the European Commission
In accordance with Article 29 (1) (a) of Regulation (EC) No 178/20029, the European Commission
asks the EFSA to issue an opinion revising, if necessary, the tolerable upper intake level (UL) for
vitamin D that is unlikely to pose a risk of adverse health effects for infants on the basis of the latest
scientiﬁc evidence.
1.3. Interpretation of the Terms of Reference and identiﬁed
subquestions (hazard characterisation, intake assessment and risk
characterisation)
Taking into account considerations in the following sections in particular on hazard identiﬁcation
(Section 1.10), EFSA interprets this mandate as follows:
 Hazard characterisation:
a) Based on a systematic literature search (Section 3), to evaluate possible relationships
between intake of vitamin D and adverse health outcomes and endpoints in infants (i.e.
up to 12 months of age), with the aim of answering the following questions:
7 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2014. Scientiﬁc Opinion on the essential
composition of infant and follow-on formulae. EFSA Journal 2014;12(7):3760.
8 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientiﬁc Opinion on the Tolerable Upper Intake Level of
vitamin D. EFSA Journal 2012;10(7):2813.
9 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety, OJ L 31, 1.2.2002, p. 1.
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i) Is there new available evidence on ‘high’ intake of vitamin D and adverse health
outcomes/adverse change in endpoints?
ii) Is there enough new evidence to change the current UL for vitamin D of 25 lg/day in
infants?
b) To perform a quantitative assessment of the dose–response, where applicable.
 Intake assessment: to assess the daily vitamin D intake in infants in Europe (Section 4).
 Risk characterisation: to evaluate the risk that some infants have an intake above the UL
for vitamin D, considering in particular the ‘high’ consumption of formulae containing up to
3 lg/100 kcal of vitamin D (Section 6).
1.4. Previous assessments on vitamin D
The UL is the maximum level of total chronic daily intake of a nutrient from all sources (i.e. foods,
including supplements2) judged to be unlikely to pose a risk of adverse health effects in humans (EFSA
NDA Panel, 2010).
In the EU, the Scientiﬁc Committee on Food (SCF, 2003) established a UL of 25 lg/day for infants
and young children aged 0–24 months based on the absence of hypercalcaemia attributable to
intervention with vitamin D2 in two studies (Ala-Houhala, 1985; Vervel et al., 1997). In these studies,
breastfed or formula-fed infants received 25 lg vitamin D/day plus the amount ingested via fortiﬁed
infant formula (IF) for up to 5 months after birth. This amount of 25 lg vitamin D/day was treated as
a no observed adverse effect level (NOAEL) and an uncertainty factor (UF) of 1 was deemed
appropriate because, in both studies, serum 25-hydroxy-vitamin D (25(OH)D) concentration
(Section 1.8) was below the threshold of increased risk for hypercalcaemia that was considered to be
above 200 nmol/L in adults. In the following sections of this Scientiﬁc Opinion, the term
‘serum’ 25(OH)D concentration will be used consistently, regardless of whether the
measurements were indeed obtained in serum or in plasma.
In North America, a UL of 25 lg/day was set for infants 0–6 months by the US Institute of
Medicine based on a NOAEL of 45 lg/day, applying an UF of 0.5 to ensure the absence of toxicity also
in small infants, and rounding up (IOM, 2011). This NOAEL derives from data on normal growth in
infants receiving a mean of 45 lg vitamin D/day (Fomon et al., 1966) (Section 3.3.5). The tolerance of
infants aged 6–12 months with a greater body mass was assumed to increase, thus IOM added
12.5 lg/day to the UL set for young infants 0–6 months, yielding a UL of 37.5 lg/day.
Upon the request from the European Commission in 2010 to revise the ULs for vitamin D set by SCF
in 2003 for all population groups, EFSA noted that there was still a paucity of data on infants on which to
base a NOAEL or a lowest observed adverse effect level (LOAEL) and discussed seven references (EFSA
NDA Panel, 2012a). This scientiﬁc opinion describes historical evidence of retarded growth from one
small study in nine infants who received various regimens of vitamin D exceeding 45 lg/day up to
1 year of age, compared to six infants who received 8.5 lg daily or less (Jeans and Stearns, 1938).
However, another small study using doses up to 54 lg vitamin D3/day (mean of 45 lg/day) until about
5 months of age did not show such an effect (Fomon et al., 1966) (Section 3.3.5). A large long-term
prospective cohort study (Hypp€onen et al., 2011) (Section 3.3.5), comparing height in subjects who
received 50 lg/day vitamin D (unspeciﬁed), < 50 lg/day or > 50 lg/day in infancy, did not conﬁrm the
ﬁndings of Jeans and Stearns (1938) on retarded growth. Early intervention studies using doses up to
25 lg vitamin D2/day (plus the amount ingested via breast milk or fortiﬁed IF) for up to 5 months after
birth did not indicate that these intakes were associated with hypercalcaemia in infants (Ala-Houhala,
1985; Vervel et al., 1997). Two other studies on infants were discussed but not used for setting the UL
because one was dealing with large vitamin D dose (‘stoss’) therapies (Barrueto et al., 2005) and the
other study was of short duration (Gordon et al., 2008). Considering the limited evidence available since
the last risk assessment (SCF, 2003), the Panel considered that the UL of 25 lg vitamin D/day
previously derived for infants from 0 to 12 months of age should be retained. In this same opinion, ULs
were set at 50 lg/day for children 1–10 years.
The Scientiﬁc Advisory Committee on Nutrition (SACN, 2016) in line with the Committee on toxicity
of chemicals in food, consumer products and the environment (COT, 2015) agreed that retaining the
UL of 25 lg/day of vitamin D set by EFSA NDA Panel (2012a) for infants, was appropriate.
In a different context, upon request from the European Commission to update the previous dietary
reference values (DRVs) set by SCF (1993), EFSA analysed the dose–response relationship between
total vitamin D intake and mean achieved serum 25(OH)D concentration (biomarker for vitamin D
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status) in each of the 83 arms of 35 trials using vitamin D3 and carried out under conditions of
assumed minimal cutaneous vitamin D synthesis (meta-regression) (EFSA NDA Panel, 2016). This
model was used to derive the vitamin D intake in adults and children required to achieve a target
serum 25(OH)D concentration of 50 nmol/L, which was based on associations with musculoskeletal
health outcomes. The resulting intake corresponded to the deﬁnition of an adequate intake (AI) for
vitamin D.10 However, too few data on infants met the inclusion criteria for such an analysis, and the
AI of 10 lg/day for infants was set based on other data (EFSA NDA Panel, 2016).
In this short overview, the Panel highlights the two reference values set for vitamin D for infants in
the EU, i.e. an AI of 10 lg/day (EFSA NDA Panel, 2016) and a UL of 25 lg/day (EFSA NDA Panel, 2012a).
The assessment of the dose–response relationship between vitamin D intake and a biomarker was
previously used by the Panel to set AIs for adults and children, but not for infants due to lack of data.
The Panel notes that previously set ULs for infants (in the EU or outside) were derived considering data
on vitamin D intake and linear growth and data on vitamin D intake and serum calcium or risk of
hypercalcaemia. The Panel also notes that, while IOM set different values for the UL for vitamin D during
the ﬁrst and second half year of life, both SCF and EFSA set one single UL for the ﬁrst year of life.
1.5. Forms of vitamin D (vitamers) and their food sources
Vitamin D is a fat-soluble and the generic term for vitamin D2 (ergocalciferol) and vitamin D3
(cholecalciferol).11 Vitamin D2 is synthesised by exposure of ergosterol in plants, fungi and yeast to
ultraviolet (UV)-B irradiation, whereas vitamin D3 may be formed in humans and in animals following
UV-B irradiation of the skin (Section 1.7.1.1) and is also produced in some plants (lichens).
The major food sources for naturally occurring vitamin D have been discussed (EFSA NDA Panel,
2016). In brief:
 for vitamin D3, these sources include animal foods such as ﬁsh (and especially fatty ﬁsh and
ﬁsh liver), offal (particularly liver), meat and meat products and egg yolks.
 25(OH)D is present in some foods of animal origin in varying amounts. ‘Due to the suggested
higher biological activity of 25(OH)D in foods compared with the native vitamin D, a
conversion factor of 5 has been used for 25(OH)D3 in the calculation of total vitamin D3 in
some food composition tables, including those in the UK, Denmark and Switzerland’.
 for vitamin D2, some higher fungi, e.g. mushrooms, are a natural source if exposed to UV-B.
Vitamin D3 and vitamin D2 may be added to foods
12 including dietary supplements.13
1.6. General considerations on food patterns in infants
Infants may be fed from birth exclusively with breast milk or exclusively with formulae or both, with
the addition, at a certain age, of complementary foods (EFSA NDA Panel, 2009).
Mean vitamin D concentrations in breast milk of healthy lactating women who are unsupplemented (or
supplemented with vitamin D below the UL) are low, ranging from 0.25 to 2.0 lg/L (Dawodu and Tsang,
2012; EFSA NDA Panel, 2013, 2016). Infant and follow-on14 formulae (IF and FoF) are currently fortiﬁed
with vitamin D15 as are some commercially available complementary foods.16 Other complementary foods
may be naturally low (e.g. fruits or vegetables) or naturally rich (e.g. ﬁsh) or fortiﬁed with vitamin D. The
10 Adequate Intake (AI): the value estimated when a Population Reference Intake cannot be established because an average
requirement cannot be determined. An Adequate Intake is the average observed daily level of intake by a population group
(or groups) of apparently healthy people that is assumed to be adequate.
11 For conversion between µg and International Units (IU) of vitamin D intake: 1 µg = 40 IU and 0.025 µg = 1 IU. For
conversion between nmol/L and ng/mL for serum 25(OH)D concentration: 2.5 nmol/L = 1 ng/mL.
12 Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of
vitamins and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26.
13 Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the
Member States relating to food supplements. OJ L 183, 12.7.2002, p. 51.
14 IF is the only processed foodstuff which wholly satisﬁes the nutritional requirements of infants during the ﬁrst months of life
until the introduction of appropriate complementary feeding (while FoF are intended for infants when appropriate
complementary feeding is introduced).
15 Commission Delegated Regulation (EU) 2016/127 of 25 September 2015 supplementing Regulation (EU) No 609/2013 of the
European Parliament and of the Council as regards the speciﬁc compositional and information requirements for infant formula
and follow-on formula and as regards requirements on information relating to infant and young child feeding. OJ L 25,
2.2.2016, p. 1.
16 Commission Directive 2006/125/EC of 5 December 2006 on processed cereal-based foods and baby foods for infants and
young children. OJ L 339, 6.12.2006, p. 16.
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Panel notes that the European Society for Paediatric Gastroenterology, Hepatology and Nutrition
(ESPGHAN) Committee on Nutrition recommends a daily oral supplementation of 10 lg vitamin D for all
infants during the ﬁrst year of life starting from birth onwards (Braegger et al., 2013; EFSA NDA Panel,
2016).
1.7. Functions, physiology and metabolism of vitamin D
The functions of vitamin D in the body are mediated by its active metabolite 1,25-dihydroxy-vitamin
D (1,25(OH)2D: 1,25(OH)2D2 or 1,25(OH)2D3 called calcitriols). They include the maintenance and
regulation of calcium and phosphorus concentrations that are critically important for the development
and maintenance of healthy bones but also signiﬁcant effects in other tissues (Section 1.7.2). General
aspects of vitamin D physiology, functions and metabolism have been discussed previously (EFSA NDA
Panel, 2016) and are summarised in the subsequent sections where special consideration is given to
infants where possible.
1.7.1. Physiology of vitamin D
1.7.1.1. Cutaneous synthesis of vitamin D
Vitamin D3 is synthesised in the skin from 7-dehydrocholesterol upon exposure to sunlight or other
sources of UV-B irradiation via the formation of previtamin D3 that thermally isomerises immediately to
vitamin D3. Vitamin D3 produced in the skin enters the circulation bound to the vitamin D-binding
protein (DBP). Prolonged dermal exposure to sunlight/UV-B irradiation leads to photodegradation of
both previtamin D3 and vitamin D3 in the skin to biologically inert isomers (Webb et al., 1989), thus
preventing vitamin D toxicity due to prolonged sun exposure (Holick, 1994).
Endogenous cutaneous vitamin D synthesis depends on many factors (e.g. latitude, season, ozone
layer, clouds, surface type such as snow, time spent outdoors, sunscreen use, clothing, skin type, age)
(EFSA NDA Panel, 2016). With increasing latitude, both the quality and quantity of sunlight are not
sufﬁcient in parts of the year for vitamin D3 synthesis in the skin to take place (Engelsen et al., 2005;
EFSA NDA Panel, 2016).
Concerns regarding UV-related skin and eye damage have led to recommendations to reduce UV
exposure in infants because it is considered a health hazard (American Academy of Pediatrics, 1999;
Wagner and Greer, 2008; Balk, 2011). As a result of this advice, the endogenous vitamin D synthesis
may be low in infants.
While for other age groups beyond infancy, the synthesis of vitamin D3 in the skin during the summer
months may be the main source of vitamin D and may fulﬁl the requirement, the Panel considers that
this may not be the case for infants, who therefore have greater reliance on dietary intake.
1.7.1.2. Intestinal absorption of vitamin D
Vitamin D from foods is absorbed throughout the small intestine with an efﬁciency varying generally
between 55 and 99% and with no discrimination between vitamins D2 and D3 (Thompson et al., 1966; Lo
et al., 1985; Jones, 2014; Borel et al., 2015; Reboul, 2015). The absorption process is more efﬁcient in
the presence of bile salts and when dietary fat is present in the lumen of the small intestine. Vitamin D
absorbed from the intestine is incorporated into chylomicrons, which reach the systemic circulation
through the lymphatic system (Jones, 2013). In a study on term infants, vitamin D2 (provided by
orogastric tube) was well absorbed both in young and older infants (one or more than 10 days of age,
respectively), with increasing absorption efﬁciency with age due to increased bile salt secretion (Hollis
et al., 1996). Vitamin D3-palmitate was equivalent with free vitamin D2 in raising circulating vitamin D
concentrations only at an age of about 3 months, due to the dependence on gastrointestinal tract
maturation and secretion of esterases (Hollis et al., 1996).
1.7.1.3. Transport in blood and metabolism of vitamin D
Vitamins D2 and D3, released either from chylomicrons or DBP, undergo 25-hydroxylation in the
liver to 25(OH)D2 and 25(OH)D3, respectively (IOM, 2011; Jones, 2014). 25(OH)D is then released into
the circulation bound to DBP. In adults, 85–90% of 25(OH)D is transported in the blood bound to DBP,
10–15% to albumin and < 1% is free (Bikle et al., 1985; Powe et al., 2013; Chun et al., 2014;
Yousefzadeh et al., 2014).
Serum 25(OH)D concentrations reﬂect the amount of vitamin D from both cutaneous synthesis and
ingested foods. Serum 25(OH)D2 is of dietary origin only, while serum 25(OH)D3 may be of dietary or
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dermal origin. The kidneys are the main site where 25(OH)D undergoes 1a-hydroxylation (Jones,
2014) to form 1,25(OH)2D. The activity of the 1a-hydroxylase is regulated by calcium, phosphate and
their regulating hormones. In the blood, 1,25(OH)2D is primarily transported bound to DBP and
albumin (Bikle et al., 1986; Jones et al., 1998; Powe et al., 2013). The serum concentration of 25(OH)
D is approximately 1,000 times higher than that of 1,25(OH)2D. In adults, serum 25(OH)D has a mean
half-life of approximately 13–15 days (Jones et al., 2014), while serum 1,25(OH)2D has a half-life of
hours (Jones et al., 1998; IOM, 2011). The Panel is not aware of data suggesting that the half-life of
serum 25(OH)D would be different in infants on usual intakes.
The C3-epimer of 25(OH)D (3-epi-25(OH)D) has been detected in the serum in 20–98% of infants
(e.g. (Singh et al., 2006; Gallo et al., 2013a)). The 3-epi-25(OH)D may represent up to about 40% of
total serum 25(OH)D concentration measured in young infants (Stepman et al., 2011; Ooms et al., 2016).
In a cohort of 1,050 infants (Kiely et al., 2017), 3-epi-25(OH)D3 was also detected in cord sera of infants
who had 25(OH)D3 > 15 nmol/L (in 99.4% of all infants), representing on average (range) 11.2 (6–35)%
of total 25(OH)D concentration. In this cohort, the cord 3-epi-25(OH)D3 concentrations were signiﬁcantly
positively associated with cord 25(OH)D3, and negatively with gestational age and maternal age.
Ooms et al. (2016) reported that 3-epi-25(OH)D3 concentrations were relatively low in the ﬁrst weeks
of life (mean (range) of 3 (1–7) nmol/L), with a low-relative contribution to 25(OH)D3 concentration
(< 10%). 3-epi-25(OH)D3 concentrations increased from the second week of life with highest levels
observed in the second and third months, reaching as high as 200 nmol/L in some infants. Relative 3-epi-
25(OH)D3 contribution to 25(OH)D3 was up to 36% in full-term infants. From age 3 months, a sharp
decline in absolute or relative 3-epi-25(OH)D3 level was seen, thereafter to remain at a relatively
constant low concentration (mean (range) 8 (1–62) nmol/L, < 10% of 25(OH)D3).
High 3-epi-25(OH)D concentrations in infancy are probably due to postnatal formation rather than
foetal stores (Bailey et al., 2014). The metabolic role of 3-epi-25(OH)D is unclear. It is converted to 3-epi-
1,25(OH)2D, which binds to the vitamin D receptor (VDR) with a lower afﬁnity than 1,25(OH)2D. It has
also been detected in the serum of older children and adults, but at much smaller concentrations (e.g.
(Bailey et al., 2013)). Speciﬁcities of the analysis of serum concentration of 25(OH)D in infants, in
particular with regard to the concentration of 3-epi-25(OH)D, are discussed in Section 1.8.6.3.
1.7.1.4. Distribution to tissues and storage
Within hours of ingestion or synthesis in the skin, vitamin D is distributed to the liver or delivered
as either vitamin D or its metabolites 25(OH)D and 1,25(OH)2D to various tissues of which adipose
tissue is considered a major repository in the body for vitamin D (Blum et al., 2008).
25(OH)D is transported via the placenta to the foetus and also converted there to 1,25(OH)2D or
24,25(OH)2D (Paulson and DeLuca, 1986; Salle et al., 2002; Kovacs, 2008; Dror and Allen, 2010; Shin
et al., 2010; Young et al., 2014).
1.7.1.5. Degradation and elimination
Free 1,25(OH)2D taken up by target cells is either rapidly metabolised or bound to VDR (Lehmann
and Meurer, 2010). Vitamin D metabolites in the body are degraded in an oxidative pathway by the
actions of CYP24A1 (24-hydroxylase) (EFSA NDA Panel, 2016). 1,25(OH)2D is a strong controller of its
own degradation by stimulating the 24-hydroxylase (IOM, 2011). The majority of the metabolites of
the vitamin D degradative pathway are excreted in the bile (Jones, 2013) and thus in the faeces. The
Panel is not aware of any speciﬁc data on vitamin D degradation and elimination in infants.
1.7.2. Functions of the biologically active metabolite 1,25(OH)2D
The principal function of 1,25(OH)2D (i.e. 1,25(OH)2D3 and 1,25(OH)2D2) is to maintain calcium
and phosphorus homoeostasis in the circulation, together with parathyroid hormone (PTH) and
ﬁbroblast growth factor (FGF-23) (EFSA NDA Panel, 2012a, 2016; Jones, 2013). The main target
tissues of 1,25(OH)2D are the intestine, the kidneys and the bone. In the intestine, 1,25(OH)2D binds
to the VDR to facilitate calcium and phosphorus absorption by active transport. In the kidney, 1,25(OH)2D
stimulates the tubular reabsorption of calcium dependent on PTH that increases the production of
1,25(OH)2D from 25(OH)D in the proximal tubule (Holt and Wysolmerski, 2011). In the bone, PTH and
1,25(OH)2D interact to activate the osteoclasts responsible for bone resorption to release calcium and
phosphorus into the circulation (Holick, 2006b, 2007). Maintenance of calcium and phosphate
homoeostasis is especially important during infancy as this is a period of rapid skeletal growth and
mineral accumulation.
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1,25(OH)2D is also important in other tissues (Bouillon et al., 2008; EFSA NDA Panel, 2012a; Jones,
2014) that have VDRs as well as the 1a-hydroxylase to convert 25(OH)D into 1,25(OH)2D (Holick,
2007). Functions of 1,25(OH)2D include cell differentiation and antiproliferative actions in various cell
types, such as bone marrow, cells belonging to the immune system, skin, breast and prostate
epithelial cells, muscle and intestine (Norman, 2008; Jones, 2014).
Although presenting structural differences, vitamin D2 and D3 trigger an identical set of biological
responses in the body, primarily by the regulation of gene expression mediated by the same VDR. None
of the steps in the speciﬁc vitamin D signal transduction cascade appears to discriminate between
vitamin D2 and vitamin D3 at the molecular level (Jones, 2013). Vitamin D2 and D3 are considered
biologically equivalent in terms of their ability to cure rickets (Jones, 2013).
1.7.3. Effects of genotypes on metabolism of vitamin D
Some polymorphisms of genes may inﬂuence vitamin D metabolism/endogenous synthesis (Berry
and Hypp€onen, 2011). Several mutations of 24-hydroxylase (CYP24A1) (Schlingmann et al., 2011;
Dinour et al., 2013) and of the renal sodium-phosphate cotransporter 2A (SLC34A1) (Schlingmann
et al., 2016) have been described in patients with idiopathic infantile hypercalcaemia (IIH). Such
mutations, in both homozygous or compound heterozygous patients, are associated with
hypersensitivity to vitamin D in prophylactic doses (10–12.5 lg/day) or in extremely high-bolus doses
(15 mg repeatedly) and have also been associated with nephrolithiasis and nephrocalcinosis (Jones G
et al., 2012; Jones et al., 2017). The frequency of IIH due to CYP24A1 mutations in Poland has been
calculated to be 1:32,465 births and the frequency of mutations of CYP24A1 in the Polish population to
be 1.11% (Pronicka et al., 2017).
However, as the distribution of all genotypes is not well known and because the impact of the
carrier state of one mutation on sensitivity to vitamin D is unclear, the Panel considers that the
available data are insufﬁcient to be currently considered in the derivation of a UL of vitamin D for
healthy infants.
1.8. Serum 25(OH)D concentration as a biomarker for vitamin D
This section is focused on serum concentration of 25(OH)D. Other biomarkers of either vitamin D
intake or status have been discussed (EFSA NDA Panel, 2016): these include free serum 25(OH)D
concentration (Powe et al., 2013; Chun et al., 2014; Johnsen et al., 2014), markers of bone formation
or turnover (Bonjour et al., 2014), serum concentrations of 1,25(OH)2D and PTH. For the reasons
previously outlined (EFSA NDA Panel, 2016), the Panel considers that these other biomarkers
cannot be used in the derivation of a UL of vitamin D for infants.
1.8.1. Serum 25(OH)D: relationship with vitamin D intake and baseline 25(OH)D
concentration
Serum concentration of 25(OH)D represents total vitamin D from exposure to both UV-B irradiation
(cutaneous synthesis) and dietary sources and is used as a biomarker of dietary vitamin D intake in
populations with low exposure to UV-B irradiation from sunlight (EFSA NDA Panel, 2012a). Oral intake
of vitamin D increases serum 25(OH)D concentrations without an effective regulatory mechanism
(Holick, 2006a; EFSA NDA Panel, 2012a).
In adults, increasing oral vitamin D intake increases serum 25(OH)D concentration until a plateau is
reached after about 6 weeks, which may indicate an equilibrium between the production and
degradation of 25(OH)D (Vieth, 1999; Viljakainen et al., 2006; Seamans and Cashman, 2009). A linear
relationship was reported between vitamin D intake and serum 25(OH)D concentrations up to a total
vitamin D intake of 35 lg/day (Cashman et al., 2011) and 50 lg/day (Cranney et al., 2007). The IOM
(2011) found a steeper rise in the serum 25(OH)D concentrations with vitamin D intakes up to 25 lg/day
and a slower, more ﬂattened response when the intake was further increased.
In adults and children, a stratiﬁed analysis of a meta-regression model of the serum 25(OH)D
response to total vitamin D intake (Section 1.4) was undertaken previously (EFSA NDA Panel, 2016).
In this analysis, predicted mean serum 25(OH)D concentrations ranged between 37 and 106 nmol/L in
adults (74 arms, 31 studies) and between 43 and 124 nmol/L in children aged 2–17 years (9 arms,
4 studies), at intakes of 5 up to 100 lg/day. No data from infants matching the selected inclusion
criteria were available for this meta-regression analysis (EFSA NDA Panel, 2016).
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In infants, serum 25(OH)D concentration increases with vitamin D2 or D3 intake. In 113 full-term
infants, who were randomised to receive 10, 30, or 40 lg/day vitamin D3 from age 2 weeks to
3 months, median baseline serum 25(OH)D concentration of 53 nmol/L increased to mean values of
88, 124 and 153 nmol/L, respectively, at 3 months, with the maximum observed concentrations of
125, 198 and 230 nmol/L (Holmlund-Suila et al., 2012) (Section 3.3.2.3). In another trial, 132 healthy,
term, singleton, breastfed infants were randomly assigned to receive either 10, 20, 30 or 40 lg/day
vitamin D3 from 1 to 12 months of age (Gallo et al., 2013a) (Section 3.3.2.2). By 3 months, 55%
(95% conﬁdence interval (CI), 38%–72%) of infants in the 10 lg/day group achieved a serum 25(OH)
D concentration of 75 nmol/L or greater vs. 81% (95% CI, 65%–91%) in the 20 lg/day group, 92%
(95% CI, 77%–98%) in the 30 lg/day group and 100% in the 40 lg/day group. Concentrations of 25
(OH)D in serum declined from 3 to 12 months of age in all groups although dietary vitamin D
(sources) increased. All dosages maintained serum 25(OH)D concentrations of 50 nmol/L or greater in
97% of infants at 3 months and sustained this in 98% to 12 months.
In healthy, breastfed, infants (n = 52) aged 1 month and who received 10 lg of either D2 or D3 daily,
mean ( SD) baseline serum 25(OH)D3 concentrations were 44.2  23.8 (D2) and 54.6  23.7 nmol/L
(D3). Mean total serum 25(OH)D concentrations were 64.8  26.2 (D2) and 76.8  17.4 nmol/L (D3) at
the 4-month follow-up (Gallo et al., 2013b). In the combined groups, the baseline serum 25(OH)D
concentration was inversely related to the change in total 25(OH)D (r = -0.52; p < 0. 001).
The Panel notes that vitamin D intake in infants increases serum 25(OH)D concentration in a
dose-dependent manner, that the extent of the increase as a result of vitamin D supplementation may
depend on baseline serum concentrations of 25(OH)D and that a given intake of vitamin D results in
higher serum 25(OH)D concentrations in infants < 6 months of age than in older infants.
1.8.2. Serum 25(OH)D: effect of vitamin D form (D2 or D3)
Several studies have shown that vitamin D2 supplements are less effective in raising or maintaining
serum 25(OH)D concentrations compared to vitamin D3 (Jones, 2013; Lehmann et al., 2013; Itkonen
et al., 2016). Although vitamins D2 and D3 are not discriminated by the speciﬁc vitamin D signal
transduction cascade and are considered biologically equivalent in their ability to cure rickets
(Section 1.7.2), data suggest that vitamin D3 may be the preferred substrate for hepatic conversion to
25(OH)D (Holmberg et al., 1986; Tripkovic et al., 2012). Data also suggest that vitamin D3 and its
metabolites have higher binding afﬁnity to DBP than vitamin D2 (Houghton and Vieth, 2006). Data
from toxicity and repletion studies suggest some preferential non-speciﬁc catabolism of vitamin D2
(compared to vitamin D3), accelerating its degradation, especially at ‘high’ doses (Jones, 2013).
Most data comparing the effect of vitamin D2 or D3 on serum 25(OH)D concentration in humans
are from studies on adults or children.
Thacher et al. (2010) administered a single oral dose of vitamin D2 or D3 of 1.25 mg to 49 Nigerian
children aged 15–120 months, of whom 28 had calcium-deﬁciency rickets and 21 were healthy controls.
Total serum 25(OH)D concentration peaked on day 3 and the incremental change was similar with
vitamins D2 and D3 in children with rickets (72.5  42.5 and 62.5  27.5 nmol/L, respectively) and in
control children (82.5  32.5 and 77.5  40 nmol/L, respectively). The disappearance rate of total
serum 25(OH)D after day 3 was similar with vitamin D2 and D3 in control children. In a linear regression
analysis with the serum 25(OH)D concentration on day 3 as a covariate, the decline in 25(OH)D
concentrations on days 7 and 14 was signiﬁcantly greater (p < 0.001) in the vitamin D2 group than the
vitamin D3 group among children with rickets, consistent with a more rapid clearance of 25(OH)D2 than
25(OH)D3.
In a systematic review and meta-analysis comparing supplementation studies in adults with vitamin
D2 and D3 (Tripkovic et al., 2012), even though bolus doses of vitamin D3 (> 125 lg/day) were more
effective for raising total serum 25(OH)D concentration compared with vitamin D2 doses (three studies
out of four), the differences between the two forms of vitamin D supplements disappeared when given
as lower daily doses (six studies). In a 12-week randomised controlled trial (RCT) in healthy South
Asian and white European women, both vitamin D3 and D2 were effective in raising serum 25(OH)D
concentrations at doses of 15 lg/day during wintertime, albeit vitamin D3 was more effective than
vitamin D2 (Tripkovic et al., 2017).
Data comparing the effect of vitamin D2 and vitamin D3 on serum 25(OH)D concentration in
infants are scarce. In breastfed infants receiving a daily supplement of 10 lg vitamin D2 or vitamin
D3 for 3 months, the change in serum 25(OH)D did not differ signiﬁcantly (Gallo et al., 2013b)
(Section 1.8.1). Another study on infants and young children with hypovitaminosis D (serum 25(OH)D
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concentration < 50 nmol/L) who were treated orally with either 50 lg/day of vitamin D2 (n = 15) or
50 lg/day of vitamin D3 for 6 weeks (n = 15), showed no statistically signiﬁcant difference between
the effects of vitamin D2 and vitamin D3 on the change in serum 25(OH)D concentration (from 39.3 to
109.8 nmol/L with vitamin D2 vs. from 34.3 to 103 nmol/L with vitamin D3; 7% difference in effect)
(Gordon et al., 2008) (Section 3.3.3.5). The Panel notes the small sample size of these studies.
The Panel notes the limited data available on infants, which do not allow a conclusion to be
drawn on whether there is a difference between vitamin D2 and D3 as regards their impact on serum
25(OH)D concentrations in infants. However, in view of the results comparing the effect of vitamin D2
and vitamin D3 on serum 25(OH)D concentration in adults, the Panel considers that, if enough data
are available, the form of vitamin D (D2 or D3 or ‘unspeciﬁed’) should be considered in the dose–
response analysis between vitamin D intake and serum 25(OH)D concentration of infants for the
assessment of an UL for vitamin D (Section 3.5 and Annex A).
1.8.3. Serum 25(OH)D: effect of frequency of vitamin D administration
Owing to its slow turnover in the body (half-life of about 2 months) (Jones, 2008), vitamin D is
often administered as single or repeated single high doses at varying intervals or weekly in equivalent
doses instead of daily. Depending on the vitamin D dose and the duration of supplementation in
adults, resulting serum 25(OH)D concentrations ‘may be comparable or somewhat lower with weekly
compared to daily supplementation’, respectively (EFSA NDA Panel, 2012a).
Several studies describe the treatment of infants and young children with or without rickets with
single (Cesur et al., 2003; Billoo et al., 2009; Mittal et al., 2014; Harnot et al., 2017) or repeated single
high-oral doses (Pietrek et al., 1976; Markestad et al., 1987; Zeghoud et al., 1994; Shajari et al., 2009;
Shakiba et al., 2010, 2014; Manaseki-Holland et al., 2012; Huynh et al., 2017) of vitamin D up to 15 mg.
In some of these studies, single high-oral doses were compared to daily oral supplementation of vitamin
D at doses between 5 and 10 lg (Shajari et al., 2009; Shakiba et al., 2010, 2014; Huynh et al., 2017).
The Panel notes that high doses (typically single or repeated high-dose oral bolus) were sometimes
associated with ‘high’ serum 25(OH)D concentrations, up to > 300 nmol/L (Markestad et al., 1987). The
Panel considers that these studies also demonstrate the different kinetics of an oral high-bolus dose with
a more rapid peak in serum 25(OH)D concentration after 2–3 weeks, which makes it difﬁcult to use these
data to draw conclusions about regular daily intakes required to obtain desirable serum 25(OH)D
concentrations or 25(OH)D concentrations that may be associated with adverse effects. Studies testing
weekly vs. daily administration in infants are scarce (Section 3.4.1 and Appendix L).
The Panel considers that, for setting the UL for vitamin D for infants, data from studies using
infrequent high doses cannot be used and decided to use only studies considering daily doses.
1.8.4. Serum 25(OH)D: other factors inﬂuencing its concentration
Besides vitamin D intake, form and frequency of consumption, baseline serum 25(OH)D
concentration and sun exposure, concentrations of 25(OH)D in serum vary according to season, with
the lowest concentrations occurring at the end of winter and the highest concentrations in summer
(Hintzpeter et al., 2008). This generally reﬂects the magnitude of endogenous synthesis of vitamin D
following UV-B irradiation (Section 1.7.1.1).
In infants, serum 25(OH)D concentrations follow a cyclical pattern during the ﬁrst year of life,
corresponding to the pattern of sun exposure (Specker et al., 1985; Specker and Tsang, 1987;
Mimouni and Shamir, 2009; Kiely et al., 2017). Seasonal variation in serum 25(OH)D concentrations in
breastfed infants depends on the time spent outdoors and on the area of skin exposed to sunlight.
According to Specker et al. (1985), in Cincinnati, a weekly exposure of 2 hours or 20 minutes of a fully
dressed (without a hat) or partially dressed infant (diaper), respectively, is sufﬁcient for maintaining
serum 25(OH)D concentration above 27.5 nmol/L. In 120 breastfeeding mother–infant pairs of
different ethnicity in the US (Dawodu et al., 2014), lowest quartile of sun exposure time,17 low
percentage of sun exposed body surface area (%BSA) exposure (p = 0.04) and low sun index18
(p < 0.001) were signiﬁcantly associated with higher prevalence of serum 25(OH)D concentration19
< 50 nmol/L in the infants. In another prospective study on breastfeeding mother–infant pairs in the
US (n = 119), China (n = 112) and Mexico (n = 113) (Dawodu et al., 2015), data on behaviour related
17 Part of the body exposed, type of covering, assessed via questionnaire.
18 % BSA x weekly hours of sun exposure, lower in winter than in other seasons.
19 Concentration analysed at 4, 26 and 52 weeks.
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to sunlight exposure of mothers and infants (% BSA and sun index) were collected at 4, 13, 26, 52
and 108 weeks post-partum through questionnaires. Serum 25(OH)D concentration was measured in
a subset of infants at 26 weeks of age during fall and winter. Across the three study sites, serum
25(OH)D concentration in infants was signiﬁcantly associated with sun index. Cumulative sun index
correlated positively with serum 25(OH)D concentration at 6 months of age in an infant population in
Delhi, and a requirement of at least 30 min weekly exposure to afternoon sunlight over 40% of body
area (infant clothed in diaper) for at least 16 weeks, was estimated to achieve serum 25(OH)D
concentrations > 50 nmol/L (Meena et al., 2017).
Body fat impacts serum 25(OH)D concentration in adults (Saneei et al., 2013; Vanlint, 2013) and in
infants (Hazell et al., 2014). Whether the age-dependent decline in serum 25(OH)D concentrations
observed from 3 to 12 months of age in the study by Gallo et al. (2013a) (Sections 1.8.1 and 3.3.2.2)
was related to the increasing body mass of the infants remained unclear. In a prospective
observational cohort study, infants were investigated with regard to vitamin D intake (diet and
supplements), anthropometry and 25(OH)D concentrations in serum at the age of 6 months (n = 134)
and 12 months (n = 98, 27% attrition) (Pludowski et al., 2011) (Section 3.3.6). Mean ( SD) daily
vitamin D intakes at 6 and 12 months of age did not differ (26.6  17.4 and 23.5  15.5 lg).
However, vitamin D intake expressed per kg body weight signiﬁcantly decreased from 3.5 lg at 6
months to 2.3 lg at 12 months (p < 0.0001), which was associated with a decline in mean serum 25
(OH)D concentration from 107.5 to 72.5 nmol/L. The Panel notes that, at a given vitamin D intake,
body mass or age may be determinants of 25(OH)D concentrations in serum.
The foetus cannot synthesise 25(OH)D and therefore relies on placental transfer (Section 1.7.1.4).
Several observational studies have reported positive correlations between maternal serum and cord
blood 25(OH)D concentrations, with coefﬁcients between 0.42 and 0.95 (Nicolaidou et al., 2006;
Bodnar et al., 2007; Josefson et al., 2013; Godang et al., 2014; Saraf et al., 2016; Wegienka et al.,
2016). Thus, factors which inﬂuence maternal serum 25(OH)D concentration, including maternal
intake, adiposity, skin pigmentation, covering and season, have an impact on the serum 25(OH)D
concentration of the newborn. Most of the studies mentioned above also report that serum 25(OH)D
concentrations are lower in the infant than in the mother. However, these studies were performed in
populations where maternal vitamin D status (serum 25(OH)D concentration) was in the low or normal
range. The impact of ‘high’ maternal vitamin D intake on neonatal vitamin D status was investigated in
an RCT of vitamin D supplementation during pregnancy conducted in the USA (Hollis et al., 2011).
Women with a singleton pregnancy (n = 502) received 10, 50 or 100 lg of vitamin D3 per day from 12
to 16 weeks’ gestation until delivery. Neonatal 25(OH)D concentration signiﬁcantly correlated with
maternal serum 25(OH)D concentration overall, 1 month prior to delivery, and at delivery (r2 = 0.6).
Mean ( SD) neonatal concentration signiﬁcantly differed by intervention group: 45.5  25.3 nmol/L,
57.0 +/24.5 nmol/L and 66.3 +/25.8 nmol/L in the 10, 50 and 100 lg groups, respectively
(p < 0.0001). The highest 25(OH)D concentration reported in neonates from the 100 lg group was
130 nmol/L. A systematic review (with meta-analysis) of RCTs (Bi et al., 2018)20 showed that maternal
vitamin D supplementation during pregnancy (compared with control group) led to signiﬁcantly higher
25(OH)D concentrations (14 RCTs with 2,361 participants) and higher calcium concentrations in the
neonates (nine RCTs with 1,007 participants).
Studies have investigated the potential of vitamin D supplementation of breastfeeding mothers to
raise serum 25(OH)D concentrations of their infants. Results show that maternal doses of 10–25 lg/day
have little or no effect on serum 25(OH)D concentrations of the breastfed infant (Greer et al., 1982;
Rothberg et al., 1982; Ala-Houhala, 1985; Ala-Houhala et al., 1988; Hollis and Wagner, 2004). Results
also show that maternal supplementation of at least 50 lg/day is required to provide a signiﬁcant
amount of vitamin D in the breast milk for breastfeeding infants (Ala-Houhala et al., 1988; Saadi et al.,
2009). In other studies, a maternal dose of 100 lg/day increased the mean infant 25(OH)D
concentration to 75 nmol/L, which was exceeded in all infants with a maternal dose of 160 lg/day (Hollis
and Wagner, 2004; Basile et al., 2006; Wagner et al., 2006). In an RCT (Hollis et al., 2015), exclusively
lactating women in Charleston, South Carolina, or Rochester, New York, at 4–6 weeks postpartum, were
allocated to either 10, 60 or 160 lg vitamin D3/day for 6 months. Only the infants of the women in the
10 lg group received oral 10 lg vitamin D3/day while the infants in the 60 and 160 lg groups received a
placebo. Supplementation of mothers only with 60 lg/day was insufﬁcient to prevent serum 25(OH)D
concentrations < 50 nmol/L in the infants. After 4 months, the mean ( SD) serum 25(OH)D
concentration of infants supplemented with 10 lg/day (109  48 nmol/L, n = 74) did not differ from
20 Published after the end of the period of the systematic literature search (Section 3.1).
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those infants whose mothers received 160 lg/day (106.9  35.1 nmol/L, n = 74). Adverse events
among mothers or infants did not differ by group and were deemed not to be related to vitamin D dose.
The Panel notes that maternal supplementation with vitamin D3 of 160 lg/day during lactation raised
serum 25(OH)D of infants no more than supplementation of the infants with 10 lg/day.
Besides vitamin D intake, form and frequency of consumption, baseline serum 25(OH)D
concentration and sun exposure, the Panel notes that other factors inﬂuencing serum 25(OH)D
concentration in infants are season, body mass (or age as a proxy) and body fat, maternal
characteristics during pregnancy and lactation, in particular maternal supplementation with vitamin D.
1.8.5. Serum 25(OH)D target concentration
The Panel considered a serum 25(OH)D concentration of 50 nmol/L as a suitable target value for all
age and sex groups including infants and set an AI for infants at 10 lg/day vitamin D (EFSA NDA
Panel, 2016).
1.8.6. Analytical methods for measuring serum 25(OH)D
1.8.6.1. Analytical methods for measuring serum 25(OH)D: general considerations
General considerations on analytical methods for the measurement of 25(OH)D concentration in
serum have been discussed previously (EFSA NDA Panel, 2016). Among the numerous methods for
this measurement, liquid chromatography-tandem mass spectrometry (LC-MS/MS) and high-
performance liquid chromatography (HPLC) methods are considered the gold standard (Wallace et al.,
2010; Carter, 2011). These methods have the advantage that they can measure 25(OH)D3 and
25(OH)D2 separately (Tai et al., 2010; Carter, 2011). Formerly, all methods suffered from the lack
of an international common standard, which contributed to the variability of results of serum 25(OH)D
measurements. The Vitamin D External Quality Assessment Scheme (DEQAS) has revealed
considerable differences between methods (both within and between laboratories), raising concerns
about the comparability and accuracy of different assays and laboratories (Snellman et al., 2010;
Carter, 2011; Farrell et al., 2012; Heijboer et al., 2012). The introduction of a standard reference
material for vitamin D in human serum by the US National Institute of Standards and Technology
(NIST) has been a step forward in providing a reference measurement procedure against which assays
could be standardised (Carter, 2012). The Vitamin D Standardization Program (VDSP) has developed
protocols for standardising procedures of 25(OH)D measurement in national health/nutrition surveys to
promote 25(OH)D measurements that are accurate and comparable over time, location and laboratory,
to improve the data basis for public health measures (Cashman et al., 2013).
1.8.6.2. Analytical methods for measuring serum 25(OH)D: speciﬁcities in infants
When comparing two commercially available immunoassays for measuring serum 25(OH)D
concentration in infants against LC-MS/MS, results (mean  SD) obtained with both immunoassays
(46.9  17.1 nmol/L with radioimmunoassay (RIA) and 75.5  29.3 nmol/L with an enzyme immune
assay (EIA)) were signiﬁcantly different from those analysed with LC-MS/MS (58.9  21.6 nmol/L)
(Gallo et al., 2014a).
The C3-epimer of 25(OH)D (Section 1.7.1.3) may interfere with the determination of 25(OH)D,
especially in HPLC and LC-MS/MS assays. LC-MS/MS is dependent on monitoring mass transitions and
LC-MS/MS methods are unable to differentiate coeluting isomeric compounds with identical elemental
composition but different structure. This has led to the overestimation of serum 25(OH)D
concentrations. Thus, LC columns capable of providing sufﬁcient chromatographic selectivity prior to
MS identiﬁcation must be employed (Bailey et al., 2013). As this problem has been recognised, many
LC-MS/MS laboratories now apply this latter approach (e.g. (Singh et al., 2006; Gallo et al., 2014a;
Kiely et al., 2017)).
The C3-epimer may not interfere with the determination of serum 25(OH)D concentration in most,
but not all, immunoassays (Bailey et al., 2013), but there may be other metabolites that do so, as
reported by Gallo et al. (2014a).
1.8.6.3. Analytical methods for measuring serum 25(OH)D: conclusions
The Panel considers that all analytical methods available to measure serum 25(OH)D concentration
in infants have uncertainties. The Panel considers that, if enough data are available, the analytical
method used to measure serum 25(OH)D concentration should be considered in the dose–response
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analysis between vitamin D intake and serum 25(OH)D concentration for the assessment of a UL for
vitamin D in infants (Section 3.5 and Annex A).
The Panel notes that the concentration of 3-epi-25(OH)D should be considered when interpreting
serum 25(OH)D concentrations of young infants in the ﬁrst 3 months of life: otherwise, the vitamin D
status may be erroneously classiﬁed as sufﬁcient due to a high proportion of 3-epi-25(OH)D in total
25(OH)D determination (Singh et al., 2006). Older LC-MS/MS methods may have overestimated serum
25(OH)D concentration in the ﬁrst 3 months of life because they were also measuring the C3-epimer,
whereas newer LC-MS/MS methods have accounted for this. Some immunoassay methods do not
detect the C3-epimer while others do.
1.8.7. Conclusion on serum 25(OH)D concentration as a biomarker for vitamin D
The Panel considers that serum 25(OH)D concentration is an accepted biomarker of vitamin D
intake in populations with low exposure to UV-B irradiation and of vitamin D status at population level
(EFSA NDA Panel, 2016). Serum 25(OH)D concentration in infants can be inﬂuenced by vitamin D
intake, form and frequency of consumption, baseline serum 25(OH)D concentration, sun exposure,
season, body mass (or age) and body fat, maternal characteristics during pregnancy and lactation, in
particular maternal supplementation with vitamin D. Factors such as the form of vitamin D (D2 or D3)
or the analytical method should be considered in the dose–response analysis between vitamin D intake
and serum 25(OH)D concentration for the assessment of an UL for vitamin D in infants if enough data
are available (Sections 3.5 and 7 and Annex A).
1.9. Proposed mechanisms of toxicity of vitamin D
Mechanisms of toxicity of vitamin D were summarised previously (EFSA NDA Panel, 2012a; SACN,
2016).
Various studies in adults and children indicate that ingestion of large doses of vitamin D (e.g.
125–1,000 lg/day over a period of at least 1 month results in an increase in the serum concentration
of 25(OH)D, while that of the active metabolite 1,25(OH)2D is unchanged (Jones, 2008) or even
reduced (IOM, 2011).
Some hypotheses for mechanisms of toxicity have been proposed. The presence of elevated serum-
free 1,25(OH)2D concentration despite normal total 1,25(OH)2D suggests that, in states of vitamin D
toxicity, 1,25(OH)2D is displaced from DBP by 25(OH)D or other metabolites, and that this could
promote entry of free 1,25(OH)2D into target cells where it could stimulate gene transcription (Pettifor
et al., 1995; SACN, 2016). It has also been suggested that serum 25(OH)D concentrations exceed
DBP binding capacity; thus, free 25(OH)D enters the cell and has direct effects on gene expression
(SACN, 2016).
As mentioned before (Section 1.7.2), the principal function of 1,25(OH)2D is to maintain calcium
and phosphorus homoeostasis. Under normal conditions, serum calcium is tightly regulated. Serum
calcium concentrations are detected by surface calcium-sensing receptors found in parathyroid and the
clear cells of the thyroid glands, kidney, intestine, bone marrow and other tissues. ‘Long-term’
ingestion of ‘large’ doses of vitamin D results in disturbance of calcium homoeostasis.
Excessive vitamin D intake leading to ‘very high’ serum 25(OH)D concentrations may lead to
hypercalcaemia (Vieth, 1990; Pettifor et al., 1995; Holick, 2006a). An epidemic of infantile
hypercalcaemia was observed in the UK in the 1950s when foods including those for infants provided
up to 100 lg/day. The reported incidence of hypercalcaemia in infants declined when vitamin D
content in these foods was reduced (Fraser, 1967; SCF, 2003). An increase in serum calcium
concentration inhibits PTH release and stimulates calcitonin release, which, in infants and children, is a
principal defence against hypercalcaemia (Weaver and Heaney, 2014). The clinical manifestations
associated with hypercalcaemia can include fatigue, muscular weakness, anorexia, nausea, vomiting,
constipation, tachyarrhythmia; soft tissue calciﬁcation; failure to thrive; polyuria, osteolysis,
dehydration and weight loss (Debre, 1948). A study in the 1930s suggested retarded linear growth in
infants who received 45–113 lg vitamin D daily (Jeans and Stearns, 1938) (Section 1.4). Soft tissue
calciﬁcation due to excessive intake of vitamin D and associated hypercalcaemia is found especially in
kidneys, the heart and arterial tissues with subsequent effects on function (Peng and Taylor, 1980).
Kidney function is affected because high concentrations of calcium (in the serum then ﬁltered in the
urine) alter the antidiuretic action of vasopressin on the renal tubules. The net result is reduced
urinary concentration ability which usually presents as polyuria. Hypercalciuria is one of the earliest
signs of vitamin D toxicity and precedes the occurrence of hypercalcaemia. The initial hypercalciuria
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may be ameliorated as renal failure progresses because of reduced calcium clearance. When reduced
renal blood ﬂow occurs, less calcium is presented to the renal glomerulus and hypercalcaemia can
rapidly progress (Cusano et al., 2011).
Consequences of sustained hypercalcaemia and hypercalciuria are nephrolithiasis (kidney stones),
nephrocalcinosis and a decrease in kidney function (Ronnefarth and Misselwitz, 2000; EFSA NDA Panel,
2012a,b). Mortality from hypercalcaemia itself is rare.
The Panel notes that vitamin D toxicity resulting from ‘long-term’ ingestion of ‘large’ doses of
vitamin D is associated with an increase in the serum concentration of 25(OH)D and some other
vitamin D metabolites but usually not of the active metabolite 1,25(OH)2D. Some hypotheses for
mechanisms of toxicity have been proposed. The presence of elevated serum-free 1,25(OH)2D
concentration despite normal total 1,25(OH)2D suggests that, in states of vitamin D toxicity, 1,25
(OH)2D is displaced from DBP by 25(OH)D or other metabolites, and that this could promote entry of
free 1,25(OH)2D into target cells where it could stimulate gene transcription. Disturbances of calcium
homoeostasis are also observed.
1.10. Hazard identiﬁcation: adverse health outcomes and endpoints
associated with excessive vitamin D intake in infants
The most suitable adverse health outcomes and endpoints regarding hypervitaminosis D in infants
were identiﬁed and selected by the Panel, considering those listed in previous assessments on ULs
(SCF, 2003; IOM, 2011; EFSA NDA Panel, 2012a; COT, 2015) (Section 1.4) and based on Section 1.9
and expert knowledge.
The Panel focussed on the following four outcomes to inform the setting of a UL for vitamin D in
infants: hypercalciuria, hypercalcaemia, ectopic calciﬁcation, e.g. nephrocalcinosis, and abnormal
growth patterns.
Taking into account the previous assessment for the setting of AIs for vitamin D (EFSA NDA Panel,
2016) (Section 1.4), which was derived in particular from the dose–response relationship between total
vitamin D intake and serum 25(OH)D concentration, the Panel also focussed on serum 25(OH)D
concentration to inform the setting of a UL. Excessive vitamin D intakes are reﬂected by increasing
serum 25(OH)D concentrations that are associated with an increased risk for the above-mentioned
adverse health outcomes. Increased serum 25(OH)D concentrations may therefore indicate a
hazardous vitamin D intake before this results in clinically manifest adverse health outcomes.
Other possible signs/symptoms of hypervitaminosis D may be, e.g. gastrointestinal symptoms
(anorexia, vomiting, abdominal pain, colic, constipation), polyuria and neurologic symptoms (loss of
consciousness), but they are not speciﬁc to hypervitaminosis D. The Panel did not consider them
among the primary outcomes and endpoints for this assessment.
The Panel selected the following adverse health outcomes and endpoints for this scientiﬁc
opinion on infants: hypercalciuria/urinary calcium, hypercalcaemia/serum calcium, ectopic calciﬁcation,
e.g. nephrocalcinosis, abnormal growth/anthropometric parameters, serum 25(OH)D concentration.
2. Data and methodologies
The following guidance documents of EFSA and SCF were taken into account by the Panel:
 Guidelines of the Scientiﬁc Committee on Food for the development of ULs for vitamins and
minerals (SCF, 2000);
 Guidance of EFSA Scientiﬁc Committee on the risk assessment of substances present in food
intended for infants below 16 weeks of age (EFSA Scientiﬁc Committee et al., 2017b);
 Guidance of EFSA Scientiﬁc Committee on the use of the benchmark dose approach in risk
assessment (EFSA Scientiﬁc Committee et al., 2009);
 Updated guidance on the use of the benchmark dose approach in risk assessment (EFSA
Scientiﬁc Committee et al., 2017a);
 Guidance of EFSA on the application of systematic review methodology to food and feed safety
assessments to support decision making (EFSA, 2010).
As mentioned in Section 1.3, the Panel undertook a systematic literature review. The
approach for this review is described in Sections 3.1 and 3.2 and the results of the identiﬁed papers
are described in Sections 3.3 and 3.5 (quantitative dose–response analysis).
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The Panel undertook an assessment of the intake of vitamin D by infants, based on data
available in EFSA (Section 4).
With the objective of comparing the outcome of the intake assessment undertaken by EFSA
(Section 4) with other available data, data were collected either from published studies or reports
from national authorities, or through a consultation of Member States (MS) via e-mail undertaken
by the European Commission.21 From this search, data or contributions discussing aspects within the
remit of this scientiﬁc opinion (e.g. ‘high’ vitamin D intake in infants, composition data of infant foods)
are presented in Sections 4.1.1 and 4.2.1.
3. Assessment of adverse effects of excess intake of vitamin D in
infants (hazard characterisation)
The strategy and methodology for the assessment of possible relationships between vitamin D
intake and adverse health outcomes in infants, including dose–response relationship(s) between
vitamin D intake and biomarker(s) where applicable, was deﬁned upfront by the Panel. The steps
described below were applied in line with this deﬁnition.
3.1. Daily vitamin D intake and adverse health outcomes in infants:
EFSA’s extensive literature search
3.1.1. Literature search: sources and forms of vitamin D
In line with the remit of this assessment, the systematic literature search dealt with daily vitamin D
intake (i.e. vitamin D2 or D3) from all dietary sources, including fortiﬁed foods and dietary
supplements. The Panel excluded data on administration modes other than the oral route.
3.1.2. Literature search: target population
In line with the remit of this assessment, the literature search dealt with full-term22 healthy infants,
up to 12 months of age, either breastfed or fed orally with a standard IF or FoF, and possibly receiving
complementary foods.
For this assessment, the Panel decided not to set speciﬁc ULs for subgroups of the infant
population on the basis of, e.g. ethnicity or environmental conditions (e.g. higher or lower exposure to
the sun).
3.1.3. Literature search: eligibility criteria
Eligibility criteria for this assessment include criteria related to the characteristics of the literature
(report characteristics) and criteria related to study characteristics and study population.
English, German and French were the selected languages and no limit on publication date was
applied to the search. The criterion related to language derives from a mapping of the 34 different
languages of the literature search in Embase using the proposed search strings (Appendix A). English
was by far the most frequent language (4,450 hits), followed by a similar number of hits in French and
German (162 and 161 hits, respectively). The choice of these three languages is a proposed trade-off
between the aim for completeness and time constraints.
Primary research papers published in scientiﬁc journals were selected. Thus, other publication types
were excluded: expert opinions, editorials, position statements, guidelines, articles from the popular
media, abstracts, conference proceedings, protocols, PhD theses, letters to the editor, narrative or
systematic reviews.
Experimental and observational studies (retrospective or prospective cohort or case–control) in
humans were selected by the Panel. Detailed information on the initial eligibility criteria on study
characteristics and study populations is available in Appendix B. In particular, preclinical studies
(animals, in vitro, in silico data) can produce valuable knowledge, e.g. on mechanisms, but
extrapolation of these data to infants is subject to uncertainties; thus, they were excluded. In addition,
the Panel focussed on oral daily vitamin D consumption (alone or not), and, for trials, doses above
10 lg/day, which corresponds to the AI for vitamin D for infants (EFSA NDA Panel, 2016). Both
vitamin D forms (vitamin D2 and vitamin D3) were considered as well as studies on ‘vitamin D’
21 EFSA wishes to acknowledge all Member State bodies that provided data on vitamin D through this consultation.
22 Full-term infants are deﬁned as infants born at or after the 37th week of gestation.
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(unspeciﬁed), but studies/arms on vitamin D metabolites were excluded. Studies/arms using bolus/
weekly/monthly doses, and case reports, were excluded from the further steps of the literature search,
but identiﬁed separately for possible qualitative consideration in the scientiﬁc opinion (Section 3.4). No
speciﬁc eligibility criterion on assessment methods, e.g. method to measure vitamin D intake or serum
25(OH)D concentration, was applied. Even though carefully collected 24 h urine would be the
preferred method for the measurement of calcium excretion (Section 3.3.2), this is difﬁcult in infants;
therefore, other types of urine collection (e.g. spot urine) were considered. Based on previous work
(Brouwer-Brolsma et al., 2016; EFSA NDA Panel, 2016), no speciﬁc eligibility criterion on latitude or
country was applied.
Study populations composed only of ill infants were excluded from this assessment because the
relationship between vitamin D intake and health outcomes in these infants may be affected by the
disease and/or medication used. An exception to this is infants with vitamin D deﬁciency rickets
undergoing treatment, possibly receiving high vitamin D doses: it was initially considered that these
studies might provide useful information for setting a UL for healthy infants. However, after a
preliminary statistical analysis of the selected studies as described in Section 3.5, an amendment to
the predeﬁned methodology was agreed and the two papers (Seino et al., 1981; Emel et al., 2012)
that comprised subjects with vitamin D deﬁciency rickets were excluded by the Panel.
3.1.4. Literature search: bibliographic databases and search strategies
Three databases were searched: Embase, Pubmed and Cochrane.23 Embase and PubMed were
considered as the leading databases for biomedical sciences, Cochrane Library is a source for
systematic reviews and RCTs of human health care interventions. These databases were identiﬁed in
line with the deﬁned scope of the review, based also on the EFSA inventory of information sources,24
and in line with the approach of the comprehensive literature search provided by an external
contractor to EFSA as supporting evidence for a previous assessment on AIs for vitamin D (Brouwer-
Brolsma et al., 2016).
Speciﬁc search strategies were created by the information specialist of EFSA. Date of search per
database, search strategies and related number of hits are indicated in Appendix C.
3.1.5. Literature search: study selection
Inclusion of papers in the assessment was undertaken through a title and abstract then full text
screening, based on the identiﬁed eligibility criteria (Section 3.1.3 and Appendix B).
At title and abstract screening, all papers proposed for inclusion by a ﬁrst reviewer went to full text
screening directly. However, all those proposed for exclusion by the ﬁrst reviewer required the
agreement of a second reviewer for exclusion. In case of doubt, papers were moved to full-text
screening.
Full-text screening was done in duplicate: if two reviewers agreed to exclude a paper, it was
excluded from the further steps; if two reviewers agreed to include a paper, it was included for the
further steps; possible divergences between the reviewers or doubts were discussed with the experts.
During the screening phase, reviewers took note of the availability of data related to information on
the mothers of the infants investigated (e.g. supplementation in pregnancy, level of education, parity),
sun exposure, season of birth or of study or skin type. This was done for possible further qualitative
discussion, as the Panel expected the number of studies mentioning these aspects to be limited (thus,
for statistical reasons, these parameters could not be considered as covariates at the step of the
quantitative analysis).
3.1.6. Literature search: included studies after the study selection process
Among the 25 papers ﬁnally included, some contained two or three studies, yielding 31 studies to
go through data extraction and appraisal. The ﬂow chart in Appendix E reports the results of the
different phases of the study selection process.
23 Dates covered by each database: 1946 to present (Pubmed), 1947 to present (Embase), inception to present (Cochrane).
24 www.metaxis.com/EFSAINVENTORY
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3.1.7. Data extraction and check of the dataset
The list of parameters to be extracted was predeﬁned (Appendix D). Data expressed only in
graphs/curves/ﬁgures were identiﬁed as such. Numerical outcomes were extracted as expressed in the
papers, e.g. absolute values or changes, percentage changes between time points, and with the unit
used in the papers. The data set was created for all time points investigated in the studies selected
after screening and was checked by a different reviewer to correct mistakes.
3.1.8. Transformation of numerical values after data extraction
EFSA applied a series of transformations to the data in order to:
 Harmonise the measurement unit used in the various studies,
o age of infants and duration of supplementation were converted into weeks,25
o values for the intake of vitamin D were converted into lg (1 IU = 0.025 lg),
o length/height measurements were converted to cm,
o for calcium, the molecular mass of 40.1 g/mol was considered,
o serum concentrations of 25(OH)D were converted to nmol/L (1 ng/mL = 2.5 nmol/L).
 Transform changes from baseline to absolute values.
 Convert values of body length, weight, head circumference expressed in z-scores according to
the growth standards of WHO Multicentre Growth Reference Study Group (2006) back to the
original values. As these WHO standards are age- and sex-speciﬁc, the gender-speciﬁc values
after transformation were averaged assuming an equal proportion of both sexes.
 Transform mean and standard deviation into a ln-transformed scale where appropriate. A
moment-based approach as described by Higgins et al. (2008) was used.
 Average data when given separately by gender (Ziegler et al., 2014).
When cut-off values for hypercalciuria are discussed (Section 3.3.2), for ease of reading, ratios of
urinary calcium/creatinine were converted to mmol/mmol by using the respective molecular masses of
40 and 113 g/mol.
3.2. Daily vitamin D intake and adverse health outcomes in infants:
appraisal of the included studies
3.2.1. Appraisal: risk of bias tool and methodology to assess the internal and
external validity
The methodology for the assessment of the internal26 and external27 validity of the selected papers
was deﬁned upfront. For the appraisal of internal validity, the risk of bias (RoB) of each individual
included study was appraised using the Ofﬁce of Health Assessment and Translation/National
Toxicology Program (OHAT/NTP) RoB tool.28 The use of the tool was limited to the aspects relevant to
clinical trials (randomised and not, controlled and not) and prospective observational studies (cohort
and case–control) in humans. The tool was structured in six bias domains (selection, confounding,
performance, attrition/exclusion, detection and selective reporting), plus ‘other sources of bias’ (e.g.
inappropriate statistical methods) (Appendix F).
As a trade-off between methodological requirements and time constraints, judgements were made
by applying a two-level rating scale:
 low RoB: there was direct or indirect evidence of low RoB practices OR it was deemed that
deviations from low RoB practices for these criteria during the study would not appreciably bias
results
 high RoB: there was direct or indirect evidence of high RoB practices OR there was insufﬁcient
information provided on the study conduct in order to exclude high RoB practices.
25 1 day = 1/7 week and 1 month = 4.33 weeks.
26 The ability of a study to provide an unbiased estimate of the true value of the parameter(s) that the study is intended to
estimate.
27 The extent to which external bias is minimised in the studies, and the results are generalisable to the assessment question.
28 https://ntp.niehs.nih.gov/ntp/ohat/pubs/riskofbiastool_508.pdf
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Although the indication of the expected direction of the bias is useful (i.e. the true effect is
underestimated/overestimated/biased in both directions), this was not deemed mandatory for this
assessment.
For each paper selected, the appraisal of internal validity was done at outcome level for the RoB
that are outcome-dependent, because, for the same study, the design and conduct may affect the risk
of bias differently depending on the outcomes measured. If the available information was unclear (e.g.
simple mention of randomisation without further details), the more conservative judgement was
selected (i.e. high RoB). Selected papers in English and German were appraised in duplicate,29 and
possible discrepancies were discussed collegially. The results of the appraisal of the internal validity per
bias domain, selected paper and health outcome/endpoint are presented in Appendices G–K.
After pilot testing of the tool, the Panel decided to appraise the RoB related to external validity on
the overall body of evidence (and not per paper) (Section 3.3.1).
3.2.2. Appraisal: deﬁnition of the risk of bias tiers per outcome
An overall judgement on the RoB was reached, resulting in each paper being allocated to a tier of
RoB by health outcome/endpoint. This information can be read vertically, i.e. for each paper, in the
tables in Appendices G–K. This was based ﬁrst on the deﬁnition of three key domains: randomisation
(for trials) or confounding factors (for observational studies), exposure characterisation (assessment of
vitamin D intake), outcome assessment. Then, for each outcome, each study was assigned to a tier of
RoB deﬁned as follows:
 Tier 1 (low overall RoB): no high RoB in key domains and at least 50% domains with low RoB.
 Tier 2 (medium overall RoB): one or more high RoB in key domains and at least 50% domains
with Low RoB.
 Tier 3 (high overall RoB): one or more high RoB in key domains and less 50% domains with
Low RoB.
This means that the same study could be in different tiers of RoB according to the health outcome/
endpoint considered: for example, the paper by Gallo et al. (2013a) was included in tier 1 of RoB for
hypercalciuria/urinary calcium, or hypercalcaemia/serum calcium, and tier 2 for serum 25(OH)D
concentration.
3.2.3. Appraisal: potential confounders and modiﬁers
The Panel identiﬁed a priori a preliminary list of potential confounders30 and/or modiﬁers31 that
could affect the relationship between vitamin D intake and health outcomes (Figure 1). Such a list was
useful for the appraisal as well as for discussion of potential covariates for the statistical analysis
(Section 3.5 and Annex A).
29 Taking into account the mother tongue of the reviewers, papers in French were not assessed in duplicate. The question
related to statistical aspects was not assessed in duplicate either.
30 Confounding occurs when a factor is associated with both the exposure and the outcome but does not lie on the causative
pathway. Confounding factors need to be eliminated to prevent distortion of association.
31 A modiﬁer occurs when exposure has a different effect among different subgroups. Effect modiﬁcation is associated with the
outcome but not the exposure.
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For this assessment:
• Maternal characteristics could be considered as confounders for all outcomes of interest, e.g.
level of education, income, age, adolescent vs. adult mothers.
• Type of feeding of the infants, frequency of vitamin D supplementation and health status of
the infants (e.g. healthy or infants with vitamin D deﬁciency rickets under treatment) could be
considered as confounders or modiﬁers (on a case-by-case basis), for all outcomes of interest.
• Genotype was considered as a possible modiﬁer for all outcomes of interest (not reported in
any of the selected papers).
• Calcium intake/supplementation of the infants was considered as a possible modiﬁer in
particular for serum calcium/urinary calcium of the infants.
• For serum 25(OH)D concentration of the infants, the list of possible modiﬁers included
vitamin D exposure of the infants before the start of the study; season of study; season of
birth; sunlight exposure of the infant (or time spent outdoors); latitude (as a proxy for sun
exposure); skin type (e.g. ethnicity, skin sensitivity, Fitzpatrick categorisation); baseline serum
25(OH)D concentration at the start of the study (for trials); characteristics of the mother, e.g.
supplementation of vitamin D during pregnancy, health or vitamin D status or dietary intakes
during pregnancy, sun exposure of the mothers, sunlight-related behaviour (e.g. use of
sunscreen, time spent outdoors etc.). Age of the infants was initially not considered as a
confounder/modiﬁer for the blood/urinary parameters; however, after discussing the available
evidence (Sections 1.8.4 and 3.5 and Annex A), the inﬂuence of body mass, which was highly
correlated to age, was investigated for serum 25(OH)D concentration (and ﬁnally, age was
considered in the dose–response analysis).
Figure 1: Confounders and modiﬁers
UL of vitamin D for infants
www.efsa.europa.eu/efsajournal 27 EFSA Journal 2018;16(8):5365
• For abnormal growth and anthropometric parameters, the list included length and head
circumference at birth (in case of preterm infants) (modiﬁer), height of the parents (in relation
to height of the child) (modiﬁer), for retrospective cohort studies (if any) infections/health
status (e.g. healthy or with vitamin D deﬁciency rickets) (modiﬁer), maternal smoking
(modiﬁer), the sex of the infants (confounder or modiﬁer on a case-by-case basis), birth
weight of the infants (confounder or modiﬁer on a case-by-case basis). For studies on mixed
populations of term and preterm infants (without results reported separately for each of these
subpopulations): length of gestation may have an inﬂuence on the growth pattern. However,
for studies on exclusively full-term infants, length of gestation was not expected to have an
impact on the outcomes of interest for this assessment.
If randomisation was appraised as acceptable for a selected trial, the potential confounders were
not considered as being an issue. In its appraisal of the RoB of the 25 selected publications, the
Panel considered that 16 were at high RoB with regard to randomisation (for randomised trials) or
adequate comparison groups (non-randomised trials, prospective cohort studies) (Appendices G–K).
3.2.4. Appraisal: sources of uncertainty in the intake of vitamin D in the included
studies
3.2.4.1. Appraisal: criterion used to appraise the risk of bias for the included studies
For the appraisal of the exposure characterisation (intake of vitamin D), the Panel decided to focus
on whether or not the included studies mention an analytical check of the actual vitamin D content of
the supplement or fortiﬁed food consumed. Where such a check was absent, there is a risk of under-
or overestimation of the actual vitamin D content. The exposure characterisation was generally
considered by the Panel to be of high RoB, i.e. 19 publications out of 25 selected (Appendices G–K).
3.2.4.2. Other sources of uncertainty in the assessment of the intake in the included
studies
• Compliance in trials (risk of overestimation of the actual vitamin D intake in case of limited
compliance). This information was extracted from the selected papers (Appendix D).
• Type of infant feeding at inclusion: included studies may be undertaken on infants that are all
exclusively breastfed, or all exclusively formula-fed, or who receive, e.g. breast milk and
formula and possibly complementary feeding (Section 1.6). This information was extracted
from the selected papers (Appendix D). In general, mean vitamin D concentrations in breast
milk of healthy lactating women, unsupplemented or supplemented with vitamin D below the
UL, are low (Section 1.6). Hence, the amount of vitamin D provided by breast milk in
exclusively breastfed infants in addition to the supplements provided in a given study might be
considered to be negligible.
• Background vitamin D intake in trials: if this intake is not reported, there is a risk of
underestimation of the actual total intake of vitamin D. This information was extracted from
the selected papers (Appendix D); however, it was absent in most of them. In particular,
among the papers included in the statistical analysis (Holst-Gemeiner et al., 1978; Gordon
et al., 2008; Holmlund-Suila et al., 2012; Gallo et al., 2013a; Grant et al., 2014; Ziegler et al.,
2014) (Section 3.5 and Annex A), only one (Gallo et al., 2013a) assessed background
vitamin D intake.
• Forms of supplemental vitamin D provided: supplements as tablets/pills, supplements as drops
(as they may be more difﬁcult to count), supplements (unspeciﬁed form), formula or any other
fortiﬁed food/meal. This information was extracted from the selected papers.
3.2.5. Appraisal: sources of uncertainty in the assessment of the outcomes/
endpoints in the included studies
3.2.5.1. Appraisal: outcome assessments with generally low risk of bias (RoB)
For hypercalciuria/urinary calcium:
Measurement of urinary calcium (as concentration or ratio over creatinine) is standard hospital
practice, so the RoB for this assessment was considered to be low for the publications that
investigated this outcome. This can be seen when reading horizontally across the table on the
appraisal of the internal validity presented in Appendix G. However, deﬁnition of hypercalciuria may
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differ according to authors/laboratories. Different methods of urine collection (24 h vs. one or more
spot samples, number of collection days, complete or incomplete urine collection, etc.) may also
prevent direct comparisons between studies (Section 3.3.2.1).
For hypercalcaemia/serum calcium:
Measurement of serum calcium concentration is standard hospital practice, so the RoB for this
assessment was considered to be low for the selected publications that investigated this outcome. This
can be seen when reading horizontally across the table on the appraisal of the internal validity in
Appendix H. However, deﬁnition of hypercalcaemia may differ according to authors/laboratories
(Section 3.3.3.1).
For nephrocalcinosis/ectopic calciﬁcation:
There is no standardised diagnostic criterion for nephrocalcinosis from the ultrasound image, i.e.
interpreting whether the observed spots are calciﬁcations or just noise on the image depends on the
skills of the radiologist/paediatrician involved in the studies. The RoB for this assessment was
considered to be low (Appendix I).
3.2.5.2. Appraisal: outcome assessment with low or high risk of bias (growth/
anthropometric parameters)
For results reported as z-scores, growth references or standards may be different according to
studies, preventing direct comparison of the results. However, the included papers for which z-scores
were extracted all used the WHO growth standards (Gallo et al., 2013a, 2016).
In addition, length/height or weight may be measured by the investigators or self-reported by the
parents, and the method of measurement may or may not be described in the papers with or without
an indication of repeated measurements (e.g. for head circumference of an infant, repeated
measurements with a non-elastic band are indicative of a better measurement quality).
This information was extracted from the studies (Appendix D), and taken into account in the
appraisal process, four publications were considered of high RoB for this outcome (Appendix J).
3.2.5.3. Appraisal: outcome assessment with generally high risk of bias (serum 25(OH)D)
All analytical methods available to measure serum 25(OH)D concentration in infants have
uncertainties (Section 1.8.6) and ‘high’ serum 25(OH)D concentration may have been deﬁned
differently by the authors of some of the included studies (e.g. as a stopping rule for the assessment
of supplementation safety). Information on analytical method(s) for 25(OH)D measurements, possible
deﬁnition of ‘high’ serum 25(OH)D concentration by the authors and the presence or absence of an
external quality control/standardisation were extracted (Appendix D). The Panel considered that the
issues related to the possible lack of external quality control and standardisation (Section 1.8.6.1) are
important for measurement of serum 25(OH)D concentration. Thus, the RoB for this assessment was
appraised as high for 19 publications that investigated this outcome (Appendix K).
3.3. Results of the included studies on daily intake of vitamin D in
infants
This assessment is based on the body of evidence obtained from the extensive literature search
performed by the EFSA (Section 3.1), i.e. studies in infants considering a daily intake of vitamin D (at
least in one arm). For the reasons described in the following sections for each outcome/endpoint, the
Panel decided to:
 meta-analyse collected data on the dose–response relationship between daily vitamin D
supplemental intake and serum 25(OH)D concentration using quantitative models (Section 3.5
and Annex A), in order to predict the expected population mean responses and individual
responses.
 whenever possible, to show graphically in forest plots or numerically in tables, the collected
data on daily vitamin D supplemental intake and the other measurements (i.e. total and ionised
serum calcium, urinary calcium/creatinine ratio, weight, length/height) and summarise
narratively (by tiers of RoB, study type and publication date) the study results (Sections 3.3.2
to 3.3.6).
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In addition, arms/studies with results not provided in relation to vitamin D intake were excluded
from the dose–response analysis or graphical representations (e.g. in the study by Pittard et al.
(1991), serum total and ionised calcium and body weight were reported by time point only and not by
dose).
The Panel was aware of a large systematic review on clinical trials in children (0–18 years), either
healthy or not, that were selected on the basis of a ‘high’ supplement dose of vitamin D used, deﬁned
as a value (daily or not) above the DRV set by the IOM for infants and children (no dose limit for low
birth weight and premature neonates) (Nama et al., 2016). The inclusion and exclusion criteria applied
for this systematic review (undertaken for a large age range of children) are close, although not
identical, to those applied by the Panel for this assessment on infants. Considering trials identiﬁed by
Nama et al. (2016) in healthy neonates or infants receiving daily doses of vitamin D above the DRV set
by the IOM, the Panel notes that 14 papers are in common with the literature selected by the
Panel (four additional trials being discussed by the Panel).
3.3.1. Characteristics of the included studies used for the assessment (body of
evidence)
Of 31 studies from 25 papers identiﬁed after the literature screening, 24 were trials (of different
designs) and 7 were prospective studies (Table 1). As mentioned in Section 3.1.3, two papers (three
studies) that comprised subjects with vitamin D deﬁciency rickets were excluded after a preliminary
statistical analysis.
For serum 25(OH)D concentration, among these 31 studies, 74 arms from trials were available,
related to different supplementation doses and corresponding to 223 measurements,32 some of which
were repeated measurements on the same study arm at different time points (Table 1).
Table 2 describes, in the 31 selected studies, the frequency of the assessment of the outcomes/
endpoints considered relevant for this scientiﬁc opinion. Data for hypercalcaemia, hypercalciuria,
abnormal growth patterns/anthropometric parameters and nephrocalcinosis are reported in italics.
Concentrations of serum 25(OH)D and total calcium were the endpoints most frequently measured
(87% and 74%, respectively), followed by anthropometric measurements (particularly body weight
and length/height).
For hypercalcaemia, hypercalciuria and ‘high’ serum 25(OH)D concentration, cut-off values used for
the diagnosis may change depending on the laboratory and the analytical methods applied. In the
following sections, in line with a previous assessment (EFSA NDA Panel, 2012a), the occurrence of
adverse health outcomes will be deﬁned according to the cut-off selected by the authors in each
individual study (Table 2). More information on the use of these cut-offs in the context of the studies
(e.g. age of the infant population to which they were applied) are reported in the following sections.
Table 1: Frequency distribution by study design among the included studies
Study frequency distribution by study design
Design Absolute frequency Relative frequency (%)
RCT 14 45
RNCT 3 10
NRCT 3 10
NRNCT 4 13
PROSP 7 22
TOTAL 31 100
ARMS 74
TIME POINTS 223
RCT: randomised controlled trial; RNCT: randomised non-controlled trial; NRCT: non-randomised controlled trial; NRNCT: non-
randomised non-controlled trial; PROSP: prospective study.
32 The count of the (intermediate and ﬁnal) time-points above does not include observations taken at the start of the studies
(later used as baseline serum 25(OH)D concentrations in the dose-response analysis, Section 3.5 and Annex A).
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Studies on exclusively breast- and formula-fed infants were equally frequent (Table 3), and the
most frequent studies were those including infants receiving mixed feeding (e.g. partial breastfeeding
or partial formula-feeding with complementary feeding).
Of the 31 studies, 19 clearly indicated that the included subjects were all full term (while the
remaining 12 did not give a clear indication on this aspect).
Regarding the source of vitamin D, this was most often supplements in an unspeciﬁed form (11 of
25 papers), then supplements as drops (10 papers), tablet/pills (two papers), a fortiﬁed formula
(one paper) and one paper reporting on a study that used both a supplement (unspeciﬁed) and a
fortiﬁed formula. Most often, the form of vitamin D (vitamer) used was vitamin D3 (13 studies of 31)
or was not mentioned (10 studies of 31), and a limited number of studies used vitamin D2 (7 of 31) or
both vitamers (1 study). The highest dose considered among the selected studies was 50 lg/day. Only
8 studies of 31 provided information on the background vitamin D intake. Supplementation duration
and age of the infants were variable, ranging from some days up to age of 1 year.
A large range of countries, thus of latitudes, was also considered (Austria, Canada, Germany,
Finland, France, Gabon, Japan, New Zealand, Poland, Switzerland, Turkey, USA).
Information on the mothers (e.g. supplementation in pregnancy, level of education) was available
for 18 of 25 papers), on sun exposure for 6 of 25 papers, on season of birth (10 of 25 papers), on
season of study (15 of 25 papers), or on skin type or pigmentation (10 of 25 papers). As anticipated
(Section 3.1.5), this information was not provided in all selected papers and, where provided, the level
of detail was variable.
The Panel notes the variability in the design of the studies selected after the literature search. The
Panel also considers that the diversity of the infant population supports the external validity of the
selected studies.
Table 2: Frequency of assessed outcomes/endpoints (possible multiple outcomes/endpoints per
study) in the included studies
Outcome
Number of
studies
% of
studies
Deﬁnition used by authors
Urinary calcium 2 6
Urinary calcium/creatinine ratio 8 26
Hypercalciuria 4 13 0.8 calcium/creatinine ratio(mg/mg)
2.2 calcium/creatinine ratio (mmol/
mmol)
Serum 25(OH)D 27 87 For ‘high’ serum 25(OH)D:
150, 250 nmol/L;
60, 100 ng/mL
Serum total calcium 23 74
Serum ionised calcium 4 13
Hypercalcaemia 7 23 2.6 mmol/L; 11.2 mg/dL
Nephrocalcinosis 2 6 Number of infants
Body weight 12 39
Length/height 12 39
Head circumference 4 13
Abnormal growth patterns/anthropometric
parameters
3 10 Number of infants
Table 3: Frequency distribution by feeding type of the included infants at the start of the studies
Type of feeding at inclusion in the studies Number of studies % of studies
Exclusively breastfed 6 19
Exclusively formula-fed 6 19
Mixed feeding 13 42
Not reported 2 7
Unclear 4 13
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3.3.2. Assessment of data on hypercalciuria
Hypercalciuria was discussed as an outcome in four studies reported in three publications (Czech-
Kowalska et al., 2012; Holmlund-Suila et al., 2012; Gallo et al., 2013a). Details of study designs are
given in Appendix L. Among the studies in which urinary calcium was measured, irrespective of
whether hypercalciuria was observed or not, ﬁve studies mentioned urinary calcium/creatinine ratio,
which were rated tier 1 (Gallo et al., 2013a), 2 (Czech-Kowalska et al., 2012; Holmlund-Suila et al.,
2012) or 3 for this outcome (Hoppe et al., 1997; Siafarikas et al., 2011).
3.3.2.1. Hypercalciuria: deﬁnitions
Hypercalciuria has been deﬁned based on urinary calcium concentration (mmol or mg per L and/or
per kg body weight per day). Whilst most authors agree that the upper limit of calcium excretion in
urine of healthy subjects is 4 mg/kg body weight per day, both in adults (Heaney et al., 1999; Curhan
et al., 2001; Chandhoke, 2007; Jones et al., 2010; Jones AN et al., 2012)) and in children (Ghazali and
Barratt, 1974; Ring and Borkenstein, 1987; Dumas, 1997; Tekin et al., 1997; Audran and Legrand,
2000; Leslie and Taneja, 2017), the applicability of deﬁnitions for adult hypercalciuria particularly to
infants is less clear. From the value of 4 mg/kg body weight per day, the other widely accepted
deﬁnitions for men (> 275 mg/day) and women (> 250 mg/day) are derived (Chandhoke, 2007)
(Leslie and Taneja, 2017), or alternatively a calcium concentration > 200 mg/L (or 5 mmol/L) in a 24 h
urine collection (Leslie and Taneja, 2017).
Although ideally the diagnosis of hypercalciuria should be based on the measurement of urinary
calcium excretion in 24 h urine, this is difﬁcult to apply in infants for practical reasons. Thus, the ratio
of calcium over creatinine (Ca/Cr) in a random or timed urine sample has been considered to deﬁne
thresholds for hypercalciuria, and random urinary Ca/Cr ratio is used as a standard hospital practice.
Most authors agree that a urinary Ca/Cr ratio (mg/mg) of 0.2–0.25 (or 0.56–0.70 mmol/mmol) is the
upper limit of a normal range in adults and children above 2 years of age (Ring and Borkenstein, 1987;
Sargent et al., 1993; Dumas, 1997; Matos et al., 1997; Tekin et al., 1997; Koyun et al., 2007; Jones
et al., 2010; Arrabal-Polo et al., 2016; Leslie and Taneja, 2017). Urinary Ca/Cr ratios are higher in infancy
and decrease with age (EFSA NDA Panel, 2012b; Gallo et al., 2014b). In randomly collected urine
samples, urinary Ca/Cr ratios of 0.9, 0.6, 0.42 and 0.22 (mg/mg) (or 2.5, 1.7, 1.2, 0.62 mmol/mmol)
have been reported for ages < 7 months, 7–18 months, 19 months to 6 years and adults, respectively
(Sargent et al., 1993).
The Panel notes that the gold standard for diagnosing hypercalciuria is the analysis of calcium in
a 24h urine, from which the calcium excretion per kg body weight per day can be calculated. An
increased urinary Ca/Cr ratio in a single urine sample can raise suspicion of hypercalciuria, but needs
conﬁrmation by repeated measurements and preferably by the measurement of the urinary calcium
excretion over 24 hours.
3.3.2.2. Hypercalciuria: studies from risk of bias tier 1
Gallo et al. (2013a) (Section 1.8.1) investigated the impact of vitamin D3 supplementation on serum
25(OH)D concentrations (dose–response), different health outcomes and side effects in 132 healthy
initially breastfed infants. From 1 to 12 months of age, the infants were randomly assigned to receive
one of the following vitamin D intervention (VIDI) groups: 10 lg/day (n = 39), 20 lg/day (n = 39),
30 lg/day (n = 38) or 40 lg/day (n = 16). Dietary intake of vitamin D was assessed by the volume of
breast milk consumed and by 3-day dietary records, whereas the endogenous synthesis of the vitamin
was estimated by %BSA exposed to sunlight on a weekly basis. Infants were monitored for safety
outcomes related to calcium homoeostasis including the urinary Ca/Cr ratio (in 4-h urine collection) at
baseline, at 2, 3, 6, 9 and 12 months of age. Urinary Ca/Cr ratios progressively declined with infant
growth. ‘Suspected hypercalciuria’ (urinary Ca/Cr ratio > 3.3 (mmol/mmol), above the hospital
reference range) was found in one child from each of the groups treated with 20, 30 and 40 lg/day;
however, all the subsequent safety checks (electrocardiogram and renal ultrasound) were normal.
3.3.2.3. Hypercalciuria: studies from risk of bias tier 2
Holmlund-Suila et al. (2012) (Section 1.8.1) conducted a double-blind dose–response RCT aiming at
determining the daily dose of vitamin D3 required to achieve serum 25(OH)D concentrations of 80 nmol/L
or above in breastfed infants without any signs of side effects. Term infants with adequate for gestational
age birth weight (n = 113) were recruited at age 2 weeks and were randomised to receive for 10 weeks
vitamin D3 at 10, 30 or 40 lg/day. Urinary Ca/Cr ratio in spot urine samples was analysed at the end of
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the intervention (when the infants were 3 months old) and did not show differences between
intervention groups. Hypercalciuria (deﬁned as urinary Ca/Cr ratio > 2.2 mmol/mmol) was found in 39%
of all participants.33 Individual urinary Ca/Cr ratios were reported for infants who had serum 25(OH)D
concentrations > 150 nmol/L (range 150–230 nmol/L) and ranged from 0.31 to 6.34 mmol/mmol.
The Panel notes that the prevalence of hypercalciuria was similar between groups. In addition, the
potential impact of differences in the feeding of infants was not taken into consideration in the analysis
and the duration of the study was comparatively short (10 weeks), which limits the ability of this
investigation to provide reliable evidence on the safety aspects of the tested levels of vitamin D intake.
Czech-Kowalska et al. (2012) followed prospectively 30 term infants with hypovitaminosis D
(baseline serum 25(OH)D concentration < 50 nmol/L) for 10 weeks from age 15 days to 94 days.
Infants were supplemented with vitamin D3 at a median intake of about 14 lg/day (median total
intake of about 18 lg/day from food and supplements).34 Infants were separated into deﬁcient
(baseline serum 25(OH)D concentration < 28 nmol/L) and insufﬁcient (baseline serum 25(OH)D
concentration 28–50 nmol/L), but data were reported for the combined group. Vitamin D and calcium
status parameters were analysed at baseline and at the end of the study. Compared with baseline,
serum 25(OH)D concentrations were six times higher at the end of the intervention (from 21.1 nmol/L
to 136.5 nmol/L). Urinary Ca/Cr ratios, measured in spot urine samples, were similar at the two time
points; however, hypercalciuria, deﬁned as urinary Ca/Cr ratio > 0.8 mg/mg (2.27 mmol/mmol35), was
found in seven infants (three of these infants had serum 25(OH)D > 150 nmol/L and one had serum
25(OH)D > 200 nmol/L) at the end of the investigation. The Panel notes that the lack of a control
group limits the value of this investigation.
3.3.2.4. Hypercalciuria: studies from risk of bias tier 3
Siafarikas et al. (2011) conducted a trial in 40 newborns who were randomised into equal groups to
receive vitamin D3 at 6.25 lg/day or 12.5 lg/day from birth until the age of 6 weeks. All infants were
breastfed and, in order to take into account the differences in sun exposure, half of the infants
completed the study during autumn/winter whereas the other half did the study during spring/summer.
There were no signiﬁcant differences in urinary calcium concentrations in spot urine samples and
urinary Ca/Cr ratios between the two groups both at baseline and at the end of the intervention. It
was unknown whether there were any cases of hypercalciuria within the two groups of infants. The
Panel notes that this is a short study and the levels of vitamin D supplementation used for intervention
were close to the AI of 10 lg/day for infants (EFSA NDA Panel, 2016); thus, side effects cannot be
expected.
Hoppe et al. (1997) followed prospectively 37 term infants from days 1 to 60 of age. Infants were
fed with unfortiﬁed breast milk (n = 16) or formula (n = 21) and received vitamin D3 supplements of
12.5 lg/day, and urinary Ca/Cr ratios were measured in spot urine samples. The Panel notes that it
was unknown whether there were any cases of hypercalciuria among the infants; however, the level of
vitamin D supplementation used was close to the AI of 10 lg/day for infants (EFSA NDA Panel, 2016);
thus, side effects cannot be expected. In addition, the infants were fed with different formulae with
unknown content of vitamin D, which does not allow calculation of the total daily intake of the vitamin
for this group.
3.3.2.5. Daily intake of vitamin D and mean urinary calcium/creatinine ratio in infants
Appendix M, showing data from the studies described in the previous sections, provides no
evidence of a dose–response relationship between vitamin D supplemental intake over the range of
doses tested and mean urinary Ca/Cr ratios.
3.3.2.6. Hypercalciuria: conclusion
The Panel notes that most of these studies were short-term interventions of a small scale and
none of them measured urinary calcium excretion over 24 hours. Although one study reported several
cases of hypercalciuria in a group of infants with vitamin D intake of about 20 lg/day (Czech-Kowalska
et al., 2012), the two RCTs which tested multiple vitamin D doses between 10 and 40 lg/day
(Holmlund-Suila et al., 2012; Gallo et al., 2013a) did not ﬁnd signiﬁcant differences in the prevalence
of hypercalciuria as deﬁned by the authors between vitamin D doses. The Panel also notes that these
33 No obvious difference in the prevalence of hypercalciuria between the three groups can be seen in Figure 3 of this paper.
34 P25–P75 intake: about 12.5–17 lg/day from supplements, about 13.5–20 µg/day from food including supplements.
35 Considering that 1 mg Ca/ L = 0.025 mmol Ca/L and that 1 mg creatinine/L = 0.0088 mmol creatinine/L.
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RCTs which involved a higher number of participants, provided inconsistent results with considerable
discrepancies in the rate of hypercalciuria (from 3–6% to 39%), and the urinary Ca/Cr ratios were not
related to the administered dose of vitamin D in any of these investigations.
The Panel considers that these studies are not informative for determining the association
between vitamin D supplemental doses and the risk of hypercalciuria.
3.3.3. Assessment of data on hypercalcaemia
Hypercalcaemia or ‘high’ serum calcium was reported as an outcome in eight studies reported in six
publications (Vervel et al., 1997; Czech-Kowalska et al., 2012; Holmlund-Suila et al., 2012; Gallo et al.,
2013a; Grant et al., 2014; Ziegler et al., 2014). Details of study design are given in Appendix L.
3.3.3.1. Hypercalcaemia: deﬁnitions
Hypercalcaemia or ‘high’ serum calcium is deﬁned based on serum total calcium concentration and/or
ionised calcium concentration. Measurement of serum calcium concentration is standard hospital
practice. However, the cut-off used to deﬁne hypercalcaemia or ‘high’ serum calcium may differ
according to the laboratory or author. Hypercalcaemia has been deﬁned as serum calcium concentration
above 2.75 mmol/L (EFSA NDA Panel, 2012a,b) or ionised calcium above 1.35 mmol/L (SCF, 2003).
However, reported serum calcium values differ by age, and the reported 97.5th centile for infants
< 12 months is higher than in adults, varying between 2.75 and 3.00 mmol/L (Gallo et al., 2014b).
Gallo et al. (2014b) measured a number of plasma and urinary analytes in 132 healthy, term,
breastfed infants participating in a vitamin D supplementation trial (Gallo et al., 2013a) (Sections 1.8.1
and 3.3.2.2). Results were not reported per group but per age in months; thus, this paper was not
among the studies included after the extensive systematic review (Section 3.1). However, it provides
additional information, as its purpose was to deﬁne reference values for analytes in blood and urine.
Ionised and total calcium in serum declined signiﬁcantly between 1 and 12 months (median values
from 1.40 to 1.33 mmol/L and from 2.53 to 2.47 mmol/L for ionised calcium and total calcium,
respectively), while serum creatinine increased signiﬁcantly. Ionised calcium was elevated at 1 month,
with a range (1.29–1.52 mmol/L) exceeding the upper limits for adults (1.15–1.29 mmol/L, Radiometer
America®). Despite the decrease over time, 25% of infants still exceeded the 97.5th centile of reference
ranges at 12 months. Similarly, total calcium concentrations were elevated compared to reference data
for older children, with about 25% of infants over the upper adult/child limits (2.23–2.58 mmol/L,
Beckman Coulter®). The decline in total calcium occurred later than that in ionised calcium. However,
clinical safety evaluations (e.g. for signs of hypercalcaemia) were normal.
The reference range for ionised calcium also differs according to the method used and there are no
agreed reference ranges for infants. Valkama et al. (2017) reported ionised calcium concentrations in
762 infants of the VIDI study, using reference ranges from the Finnish HUSLAb laboratory36 (< 4 days
1.05–1.5 mmol/L pH 7.4; 1–30 days 1.1–1.4 mmol/L pH 7.4; 1–12 months 1.16–1.39 mmol/L pH 7.4).
They observed a marked decrease in the prevalence of ‘mild hypercalcaemia’, deﬁned as up to 10%
above the upper limit for age, from 6 to 12 months. Higher ionised calcium concentrations were
associated with female sex and younger age. They concluded that it was uncertain whether these
mildly elevated values represented ‘true’ hypercalcaemia or rather ‘false’ reference values. Only 4 of
the 762 infants (0.5%) had both mild hypercalcaemia and subnormal PTH concurrently at 12 months,
and most of the infants had normal PTH, suggesting that these mildly elevated ionised calcium
concentrations were physiological and not clinically relevant.
The Panel notes that the available data suggest that both total and ionised calcium
concentrations may be higher in infants compared to older children and adults, and that it is not
possible to deﬁne a clear cut-off for hypercalcaemia. In the discussion of the following publications,
the deﬁnition of hypercalcaemia used by the authors, generally based on a ‘high’ serum calcium
concentration, are reported. However, the Panel notes that as serum calcium is tightly regulated
(Section 1.9), single measurements of serum calcium, which are generally reported in the following
publications, may not provide an indication of the risk of sustained elevated serum calcium (indicative
of hypercalcaemia per se).
36 http://www.hus.fi/en/medical-care/laboratory/Pages/default.aspx
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3.3.3.2. Hypercalcaemia: studies from risk of bias tier 1
Gallo et al. (2013a) (Sections 1.8.1 and 3.3.2.2) randomised healthy breastfed infants to receive
daily doses of vitamin D3 between 10 and 40 lg from 1 to 12 months. ‘Suspected hypercalcaemia’ was
based on serum-ionised calcium concentration above the hospital reference range (1.15–1.38 nmol/L)
and was reported in 0, 2, 2 and 2 infants in each of the study groups, respectively. However,
electrocardiograms and renal ultrasound in these suspected cases revealed no abnormalities.
Ziegler et al. (2014) conducted an RCT on healthy breastfed infants randomised to receive 5 (n = 56),
10 (n = 60), 15 (n = 56) or 20 (n = 41) lg vitamin D/day from 28 days to 9 months of age. Calcium
concentrations > 12.0 mg/100 mL (3 mmol/L) were observed on one occasion with 5 lg/day, on four
occasions with 10 lg/day, on three occasions with 15 lg/day and on three occasions with 20 lg/day.
The rationale for this cut-off was not provided and it was not referred to as ‘high serum calcium’ or as
‘hypercalcaemia’ by the authors, although in the discussion, they comment that there was no risk of
hypercalcaemia even with 20 lg/day. No relationship could be derived between serum 25(OH)D
concentration and risk of hypercalcaemia.
3.3.3.3. Hypercalcaemia: studies from risk of bias tier 2
Holmlund-Suila et al. (2012) randomised healthy breastfed infants to receive daily doses of
vitamin D3 between 10 and 40 lg/day from 2 weeks to 3 months of age (Sections 1.8.1 and 3.3.2.3).
Mean serum calcium concentration did not differ between groups and there was no correlation
between serum calcium and 25(OH)D concentrations. Individual serum calcium concentrations were
reported for infants who had serum 25(OH)D > 150 nmol/L (range: 150–230 nmol/L) and ranged from
2.44 to 2.78 mmol/L (3 being above 2.75 mmol/L). No infant developed hypercalcaemia, which in this
study was assessed based on symptoms (nausea, vomiting, poor feeding or prolonged constipation)
rather than deﬁned by serum calcium concentration.
Czech-Kowalska et al. (2012) studied prospectively 30 term infants with baseline serum 25(OH)D
concentration < 50 nmol/L receiving vitamin D3 supplements (median total intake of about 18 lg/day)
(Section 3.3.2.3). Although no deﬁnition was provided, the authors reported that none of the infants
had ‘hypercalcaemia’ after 10 weeks.
Grant et al. (2014) conducted an RCT investigating daily supplementation of pregnant women
(from 27 weeks of gestation to birth) and their infants (from birth to 6 months; 95% breastfed at
birth) with placebo (n = 87) or vitamin D3 at 25 lg to the mother/10 lg to the infant (n = 87) or
50 lg to the mother/20 lg to the infant (n = 86). Hypercalcaemia, deﬁned as a serum total calcium
concentration above 11.2 mg/dL (2.8 mmol/L), was not reported in any infant, including ﬁve infants
with serum 25(OH)D concentration > 250 nmol/L at 2 months.
3.3.3.4. Hypercalcaemia: studies from risk of bias tier 3
Vervel et al. (1997) (Section 1.4) conducted an RCT to measure serum 25(OH)D concentration at 1
(n = 70) and 3 months (n = 52) in infants born to mothers with or without vitamin D supplementation
during pregnancy (Section 1.4). Infants were fed vitamin D fortiﬁed milk and randomised to receive
either 12.5 lg or 25 lg D2 per day. Mean serum total calcium concentrations did not differ between
groups at 1 and 3 months of age. Serum calcium concentrations at 3 months ranged from 2.42 to
2.80 mmol/L in infants who received 12.5 lg/day in addition to fortiﬁed IF and from 2.46 to
2.79 mmol/L in those supplemented with 25 lg/day. Among infants from unsupplemented mothers,37
the percentage of infants with serum calcium concentration > 2.60 mmol/L was 15% and 50% in the
25 lg D2 group at 1 and 3 months, compared to 36% and 60% of the 12.5 lg D2 group. However,
the choice of this cut-off of 2.60 mmol/L was not justiﬁed by the authors and it was not deﬁned by
them as ‘hypercalcaemia’.
3.3.3.5. Hypercalcaemia: other data
One additional publication mentioned hypercalcaemia in the discussion section, but it was not
described or deﬁned in the methods or results. Gordon et al. (2008) (rated as tier 1 for serum calcium,
Sections 1.4 and 1.8.2) randomised 40 infants and young children aged 8–24 months with
hypovitaminosis D (serum 25(OH)D concentration < 50 nmol/L) to 50 lg/day vitamin D2 or D3 for
6 weeks. A higher overall incidence of ‘mild hypercalcaemia’ (not deﬁned) was reported at baseline in
37 % Infants from supplemented women above 2.60 mmol/L: in the 25 µg group, 14 % at 3 months (19% at 1 month); in the
12.5 µg group, 25 % at 3 months (17 % at 1 month).
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contrast to at the end of the study, possibly related to vitamin D insufﬁciency (hypovitaminosis). All
subjects were reported to be asymptomatic, and there was no statistically signiﬁcant correlation
between the presence of ‘mild hypercalcaemia’ at baseline and after each intervention.
One study presented data on serum ionised calcium but did not deﬁne or discuss hypercalcaemia.
In the study by Pittard et al. (1991) in term infants supplemented with vitamin D at 10 (n = 11) or
20 lg/day (n = 5), serum total and ionised calcium at eight time points from 0 to 16 weeks of age
were reported as 2.2–2.4 mmol/L and 1.2–1.4 mmol/L, respectively. However, the values were not
reported in relation to the dose of vitamin D (some infants received 10 or 20 lg of vitamin D daily,
others received 0.85 or 1.5 lg 25(OH)D3).
The Panel notes that two papers published after the end of the period of the systematic literature
search (Section 3.1) reported ﬁrst the results of a preliminary analysis (Valkama et al., 2017)
(Section 3.3.3.1), then the ﬁnal analysis from the VIDI study (published after the end of the public
consultation on this opinion) (Rosendahl et al., 2018). The incidence of hypercalcaemia was evaluated
in 987 eligible healthy infants who randomly received 10 or 30 lg of vitamin D3 supplements daily
from age 2 weeks to 24 months (762 included in Valkama et al. (2017); 12 infants were excluded after
randomisation, leaving 489 and 486 in the 10 or 30 lg group, respectively, in Rosendahl et al.
(2018)). At birth, about 95% of the infants had serum 25(OH)D concentration above 50 nmol/L.
Hypercalcaemia was deﬁned by the authors as ionised calcium above 1.39 mmol/L at 6 and 12 months
(Section 3.3.3.1) and above 1.35 mmol/L at 24 months. ‘Severe hypercalcaemia’ was deﬁned as
ionised calcium above 1.53 mmol/L (10% higher than the upper limit of the reference range) at 6 and
12 months and above 1.48 mmol/L at 24 months. In cases of ‘severe hypercalcaemia’, serum 25(OH)D
and calcium concentrations would be measured again, and symptoms indicative of hypercalcaemia
would be investigated. Mean ionised calcium concentrations did not differ between groups. Numbers
(%) of subjects with calcium concentrations above the value deﬁning hypercalcaemia were 121 (27%)
and 124 (28%) at age 6 months in the 10 lg and 30 lg group, respectively, 6 (1%) and 10 (2%) at
age 12 months and 27 (7%) and 32 (9%) at age 24 months. No ‘severe hypercalcaemia’ occurred and
no clinical signs suggestive of hypercalcaemia were reported. The Panel notes that this RCT had the
longest duration of daily vitamin D supplementation in infants and young children.
3.3.3.6. Daily intake of vitamin D and mean serum total calcium concentration in infants
Mean serum total calcium concentration was reported as an outcome in ﬁve RCTs (Gordon et al.,
2008; Holmlund-Suila et al., 2012; Gallo et al., 2013a; Grant et al., 2014; Ziegler et al., 2014) and one
observational study (Czech-Kowalska et al., 2012) (tiers 1 or 2) previously described. It was also
measured in eight studies assessed as tier 3 (Pincus et al., 1954; Fomon et al., 1966; Ala-Houhala,
1985; Pittard et al., 1991; Vervel et al., 1997; Zeghoud et al., 1997; Nguema-Asseko et al., 2005;
Siafarikas et al., 2011). Details of study design are given in Appendix L; a brief description of the
studies is provided below for those not already discussed. Data on serum calcium were also reported
by Hazell et al. (2017) in a 3-year follow-up of subjects from the study by Gallo et al. (2013a).
However, the Panel considered that the 3-year time interval was too long for these measurements to
indicate an effect of vitamin D intake during infancy on serum calcium.
Ala-Houhala (1985) (Section 1.4) studied 100 healthy mother-term infant pairs during summer and
winter and measured serum calcium and 25(OH)D concentrations. All infants were exclusively breastfed
and subjects were randomly allocated to three supplementation strategies: a maternal supplement of
25 lg/day or an infant supplement of 10 lg or 25 lg/day. Fomon et al. (1966) (Section 1.4) measured
serum calcium at monthly intervals in healthy term male infants. The infants received formula feeding
providing vitamin D at around (i) 45 lg/day (n = 13) or (ii) 11 lg/day (n = 11) or (iii) were breastfed and
additionally obtained a single formula feeding together with a supplement which accounted to a total
daily vitamin D intake of approximately 7.5 lg (n = 26). Pincus et al. (1954) measured serum calcium on
days 1 and 5 of life in healthy term infants divided into ﬁve groups: breastfed with 15 lg (n = 13) vitamin
D/day vs. no supplement (n = 15); fed formula without vitamin D plus either 15 lg (n = 30) vitamin D
supplement per day or no supplement (n = 46); fed formula containing 10 lg vitamin D/day (n = 52).
Nguema-Asseko et al. (2005) measured serum calcium at birth, 3 and 6 months in healthy term infants
from Gabon. All infants were exclusively breastfed until 3 months and were assigned to receive vitamin D
at 25 lg/day (n = 41) vs. no supplement (n = 38). Siafarikas et al. (2011) measured serum calcium at
delivery and 6 weeks of age in 40 healthy term breastfed infants, randomised to either 6.25 lg or
12.5 lg vitamin D3/day (Section 3.3.2.4). Zeghoud et al. (1997) measured serum calcium in 80 healthy
term infants 3–6 days after delivery; repeated samples were obtained from 52 formula-fed infants who
received either 12.5 or 25 lg vitamin D2/day at 1 and 3 months of age.
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Data on mean serum total calcium from the studies appraised as tier 1 or 2 are shown in a forest
plot (Figure 2). The Panel concludes that this forest plot does not suggest any clear trend between
vitamin D intake ranging from 5 to 50 lg/day or infant age and mean serum total calcium
concentration. Data on mean serum total calcium according to different doses of vitamin D from the
studies appraised as tier 3 are shown in Appendix N. The Panel concludes that these studies do not
provide useful information with respect to the deﬁnition of a UL for vitamin D.
*Vitamin D3 **Vitamin D2
CI: conﬁdence interval; D: vitamin D dose (lg/day).
Values for trials (NRCT: non-randomised controlled trial; NRNCT: non-randomised non-controlled trial; RCT:
randomised controlled trial; RNCT: randomised non-controlled trial) and prospective studies (PROSP) are indicated
separately.
Age: age of the infants in weeks (rounded). Calcium concentrations at baseline are not shown. Measurements
before 6 months of age (blue) or after 6 months of age (green).
Figure 2: Forest plot of total calcium in serum for studies from tiers 1 and 2 for the RoB
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3.3.3.7. Daily intake of vitamin D and mean serum ionised calcium concentration in
infants
The RCT by Gallo et al. (2013a) described above (tier 1) provides data on daily vitamin D intake
and mean serum concentrations of ionised calcium (Appendix O), in infants who were randomised to
receive vitamin D supplements of 10, 20, 30 or 40 lg/day. The data show no dose–response
relationship between vitamin D supplemental intake and mean ionised calcium concentrations,
although concentrations were lower in older infants, as reported by Gallo et al. (2014b) in line with
Valkama et al. (2017).
3.3.3.8. Hypercalcaemia: conclusion
The Panel concludes that the available data on the relationship between vitamin D intake and
‘high serum calcium’ or ‘hypercalcaemia’ have a number of limitations which make interpretation
problematic, including variable quality as indicated by the risk of bias assessments. The Panel notes
that as serum calcium is tightly regulated (Section 1.9), single measurements of serum calcium, often
reported in the discussed publications, may not provide an indication of the risk of sustained elevated
serum calcium (indicative of hypercalcaemia per se).
Among the publications providing data on these outcomes, one did not observe hypercalcaemia but
did not provide any deﬁnition (Czech-Kowalska et al., 2012), three (Vervel et al., 1997; Grant et al.,
2014; Ziegler et al., 2014) used a cut-off for total calcium in serum (2.8, 2.6 or 3.0 mmol/L), but only
the one (Grant et al., 2014) used it to deﬁne hypercalcaemia, one diagnosed hypercalcaemia based on
symptoms (Holmlund-Suila et al., 2012) and two (in three publications) diagnosed hypercalcaemia
based on a serum-ionised calcium above the upper limit for a hospital range (Gallo et al., 2013a;
Valkama et al., 2017; Rosendahl et al., 2018). One study referred to ‘mild’ hypercalcaemia in the
discussion only without providing deﬁnition (Gordon et al., 2008), and a further study presented data
on ionised calcium (Pittard et al., 1991), but did not discuss or deﬁne hypercalcaemia. No clinical signs
suggestive of hypercalcaemia were reported in healthy infants receiving up to 40 lg vitamin D/day (for
2.5 months or 11 months), including infants with serum 25(OH)D concentrations above 150 or
250 nmol/L. One study in infants with baseline serum 25(OH)D < 50 nmol/L who received 50 lg/day
reported no cases with symptoms of ‘hypercalcaemia’ (Gordon et al., 2008). The evaluated studies do
not provide an indication of a clear relationship between vitamin D intake and risk of hypercalcaemia.
The forest plot (Figure 2) and table (Appendix N) also provided no evidence of a dose–response
relationship between vitamin D supplemental intake over the range of doses tested and mean serum
total calcium. The single study included from the systematic literature search (Gallo et al., 2013a)
reporting mean serum concentration of ionised calcium in infants receiving different vitamin D
supplements also showed no indication of a dose–response relationship (Appendix O).
The Panel considers that these studies are not informative for determining the association
between vitamin D supplemental doses and the risk of hypercalcaemia.
3.3.4. Assessment of data on ectopic calciﬁcation (e.g. nephrocalcinosis)
Nephrocalcinosis was discussed as an outcome only in one study, which was rated tier 3 of RoB for
this outcome (Hoppe et al., 1997). It was also checked in Gallo et al. (2013a) (tier 1 for urinary and
serum calcium, and anthropometric parameters, tier 2 for serum 25(OH)D concentration). Details of
the study design are given in Appendix L.
3.3.4.1. Ectopic calciﬁcation, e.g. nephrocalcinosis: deﬁnition
Calcinosis is a chronic disease condition, whilst calciﬁcation can be acute and may even be
reversible. Nephrocalcinosis is one manifestation of ectopic calciﬁcation; besides nephrocalcinosis,
other calcium depositions can be observed in skin, adipose tissue and blood vessels of very severely ill
infants.
3.3.4.2. Nephrocalcinosis: available studies
Hoppe et al. (1997) studied prospectively 37-term infants from days 1 to 60 of age, fed with
unfortiﬁed breast milk or formulae and supplemented daily with 12.5 lg vitamin D3 (Section 3.3.2.4).
Renal ultrasonography conducted in 26 infants did not ﬁnd nephrocalcinosis. The Panel also notes that
the dose was close to the AI of 10 lg/day (EFSA NDA Panel, 2016) and the period of intervention was
short; therefore, nephrocalcinosis could not be expected.
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In the RCT by Gallo et al. (2013a) (Sections 1, 3.3.2 and 3.3.3), infants were supplemented with
vitamin D3 doses between 10 and 40 lg/day from 1 to 12 months. Infants with ‘suspected
hypercalciuria’ or ‘suspected hypercalcaemia’ underwent renal ultrasound and electrocardiogram in a
secondary analysis, but no abnormalities were detected.
3.3.4.3. Nephrocalcinosis: conclusion
The Panel notes that only two studies monitored the risk of developing nephrocalcinosis as a result
of vitamin D supplementation with a dose up to 40 lg/day and did not ﬁnd any cases of
nephrocalcinosis. The Panel notes that, in one of these studies, the supplemental vitamin D intake was
close to the AI (total daily intake unknown) and the duration of the study was short.
The Panel considers that these studies are not informative for determining the association
between vitamin D supplemental doses and the risk of nephrocalcinosis.
3.3.5. Assessment of data on abnormal growth patterns
Eleven papers discussed abnormal growth patterns and/or anthropometric parameters (Fomon
et al., 1966; Pittard et al., 1991; Nguema-Asseko et al., 2005; Hypp€onen et al., 2011; Siafarikas et al.,
2011; Czech-Kowalska et al., 2012; Holmlund-Suila et al., 2012; Gallo et al., 2013a, 2016; Ziegler
et al., 2014; Hazell et al., 2017) (all tiers). Details of study design are given in Appendix L and tiers of
RoB for all studies are indicated below.
3.3.5.1. Abnormal growth patterns: deﬁnition
Various anthropometric measurements such as weight, length/height, head circumference and their
respective z-scores have been used to assess growth in studies on vitamin D intake. Abnormal growth
is typically deﬁned as growth rate outside the normal range (3rd–97th centile) of the standard WHO
growth curves for boys and girls or z-scores of below -2 or above +2.
Some of the available studies presented changes of anthropometric measurements or z-scores
between different time points, which can be considered as growth. However, others have expressed
the results in absolute values of attained weight/length/head circumference, which cannot be
considered characteristics of growth, but these measurements might be still informative for
discrimination of the effects of different doses of vitamin D.
3.3.5.2. Abnormal growth patterns: studies measuring growth
In the RCT by Gallo et al. (2013a) (tier 1) (Sections 1, 3.3.2, 3.3.3 and 3.3.4), infants were
supplemented with vitamin D3 doses between 10 and 40 lg/day from 1 to 12 months. Weight, length
and head circumference were measured and the respective z-scores were evaluated at baseline
(1 month of age) and at 2, 3, 6, 9 and 12 months of age. The growth of all the infants participating in
the trial was within the normal rate and there were no signiﬁcant differences between groups in the
growth parameters at any of the investigated time points. There was, however, a signiﬁcant attrition in
the highest dose group. The participants in this study were followed further at the age of 3 years and
the z-scores of height for age or weight for age did not show any signiﬁcant differences among the
vitamin D groups (Gallo et al., 2016; Hazell et al., 2017) (tier 1).
Ziegler et al. (2014) (tier 1) (Section 3.3.3.2) randomised healthy breastfed infants to four groups
supplemented with vitamin D between 5 and 20 lg/day from the age of 28 days to 9 months. Weight
and length gain from 1 to 4 months and from 4 to 9 months were not signiﬁcantly different between
groups in each sex.
Holmlund-Suila et al. (2012) (tier 2) (Sections 1.8.1, 3.3.2 and 3.3.3) randomised breastfed infants
to receive vitamin D3 doses between 10 and 40 lg/day from 2 weeks to 3 months of age. Weight,
length, head circumference, length of left tibia, circumference of the left calf and their changes before
and after intervention (both sexes assessed together) did not show signiﬁcant difference among
groups.
Fomon et al. (1966) (tier 3) (Sections 1.4 and 3.3.3.6) followed 50 healthy full-term male infants
receiving either formulae with different vitamin D content or breast milk plus formulae and supplement
from 9 days until 168 days of age. The rates of length and weight gain of the different feeding groups
were similar at all time points of the investigation. The Panel notes that this is a non-randomised
investigation based on a small number of infants only of male sex, which limits the generalisability of
its results.
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3.3.5.3. Studies measuring attained weight/height/head circumference
Hypp€onen et al. (2011) (tier 3) analysed the link between vitamin D supplementation in infancy and
the attained height in childhood and early adulthood in 10,060 participants of the Northern Finland
Birth Cohort study. Data on vitamin D dose in infancy (< 50 lg/day, 50 lg/day or > 50 lg/day) and
frequency of supplement usage (none, irregular or regular) were obtained when the children were
1-year old whereas information for body height as well as various relevant confounders was collected
at ages 1 year, 14 years and 31 years. The study did not ﬁnd a signiﬁcant association between the
dose or frequency of vitamin D supplement use and the height of participants at the three different
time points after adjustment for multiple confounders. The Panel notes the high RoB due to the fact
that a large proportion of the data on height, vitamin D supplement use and various confounders was
based on self-reporting.
Nguema-Asseko et al. (2005) (tier 3) (Section 3.3.3.6) measured similar weight, length and head
circumference in infants in Gabon in the supplemented (25 lg/day of vitamin D) and non-
supplemented groups, at the end of the 3-month intervention.
Pittard et al. (1991) (tier 3) (Section 3.3.3.5) measured the weight of term infants supplemented
with 10 or 20 lg/day from birth to the age of 16 weeks. The postnatal weight gain of all infants
during the study period was consistent with the accepted normal values and both groups grew
normally; however, comparison between groups was not presented.
Siafarikas et al. (2011) (tier 3) (Sections 3.3.2.4 and 3.3.3.6) randomised newborns to receive
either 6.25 or 12.5 lg/day vitamin D3 from birth until the age of 6 weeks. At the end of the
intervention period, weight and length were signiﬁcantly lower in the infants supplemented with
vitamin D at 12.5 lg/day compared with those who received vitamin D at 6.25 lg/day (4,195 vs.
4,768 g, p = 0.02; 56 vs. 58 cm, p = 0.02). The Panel notes that this is a short study and the
intervention dose of vitamin D was close to the AI.
Czech-Kowalska et al. (2012) (tier 3) (Sections 3.3.2.3 and 3.3.3.3) provided vitamin D3
supplements (median total intake of about 18 lg/day) to 30 term infants. Weight and length of the
infants were within the normal range at the age of 15 and 94 days.
Forest plots representing the results on mean attained length and weight in arms receiving different
vitamin D doses in two RCTs (Holmlund-Suila et al., 2012; Gallo et al., 2013a) and two prospective
observational studies (Gallo et al., 2016; Hazell et al., 2017) (tiers 1 and 2) are presented in
Appendix P. The forest plots provide no evidence of a dose–response relationship between vitamin D
supplemental intake over the range of doses tested and mean attained length and weight.
3.3.5.4. Abnormal growth patterns: conclusion
The Panel notes that the results of the studies investigating the association between levels of
vitamin D intake ranging from 6.25 lg/day to over 50 lg/day and growth patterns and/or
anthropometric parameters are consistent between themselves. They do not show any relationship
between vitamin D intake and abnormal growth patterns, and therefore contradict the conclusions of
the early study by Jeans and Stearns (1938) (Section 1.4). Most of the evidence is based on small-
scale observational studies of short duration and/or not primarily designed to investigate this question.
The Panel considers that these studies are not informative for determining the association
between vitamin D supplemental doses and the risk of abnormal growth patterns.
3.3.6. Assessment of data on ‘high’ serum 25(OH)D concentration
‘High’ serum 25(OH)D was reported as an outcome in seven studies from ﬁve publications (Vervel
et al., 1997; Czech-Kowalska et al., 2012; Holmlund-Suila et al., 2012; Gallo et al., 2013a; Grant et al.,
2014), rated as tier 2 except Vervel et al. (1997) rated as tier 3. There were no studies rated tier 1 for
the RoB.
Thirteen studies were not used in the dose–response analysis (Section 3.5 and Annex A), because
they were either trials rated tier 3 for RoB or prospective observational studies. Of these 13 studies,
six trials (Ala-Houhala, 1985; Pittard et al., 1991; Vervel et al., 1997; Zeghoud et al., 1997; Nguema-
Asseko et al., 2005; Siafarikas et al., 2011) and three prospective observational studies (Czech-
Kowalska et al., 2012; Gallo et al., 2016; Hazell et al., 2017) were already discussed in earlier sections.
Three other trials (Ribot, 1981; Kunz et al., 1982; Pehlivan et al., 2003), and one other prospective
observational study (Pludowski et al., 2011) were also excluded from the dose–response analysis.
Details of study design are summarised in Appendix L.
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3.3.6.1. ‘High’ serum 25(OH)D concentration: deﬁnitions from ofﬁcial bodies and medical
societies
Different values have been considered by different authors and expert groups as representing a
‘high’ serum 25(OH)D concentration, generally considering this concentration in relation to symptoms
of vitamin D toxicity, hypercalcaemia or chronic disease outcomes and mortality. The rationale for the
different values selected is summarised below.
The SCF (2003) reported that the ‘upper reference level of 25(OH)D for infants is 130–150 nmol/L’
(Markestad, 1984; Holick, 1999). It considered that 130–150 nmol/L was well below the threshold of
increased risk for hypercalcaemia, which was said to be above 200 nmol/L in adults.
The previous EFSA opinion on the UL for vitamin D highlighted the lack of additional data available
at that time and noted that serum 25(OH)D concentrations associated with hypercalcaemia vary over a
wide range, such that the 25(OH)D concentration in serum cannot be considered a suitable predictor
of hypercalcaemia (EFSA NDA Panel, 2012a). It also indicates that the IOM (2011) considered, among
other data, ‘evidence from observational studies on chronic disease outcomes suggesting an increase
in risk associated with 25(OH)D concentrations above approximately 125–150 nmol/L’, and discusses a
‘U’ or ‘J’-shaped relationship between serum 25(OH)D concentrations and mortality or other chronic
disease outcomes in adults (EFSA NDA Panel, 2012a).
Several epidemiological studies have explored the relationship between serum 25(OH)D
concentration and mortality in adult and elderly populations (Autier and Gandini, 2007; Melamed et al.,
2008; Pilz et al., 2009; Hutchinson et al., 2010; Michaelsson et al., 2010;). The studies generally had
measurements of serum 25(OH)D concentration at a single time point and examined associations
between this measurement and the outcome (e.g. mortality) reported a few years later. Although the
analyses adjusted for potential confounders, they cannot exclude the possibility of residual
confounding or demonstrate causality. Furthermore, the concentrations associated with increased risk
in these studies did not exceed 125 nmol/L and were well below what would be considered to be
‘high’ serum 25(OH)D concentration based on risk of hypercalcaemia or toxicity. The Panel considers
that these data on chronic exposures and outcomes in adults cannot be used to determine what
constitutes a ‘high’ serum 25(OH)D concentration or to inform the setting of an UL for infants,
especially taking into account the relatively short period of exposure to a given amount of vitamin D
during infancy and the generally decreasing intake of vitamin D per kg body weight with age.
The Scientiﬁc Opinion which described how AIs for vitamin D were set (EFSA NDA Panel, 2016),
noted that ‘high serum 25(OH)D concentrations (> 220 nmol/L) may lead to hypercalcaemia, which
may eventually lead to soft tissue calciﬁcation and resultant renal and cardiovascular damage’. One of
the supporting references for this statement itself refers to a study by Heaney et al. (2003), in which
vitamin D3 was administered daily in doses of 0, 25, 125 and 250 lg for approximately 20 weeks
during the winter to 67 healthy men living in Omaha. No change in serum calcium was observed with
a serum 25(OH)D concentration of 220 nmol/L at an oral intake of 250 lg vitamin D3/day.
The Endocrine Society (Holick et al., 2011) stated ‘although it is not known what the safe upper
value for 25(OH)D is for avoiding hypercalcaemia, most studies in children and adults have suggested
that the blood levels need to be above 150 ng/mL [375 nmol/L] before there is any concern. Therefore,
a UL of 100 ng/mL [250 nmol/L] provides a safety margin in reducing risk of hypercalcaemia’.
A global consensus recommendation from 11 international scientiﬁc organisations, 10 of them
paediatric (Munns et al., 2016), also stated that ‘toxicity is deﬁned as hypercalcemia and serum 25
(OH)D > 250 nmol/L with hypercalciuria and suppressed PTH. [. . .] To allow a large safety margin, the
consensus group felt it prudent to use the concentration of 250 nmol/L as the recommended upper
limit of serum 25(OH)D – even if symptomatic toxicity from RCTs has only been reported at levels
> 500 nmol/L’.
The Panel notes the heterogeneity of the values proposed by the scientiﬁc bodies and medical
societies to deﬁne ‘high’ serum 25(OH)D concentration, and that they are not speciﬁcally derived for
infants.
3.3.6.2. ‘High’ serum 25(OH)D concentration: studies from risk of bias tier 2
Holmlund-Suila et al. (2012) randomised breastfed infants to receive vitamin D3 doses between
10–40 lg/day from 2 weeks to 3 months of age (Sections 1, 3.3.2, 3.3.3 and 3.3.5). The authors
deﬁned ‘high’ serum 25(OH)D concentration in this study as > 150 nmol/L measured by automated
chemiluminescence immunoassay (CLIA, which does not recognise the C3-epimer according to Bailey
et al. (2013)). Individual ‘high’ serum 25(OH)D concentration > 150 nmol/L was reported, in 7/35 and
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20/37 infants from the 30 and 40 lg/day groups, respectively. No infant developed hypercalcaemia and
there was no difference in the rate of hypercalciuria between groups. Although the concentration was not
used in this study as ‘high’ serum 25(OH)D concentration, the Panel also notes that some of the infants
(n = 4 out 37) receiving 40 lg/day of vitamin D had 25(OH)D concentrations beyond 200 nmol/L.
Gallo et al. (2013a) (Sections 1, 3.3.2, 3.3.3, 3.3.4 and 3.3.5) supplemented infants with vitamin D3
doses between 10 and 40 lg/day from 1 to 12 months. The authors reported that 15/16 infants in the
40 lg per day group reached the ‘high’ serum 25(OH)D concentration speciﬁed in the stopping rules for
the trial (250 nmol/L at the age of 3 months measured using enzyme-linked immunosorbent assay
(ELISA)) and were subsequently given 10 lg/day. However, no infant was symptomatic and no
abnormalities of growth were observed during the study. Although this analytical method was not used
in this study for the stopping rules concentration, the Panel also notes that, reading on the ﬁgure
reporting the individual curves of serum 25(OH)D concentration measured by LC-MS/MS according to
age in each group, at age 3 months, some of the infants receiving 30 lg/day (n = 3 out 27) and more
infants receiving 40 lg/day (n = 5 out of 13) had serum 25(OH)D concentrations beyond 200 nmol/L.
Grant et al. (2014) (Section 3.3.3.3) randomly supplemented pregnant women daily during
pregnancy and their infants from birth to 6 months (vitamin D3 at 25 lg to the mother/10 lg to the
infant or 50 lg to the mother/20 lg to the infant, compared with placebo). At 2 months, ‘high’ serum
25(OH)D concentration, deﬁned in this study as > 250 nmol/L measured by LC-MS, was reported in
one infant from the 25/10 lg/day group (325 nmol/L) and in four infants from the 50/20 lg/day
group (260, 320, 325, 335 nmol/L). None of these infants had ‘hypercalcaemia’ deﬁned by ‘elevated
serum calcium concentration’ (> 11.2 mg/dL, i.e. 2.8 mmol/L).
Czech-Kowalska et al. (2012) (Sections 3.3.2.3 and 3.3.3.3) studied prospectively 30 term infants
with baseline serum 25(OH)D concentration < 50 nmol/L receiving vitamin D3 supplements (median
total intake of about 18 lg/day). The authors reported data on ‘high’ serum 25(OH)D concentration
for 30 term infants, measured by CLIA. Serum 25(OH)D concentration > 150 nmol/L was reported in
12 infants (40%), of whom ﬁve had 25(OH)D > 200 nmol/L. None of the infants had
hypercalcaemia, and the incidence of hypercalciuria did not differ between infants with ‘normal’ or
‘high’ serum 25(OH)D concentration. Seven infants from the study had hypercalciuria (deﬁned as
urinary Ca/Cr ratio > 0.8 mg/mg, i.e. 2.27 mmol/mmol), of whom three had serum 25(OH)D
concentrations > 150 and 1 > 250 nmol/L.
3.3.6.3. ‘High’ serum 25(OH)D concentration: studies from risk of bias tier 3
Vervel et al. (1997) fed infants (born to mothers with or without vitamin D supplementation during
pregnancy) vitamin D fortiﬁed milk and randomised them to receive daily either 12.5 lg or 25 lg D2
(Sections 1.4 and 3.3.3.4). None of the infants had serum 25(OH)D concentration, measured by
competitive protein-binding assay (CPBA), above the ‘upper limit of observed values in healthy adults’
(100 nmol/L)’, the highest reaching 87.5 nmol/L at 1 month or 92.5 nmol/L at 3 months.
3.3.6.4. ‘High’ serum 25(OH)D concentration: other data
In a preliminary analysis (n = 762 included out of 987 eligible) (Valkama et al., 2017)38 and the
ﬁnal analysis (n = 975 randomised out of 987 eligible) (Rosendahl et al., 2018)39 from the VIDI study
(Sections 3.3.3.1 and 3.3.3.5), serum 25(OH)D concentration was measured using CLIA in infants
randomised to receive either 10 or 30 lg/day vitamin D3 from 2 weeks to 2 years (489 and 486
subjects, respectively). At birth, about 95% of the infants had serum 25(OH)D concentration above
50 nmol/L. Results for the whole study population showed that 18% had serum 25(OH)D
concentration > 125 nmol/L at 12 months, but this was not associated with clinical symptoms
suggestive of hypercalcaemia (Valkama et al., 2017). The numbers (%) of individuals with serum 25
(OH)D concentration above 125 nmol/L were 23 (4.8%) and 19 (4.0%) in cord blood in the 10 and
30 lg group, respectively, and 6 (1.5%) and 130 (32.2%) at 12 months and 13 (3.2%) and 159
(38.8%) at 24 months (Rosendahl et al., 2018). No infant had a concentration greater than 250 nmol/L.
Sharma et al. (2017) reported an increase of subclinical and overt hypervitaminosis D over a 6-year
period (2011–2016) in a hospital setting in India based on 5,527 reports from patients of all ages.
Hypervitaminosis D, deﬁned in this study as serum 25(OH)D concentrations > 250 nmol/L, was found in
4.1% of the patients of whom 2.7% had serum 25(OH)D > 375 nmol/L. Patients aged < 20 years had
signiﬁcantly higher hypervitaminosis D than the older age groups. Serum 25(OH)D concentration had a
38 A paper published after the end of the literature search undertaken by the Panel.
39 A paper published after the end of the public consultation for this opinion.
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signiﬁcant positive correlation with serum calcium concentration (r = 0.212, p < 0.001). Among the
patients with serum 25(OH)D concentration in the categories 250–375 and > 375 nmol/L, 8.11% and
30.5%, respectively, had elevated serum calcium concentration (> 2.55 mmol/L). However, among
patients with serum 25(OH)D concentrations in the categories 75–250 and 50–75 nmol/L, only 0.58%
and 0.1%, respectively, had elevated serum calcium concentration, and no cases of elevated serum
calcium were found in patients with serum 25(OH)D concentrations < 50 nmol/L.
From these papers and those discussed in the previous sections (i.e. Sections 3.3.6.2–3.3.6.4), the
Panel notes that one study (Grant et al., 2014) reported ‘high’ serum 25(OH)D concentration
measured using LC-MS when infants were 2 months of age, which could have included the C3-epimer
(thus leading to a possible overestimation of serum 25(OH)D concentration); the remaining studies
used assays which do not measure the C3-epimer (Bailey et al., 2013).
3.3.6.5. ‘High’ serum 25(OH)D concentration: conclusion
From the previous Sections (Section 3.3.6.2–3.3.6.4) on available data from collected studies on
achieved serum 25(OH)D concentration after (varying levels of) daily vitamin D supplementation in
infants, no clinical symptoms suggestive of hypercalcaemia or abnormal growth were observed in
infants who had serum 25(OH)D concentration above 125, or 150, or 200 or 250 nmol/L (depending
on the study considered).
In the previous sections, the Panel also considered previous assessments of EFSA and other bodies
that discussed ‘high’ serum 25(OH)D concentration (not speciﬁcally for infants). These values range
between 125 and 250 nmol/L. The Panel considers that epidemiological data on chronic exposures
to vitamin D and adverse outcomes in adults cannot be used to determine what constitutes a ‘high’
serum 25(OH)D concentration or to inform the setting of a UL for infants, especially taking into
account the short period of exposure to a given amount of vitamin D during infancy and the
decreasing intake of vitamin D per kg body weight with age. The Panel considers that the evidence
used to deﬁne previously described cut-offs for ‘high’ serum 25(OH)D concentrations is not sufﬁcient to
deﬁne an ‘evidence-based’ value for ‘high’ serum 25(OH)D concentration as a safety cut-off in infants.
However, based on previous opinions/assessments in particular that of the EFSA NDA Panel (2016)
which considered that a concentration above 220 nmol/L may lead to hypercalcaemia (Section 3.3.6.1),
together with available data from infants assessed in this Opinion, the Panel considers that a serum 25
(OH)D concentration of 200 nmol/L or below is unlikely to pose a risk of adverse health outcomes
(hypercalciuria, hypercalcaemia, nephrocalcinosis, abnormal growth) in healthy infants. This should not
be regarded as a cut-off for toxicity but as a conservative value from which a UL could be derived
using a meta-regression analysis on the relationship between daily supplemental vitamin D intake and
serum 25(OH)D concentration (Section 3.5).
3.4. Case reports of vitamin D intoxication and studies using non-daily
doses of vitamin D in infants
3.4.1. Identiﬁcation of papers
During the screening of the literature by EFSA, case reports on at least one of the adverse health
outcomes/endpoints identiﬁed, following vitamin D intake in infants, were not considered for further
data extraction, appraisal and dose–response analysis due to the high RoB. However, reports on
individual cases with a clear identiﬁcation of the ingested dose of vitamin D and of at least one of the
adverse health outcomes/endpoints observed in infants were ﬂagged during the screening, for possible
qualitative consideration in the scientiﬁc opinion, separately from the other included study designs.
Although no requirement on frequency of vitamin D consumption was applied to the search
(Appendix B), the Panel considered that changes in serum or urinary calcium concentrations or serum
25(OH)D concentrations after non-daily or single large doses of vitamin D cannot be directly compared
with those occurring after daily consumption. Thus, while trials on daily doses were selected during the
literature search, for further data extraction, appraisal and quantitative analysis, trials on weekly or
monthly doses, bolus doses or ‘stoss’ prophylaxis were ﬂagged at full-text screening, as for case
reports, for possible qualitative consideration in the scientiﬁc opinion, separately from the other
included study designs (Section 1.8.3). For these study types, the aim of this non-exhaustive data
collection was to possibly identify supportive evidence.
A limited data extraction from case reports and studies using non-daily vitamin D doses was
undertaken, for an easier comparison between papers (Appendix D). Through the literature search,
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116 case reports were identiﬁed, from which several were excluded for diverse reasons, e.g. not on
adverse outcomes in infants, not on vitamin D2 or D3, vitamin D administered to the mother and not
the infant, not in the included languages, not on oral route. The remaining 89, of which the majority
(2/3) were in English, and the rest in German or French, were screened by reviewers, and most of
them were further excluded for diverse reasons (e.g. not in infants, premature infants, not a case
report, vitamin D dose unknown, etc.). Additional case reports were identiﬁed through hand-search.
Through the literature search by EFSA, three studies comparing one arm receiving daily dose with
at least one receiving a non-daily dose were identiﬁed (Holst-Gemeiner et al., 1978; Gordon et al.,
2008; Emel et al., 2012), as well as 18 studies only on non-daily doses (Pietrek et al., 1976; Markestad
et al., 1987; Zeghoud et al., 1994; Cesur et al., 2003; Billoo et al., 2009; Shajari et al., 2009; Shakiba
et al., 2010, 2014; Manaseki-Holland et al., 2012; Mittal et al., 2014; Harnot et al., 2017; Huynh et al.,
2017) were identiﬁed and brieﬂy discussed (Section 1.8.3).
3.4.2. Results of the case reports on vitamin D intoxication in infants
Case reports of hypervitaminosis D – when carefully documented with regard to total daily vitamin
D dose and length of administration/intake as well as appearance of adverse effects – might provide
an indication of the approximate magnitude of vitamin D dose that overwhelms the homoeostatic
control mechanisms in infants. Cases of prolonged daily consumption of vitamin D can be stratiﬁed
according to dose, e.g. a group 1 with up to 20 times the AI vs. a group 2 with much higher multiples,
up to >1,000 times the AI set for infants (EFSA NDA Panel, 2016); and they should be differentiated
from reports on repeated administration of single milligram doses (5–15 mg) of vitamin D which was
the custom for rickets prophylaxis in some countries (Dietzsch, 1957; Braun and Kauderer, 1966; West
et al., 1971; Ulbrych-Jablonska, 1972; Misselwitz and Hesse, 1986; Mete et al., 1997; Doneray et al.,
2008; Sharawat, 2016) up to the 1980s. The Panel considers that case reports on repeated vitamin D
administration of single milligram doses are not informative for the identiﬁcation of a LOAEL or NOAEL
of chronic daily vitamin D consumption.
From the eligible case reports listed, only ﬁve belong to group 1 (Table 4) and may be considered
informative because the vitamin D intake consisted of multiples (4.5–20 times) of recommended dose
for the prevention of rickets (AI of 10 lg/day) for durations of 1–4 months in infants aged 2 weeks to
2 months (Marie et al., 1969; Chambellan-Tison et al., 2007; Ahmad and Al-Agha, 2013; Pavlovic and
Berenji, 2014; Radlovic et al., 2014). All infants showed hypercalcaemia and hypercalciuria with
decreased concentrations of PTH and serum concentrations of 25(OH)D at or above 175 nmol/L. Two
infants had nephrocalcinosis (Ahmad and Al-Agha, 2013; Chambellan-Tison et al., 2007) and one of
them also developed nephrocalcinosis with nephrogenic diabetes insipidus after 3 months (Ahmad and
Al-Agha, 2013). One infant who had a vitamin D intake 16 times the AI for 1 month did not develop
clinical symptoms but needed more than 2 months of treatment for normalisation of abnormal
laboratory values (Radlovic et al., 2014). In summary, these case reports indicate that daily vitamin D
intakes between 44 and 200 lg/day by young infants can lead to signs of hypervitaminosis D within
1 month, with clinical symptoms taking somewhat longer to develop. Four of the ﬁve cases were
breastfed infants, which mean that the total vitamin D intake would not be much higher than the intake
from supplements. The intake in all of these cases was higher than the present UL for vitamin D.
The other case reports from group 2 concern infants who were given extremely high daily vitamin D
doses (up to > 1,000 times the recommended prophylactic dose) either because of misunderstanding
and mislabelling of the preparation or without a clear explanation, for time periods of 10–60 days. All
developed severe symptoms of vitamin D intoxication (Lukaszkiewicz et al., 1987; Besbas et al., 1989;
Elarqam et al., 2007; Rajakumar et al., 2013; Kara et al., 2014; Smollin and Srisansanee, 2014; Ketha
et al., 2015; Sagsak et al., 2015). In addition to these case reports, fatalities have been anecdotally
reported due to overdoses of vitamin D2, including two children who died at the age of 20 and 16 months
after having received a total dosage of 280 and 455 mg, respectively (Debre, 1948).
Recent cases of hypervitaminosis D were also reported in Denmark, due to the administration of a
supplement which inadvertently provided about 750 lg vitamin D/day (Bøgevig et al., 2017; Stafford,
2016). Infants and young children who had taken this supplement were < 2 years of age and were
found to have serum 25(OH)D > 150 nmol/L and serum ionised calcium of > 1.35 mmol/L up to
> 1.49 mmol/L. Clinical symptoms included reduced appetite, vomiting, irritability and failure to thrive.
The Panel considers that these very high doses of vitamin D administered for 1–2 months are
clearly toxic and need not be considered when searching for a LOAEL for vitamin D in infants. The
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Panel notes that there are no reports of signs of vitamin D overdose with an intake corresponding to
the present UL of 25 lg/day (EFSA NDA Panel, 2012a).
Table 4: Case reports of infants with hypervitaminosis D due to daily ingestion of vitamin D
Author Patient
Vit D dose
per day
Duration of
vit D intake
Symptoms Laboratory
Daily administration of vitamin D at doses up to 20times the AI
Marie et al.
(1969)
8-month-old boy
born at term,
3 months full
formula-fed, then
start
complementary
feeding; anorexia
Birth to 4 months
‘normal’ vitamin D
prophylaxis;
At age 4 months,
start 100 lg/day
At age 6 months,
200 lg/day
4 months
2 months
2 months
Anorexia starting
1 month after
increase of
vitamin D dose,
abnormal ECG
(shortening QT
interval),
decreased
glomerular
ﬁltration, X-ray
dense end
metaphyseal
bands
Ca in serum
4.5 mmol/L
Ca in urine 8 mg/kg
per day
Chambellan-
Tison et al.
(2007)
4-month-old boy,
breastfed,
prescribed 30 lg
vitamin D/day,
received about 70
lg/day
70 lg/day 4 months Since 2 weeks
anorexia,
hypotonia,
weakness,
constipation,
polyuria,
dehydration,
neurological
symptoms,
nephrocalcinosis,
abnormal ECG
(prolonged QT
interval)
Ca in serum
4.28 mmol/L
Ionised Ca
2.52 mmol/L (normal
< 1.32)
Ca in urine 3.6 mmol/
kg per day
Ca/Cr in urine 5.3
(unit not reported)
(normal 0.5)
25(OH)D
800 nmol/L
PTH ↓
Ahmad and
Al-Agha
(2013)
Premature
(30 weeks, birth
weight 950 g,
hyaline membrane
disease treated
with TPN
(4 weeks)
2–5 months of
age: 35 lg/day
plus vit D from
formula:
40–50 lg/day)
(calculated)
3 months 5 months of age:
Weight 2.2 kg
< 5th centile,
hypotonia,
polyuria,
hypernatraemia,
nephrogenic
diabetes
insipidus,
medullary
nephrocalcinosis
5 months of age:
Ca in serum
2.95 mmol/L,
Ca in urine
6.52 mmol/L,
25(OH)D 175 nmol/L,
PTH ↓
Na 156 mmol/L, Cl
112 mmol/L,
osmolality in serum
320, in urine
20 mosmol/kg
Radlovic
et al. (2014)
1.5-month-old
girl. Full-term
healthy, birth
weight 3,600 g,
exclusively
breastfed;
received by
misunderstanding
16 times
prophylactic dose.
At age 1.5 mo,
length and weight
50th centile
From age 15 days
to 45 days 167 lg
vitamin D3/day
1 month No clinical
symptoms
1.5 month: Ca in
serum 2.72 mmol/L
25(OH)D
> 400 nmol/L
PTH ↓
Ca/Cr in urine
1.6 mg/mg (normal
< 0.8 mg/mg)
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3.5. Daily intake of vitamin D vs. mean achieved serum 25(OH)D:
assessment of the dose–response relationship
The Panel performed a statistical analysis to characterise the dose–response relationship between
‘high’ daily supplemental intake of vitamin D and mean achieved serum 25(OH)D concentration in study
arms in healthy infants. The aim of this analysis was to estimate the percentage of infants that might
exceed a serum 25(OH)D concentration of 200 nmol/L (Section 3.3.6), which the Panel considered
unlikely to pose a risk of adverse health outcomes (hypercalciuria, hypercalcaemia, nephrocalcinosis,
abnormal growth patterns) in healthy infants. A detailed description of the statistical analysis performed
to set up the intake–response model and to derive the percentage exceedance is provided in Annex A.
3.5.1. Identiﬁcation of the ﬁnal body of evidence for the analysis
Out of the 31 studies included after the extensive literature review undertaken by EFSA
(Sections 3.1 and 3.2), 22 measured serum 25(OH)D concentration, four of which were prospective
observational studies and the others were trials of various type of design.
In order to reduce methodological and biological heterogeneity:
 observational studies were discussed narratively in earlier sections and excluded from the
statistical analysis.
 after preliminary analysis, studies/arms on infants with vitamin D deﬁciency rickets and/or
pertaining to RoB tier 3 were excluded from the dose–response analysis.
The ﬁnal body of evidence kept for the statistical analysis was composed of six studies (Holst-
Gemeiner et al., 1978; Gordon et al., 2008; Holmlund-Suila et al., 2012; Gallo et al., 2013a; Grant
et al., 2014; Ziegler et al., 2014), comprising 17 arms and 58 observations at different time
points. Of these six studies, all administering vitamin D3 doses, ﬁve were RCTs (Appendix L).
Transformation was applied to data in order to recategorise some variables (Table 5).
Author Patient
Vit D dose
per day
Duration of
vit D intake
Symptoms Laboratory
Pavlovic and
Berenji
(2014)
4.5 months with
weight loss
(4.25 kg i.e
< 3rd centile),
Breastfed for
2.5 months,
thereafter formula
33 lg/day
44 lg/day
From
2 weeks to
2.5 months
of age (D2)
= 8 weeks
from
2.5 months
of age plus
11 lg (D3)
from formula
= 8 weeks
Vomiting,
constipation
Ca in serum
4.91 mmol/L,
Ca/Cr in urine 2.81
(unit not reported)
(normal < 0.2),
25(OH)D >
375 nmol/L
PTH ↓
25(OH)D: 25-hydroxy-vitamin D, Ca/Cr: calcium/creatinine ratio, ECG: electrocardiogram, PTH: parathyroid hormone.
Table 5: Categorising variables
Variable Categories
Latitude (degrees) 1: between 40° and +40°(a)
2: (between 50° and 40°) or (between +40° and +50°)
3: (50° and below) or (+50° and above)
Supplementation duration in months (weeks) 0: baseline
1: (0,4]
3: (4,12]
6: (12,24]
12: > 24
Analytical method for 25(OH)D CPBA: CPBA(a)
LC-MS/MS: LC-MS/MS
RIA: RIA or CLIAs
NA: not speciﬁed
UL of vitamin D for infants
www.efsa.europa.eu/efsajournal 46 EFSA Journal 2018;16(8):5365
3.5.2. Dose–response modelling of study arm mean serum 25(OH)D
concentration and daily vitamin D supplemental intake
Mean serum 25(OH)D concentration, as the continuous outcome, was analysed by EFSA using the
summary data extracted for each study arm and time point: the sample size, the mean and standard
deviation of the baseline and achieved serum concentration of 25(OH)D.
Background intake was reported in only one of the included trials (Gallo et al., 2013a). The
Panel decided not to impute the background intake to generate total vitamin D intake estimates, as
the purpose of this assessment was to set a UL (and not an average requirement or an AI) and
considering the time constraints for this assessment. Therefore, the intake–response relationship was
established only on the basis of the additional dose of vitamin D provided in the six trials. The
Panel considers that not including the background intake would lead to an underestimation of the
vitamin D dose corresponding to the UL and assessed the approach as conservative.
This additional dose of vitamin D was always provided through a supplement and not a fortiﬁed
food. The following analysis was thus done under the assumption that the differences in bioavailability
of vitamin D when supplemented, naturally present or added to food could be considered limited, as
only scarce data on this aspect are available (EFSA NDA Panel, 2016) (Section 5.6.3).
3.5.2.1. Moderator variables
A number of factors potentially inﬂuencing the dose–response relationship listed a priori
(Section 3.2.3) were visually investigated in order to select those to be included in the model to
characterise the heterogeneity of results across arms and repeated measurements. These factors
included: baseline mean serum concentration, analytical methods, latitude categories, categories of
supplementation duration, (mean) age (in weeks) vs. (mean) body weight (in g), feeding type at study
start, categories of duration of gestation. Possible effects of genotypes (e.g. ethnicity) and some
lifestyle habits were rarely reported in the included trials and therefore not further analysed.
Graphical investigation shows that higher values of the biomarker are achieved when the
concentration at baseline is higher. The effect of the initial concentration is more evident at more
extreme vitamin D intake levels (below 10 and above 30 lg/day). The variable was included by default
in the model for biological reasons (Section 1.8.1).
Only two analytical methods used in the studies were ﬁnally included in the body of evidence
(LC-MS/MS and ‘RIA’, see Table 5). The measurements provided by the RIA method were higher for
doses up to around 35 lg/day. The reverse occurs for higher doses.
For latitude, analysis indicated higher concentration of serum 25(OH)D for infants living in
northern countries. This conﬂicts with the expectation of a lower vitamin D cutaneous synthesis at
higher latitudes (Section 1.7.1.1). A possible explanation for this result was that the latitude in these
studies was masking other country-speciﬁc factors (e.g. country-speciﬁc practices for maternal or
infantile vitamin D supplementation) and/or infant sun exposure was too limited to expect an effect on
the biomarker. The Panel thus decided to discard this factor from the model.
At different supplementation durations, differences in the shape of the dose–response
relationship and in the achieved serum concentration of 25(OH)D were identiﬁed, ‘6-months’ (i.e. more
than 3–6 months, Table 5) was the category leading to the highest study arm mean concentrations at
the highest vitamin D doses.
The Panel discussed whether body weight or age was more relevant to explain the achieved
mean serum 25(OH)D concentration (Section 3.2.3). The two variables were highly correlated
(r = 0.99) in the available body of evidence (multicollinearity), therefore, one variable was included in
the model. Age was selected, because it was always reported for the study participants whereas body
weight was sometimes missing.
Variable Categories
25(OH)D baseline concentration (nmol/L) 1: [10,30)
2: [30,60)
3: [60,100)
CLIA: automated chemiluminiscence immunoassay; CPBA: competitive protein-binding assay; LC-MS/MS: liquid chromatography-
tandem mass spectrometry; RIA: radioimmunoassay.
NB: ranges expressed as [a–b) mean including a but excluding b.
(a): Not present in the ﬁnal body of evidence
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As for type of feeding at the start of the study, the Panel considered that feeding can change
quickly at this stage of the life and probably observations taken only at baseline are not very indicative
of the feeding type in the following weeks. This variable was therefore discarded from further analysis.
The intake–response relationship did not result in a clear pattern for different categories of
duration of gestation (i.e. arms composed of full-term infants or mixed populations).
Eventually all the moderator variables from the original list were selected for the next
steps of the analysis except latitude, mean body weight and type of feeding at start of the study for
the reasons explained above.
3.5.2.2. Model assumptions: linearity, constant variance and normality
Normality, uniformity of the variance at the various doses (i.e. homoscedasticity) and
linearity are standard assumptions in regression and meta-regression analysis. Graphical
representations can help to identify important deviations from these assumptions.
The assumption of linearity was conﬁrmed after exploring the possible shape of the dose–
response relationship, looking at the graphical display of mean serum 25(OH)D concentration with
respect to vitamin D intake levels, without considering any adjustment for moderator variables
(Annex A). It was concluded that the assumption of linearity seems to ﬁt the data relatively well,
except at high vitamin D intake (i.e. 40 lg/day and above), where most of the points systematically lie
above or below the regression line.
From a biological viewpoint, it would be realistic to expect that the achieved serum 25(OH)D
concentration levels off at high doses of vitamin D (instead of continuously increasing at the same
rate). However, in the six selected trials, only infants with hypovitaminosis, i.e. serum 25(OH)D
< 50 nmol/L (Gordon et al., 2008) received 50 lg of vitamin D/day. Thus, scarcity of data at high
doses and characteristics of the population do not allow resolution of uncertainty around the true
shape of the dose–response relationship at high vitamin D intakes in infants.
Potential deviation from the assumption of normality was also checked. Looking at the distribution
of mean serum 25(OH)D concentration in the different arms and time points, it was concluded that
approximation to normality is not fully achieved, since the right (upper) tail of the distribution is longer
than in a normal distribution (right skewness) (Annex A). A distribution stratiﬁed by vitamin D intake
doses and moderator variables would have allowed a better investigation of normality assumption. This
was precluded by the limited number of observations.
As a consequence, besides the analysis using the original scale, a natural logarithmic
transformation (ln-transformation) of the response variable (mean achieved serum 25(OH)D
concentration), explanatory variable (vitamin D intake) and one covariate (baseline serum 25(OH)D
concentration) was applied. This ln-transformation aimed to improve approximation to normality,
reduce skewness and improve the uniformity of variance at a cost of slightly worsening the linear ﬁt.
3.5.2.3. Best predictive model
A mixed effect meta-regressive dose–response model was used, to explain the effect of
moderator variables on the intake–response relationship and to account for the hierarchical structure in
the data. Eventually, based on the overall goodness of ﬁt, the biological relevance of the moderator
variables and their statistical signiﬁcance, the best predictive model identiﬁed (see Annex A) included,
in addition to daily supplemental intake of vitamin D, a subset of the moderator variables, i.e.
baseline mean serum 25(OH)D concentration, supplementation duration category and
age. The formal structure of the best predictive model of study arm mean serum 25(OH)D
concentration on vitamin D supplemental intake is described below:
 achieved S25(OH)D = b0(baseline S25(OH)D) + b1(vitamin D intake) + b2(age) + b3
(supplementation duration category) + random effect of the study arm + random effect of the
repeated measures within a study arm (model 1).
 ln(achieved S25(OH)D) = b0ln(baseline S25(OH)D) + b1ln(vitamin D intake) + b2(age) + b3
(supplementation duration category) + random effect of the study arm + random effect of the
repeated measures within a study arm (model 2).
The parameters of the variables were estimated for the two above models using respectively:
 All variables in the original scale (model 1);
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 Ln-transformation of the mean achieved serum 25(OH)D concentration), of vitamin D
supplemental intake and of baseline serum 25(OH)D concentration (model 2), keeping age and
duration in the original scale.
No major patterns were identiﬁed that could raise concerns for any of the two models regarding
linearity of the relationship or the presence of outliers (see Section 1.1.6 of Annex A).
The Panel notes that the ln-transformed model is better meeting the assumptions of normality
and homoscedasticity, whereas the model in the original scale better ﬁts linearity. The Panel also notes
that both models (both scales) considered together give a sense of the uncertainty associated
with the several choices made at a methodological level and their inﬂuence on the results.
3.5.2.4. Predicted distribution of study arm mean and individually achieved serum
25(OH)D concentration
From the six selected trials corresponding to 17 arms and 58 time points of measurements of mean
25(OH)D concentration, the distribution of the mean achieved level of serum 25(OH)D was simulated
using the two predictive models, i.e. original and ln-transformed described in the previous section. The
predicted values were further analysed in order to simulate distributions of serum 25(OH)D
concentration that may be achieved by individuals.
Predicted distribution of study arm mean serum 25(OH)D concentration
The hypothesis was that study arm means in the body of evidence represent a random sample from a
theoretical population of study arm mean values whose distribution can be described conditionally to the
value of the explanatory variables vitamin D intake, baseline serum 25(OH)D concentration and age.
Since few observations were available in the body of evidence, an empirical distribution was generated
with a large number of simulations (random draws) to approximate better the true distribution.
To make the model predictions more realistic, a probability distribution was used for the baseline
value of serum 25(OH)D concentration, to reﬂect the variability that is expected for this factor in a
theoretical population of studies.40 The distribution was elicited based on expert’s knowledge. A
truncated normal distribution of baseline serum 25(OH)D concentration, with a mean of
50 nmol/L, a standard deviation of 20 nmol/L and range between 10 and 100 nmol/L, was considered
realistic by the Panel (Annex A). A truncated normal distribution was preferred to avoid values
biologically unrealistic (i.e. baseline study mean concentrations below 10 and above 100 nmol/L).
In addition, a range of 5–50 lg/day for daily supplemental vitamin D intake (range covered in the
body of evidence) and a range of 1–52 weeks for the age of the infants (corresponding to the target
population age) were considered appropriate (Annex A).
The supplementation duration category was always set at ‘6 months’ (i.e. more than 3 months up
to 6 months, Table 5). This duration was chosen since it was the one corresponding to the highest
achieved serum 25(OH)D concentration at higher doses among the selected studies (Section 3.5.2.1).
Monte Carlo techniques (Burmaster and Anderson, 1994) were used to combine the empirical
distribution of the baseline serum 25(OH)D concentration and values of daily vitamin D intake and age, to
predicted study arm mean of the achieved serum 25(OH)D concentration. A total of 1,196,000 predictions
were generated. The empirical distributions and the related quartiles of the predicted mean achieved
serum 25(OH)D obtained using the model in the original and ln-transformed scale are provided in Annex A.
Predicted distribution of individually achieved serum 25(OH)D concentration
Each predicted value of the study arm mean 25(OH)D concentration was used to simulate a
distribution of individually achieved concentration of the biomarker (serum 25(OH)D).
An average coefﬁcient of variation was estimated from the selected studies and applied to the
study arm means to derive the interindividual variability of the populations of individually achieved
serum 25(OH)D concentration.
Two sets of distributions of individually achieved serum 25(OH)D concentrations were generated.
Each set was stratiﬁed by baseline serum 25(OH)D concentration (categories: 10 to 30 nmol/L; 30 to
60 nmol/L; 60 to 100 nmol/L) and supplemental vitamin D intake (classes from 5 to 50 lg/day, of size
5 lg/day). The percentage of infants with an individually achieved estimated serum concentration of
25(OH)D above 200 nmol/L was computed, separately for the infants below the age of 6 months and
between 6 and 12 months.
40 Using e.g. average values for these variables would not have been sufﬁciently conservative for establishing a UL
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The predictions of percentage of individuals above a certain serum 25(OH)D concentration obtained
on the basis of the two models – the one in the original scale and the one in ln-transformed scale for
response, intake and baseline value of the biomarker – have been interpreted jointly.
3.5.2.5. Results – Percentage of infants exceeding a serum concentration of 25(OH)D
The predicted percentage of infants expected to exceed 200 nmol/L for serum 25(OH)D
concentration is reported in Tables 6–7 for the models in the original and ln-transformed scale, (i) for
infants up to the age of 6 months and (ii) and between 6 months and 12 months.
For infants younger than 6 months, based on the results of the prediction model in the original
scale (Table 6a), at a vitamin D intake of up to 25 lg/day, which is the UL previously set by EFSA NDA
Panel (2012a), depending on the baseline serum 25(OH)D concentration, 0–4% of infants would achieve
serum 25(OH)D concentrations above 200 nmol/L. The results of the ln-transformed scale, up to a
vitamin D supplemental dose of 25 lg/day, are consistent with the results in the original scale (Table 6b).
Table 6: Percentage of infants up to 6 months of age (26 weeks included) exceeding the serum 25
(OH)D concentration of 200 nmol/L. Model in the original and ln-transformed scale
Table 6a: original scale Table 6b: ln-transformed scale
Vitamin D
intake
(lg/day)
%infants with achieved serum
25(OH)D concentration exceeding
200 nmol/L
%infants with achieved serum
25(OH)D concentration exceeding
200 nmol/L
For baseline serum 25(OH)D (nmol/L) For baseline serum 25(OH)D (nmol/L)
[10, 30) [30,60) [60,100] Any [10, 30) [30,60) [60,100] Any
[5–10) 0 0 0 0 0 0.1 1.4 0.5
[10–15) 0 0 1 0 0 0.2 2.2 0.8
[15–20) 0 1 2 1 0 0.3 2.9 1.0
[20–25) 0 2 4 2 0 0.4 3.5 1.3
[25–30) 1 3 7 4 0 0.5 4.1 1.5
[30–35) 3 6 11 7 0 0.6 4.6 1.7
[35–40) 6 10 16 11 0 0.7 5.2 1.9
[40–45) 10 15 21 17 0 0.8 5.6 2.1
[45–50) 15 20 27 22 0 0.9 6.0 2.3
Table 7: Percentage of infants between 6 and 12 months of age (26 weeks excluded) exceeding
the serum 25(OH)D concentration of 200 nmol/L. Model in the original and ln-transformed
scale
Table 7a: original scale Table 7b: ln-transformed scale
Vitamin D
intake (lg/day)
%infants with achieved serum
25(OH)D concentration exceeding
200 nmol/L
%infants with achieved serum
25(OH)D concentration exceeding
200 nmol/L
For baseline serum 25(OH)D (nmol/L) For baseline serum 25(OH)D (nmol/L)
[10, 30) [30,60) [60,100] Any [10, 30) [30,60) [60,100] Any
[5–10) 0 0 0 0 0 0 0. 6 0.2
[10–15) 0 0 0 0 0 0.1 1 0.3
[15–20) 0 0 0 0 0 0.1 1.4 0.5
[20–25) 0 0 1 0 0 0.1 1.7 0.6
[25–30) 0 1 2 1 0 0.2 2.1 0.7
[30–35) 1 2 4 2 0 0.2 2.4 0.8
[35–40) 2 4 8 5 0 0.3 2.7 1.0
[40–45) 4 7 12 8 0 0.3 3.0 1.1
[45–50) 7 11 17 12 0 0.3 3.3 1.2
NB: ranges expressed as [a–b) mean including a but excluding b.
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For infants between 6 and 12 months of age, the predicted percentage of individuals
exceeding serum 25(OH)D concentrations of 200 nmol/L would be 0–1% at supplemental vitamin D
intake of up to 25 lg/day, 0–2% at intakes of up to 30 lg/day and 1–4% at intakes at of up to
35 lg/day (Table 7a, original scale). For the ln-transformed scale, these percentages range from 0 to
around 2% for doses up to 35 lg/day (Table 7b).
As indicated in Section 3.5.2.3, both models (both scales) considered together give a sense
of the uncertainty associated with the several choices made at a methodological level and their
inﬂuence on the results. The above results represent predictions obtained from modelling, simulations
and related assumptions (previously speciﬁed). The exceedance percentages should not be
interpreted as precise estimates, rather as informed quantitative judgements about the
expected percentage of infants that might exceed the serum 25(OH)D concentration at the various
vitamin D intake, given baseline values of the biomarker and age groups (Annex A).
3.5.2.6. Unaddressed sources of uncertainty
Some uncertainty sources could not be addressed in this statistical analysis while developing the
intake–response model and deriving percentages of exceedance. They are listed below:
 The intake–response relationship is estimated using aggregated data, i.e. study arm mean
value. The relationship observed averaging across trials might not be the same as the one
observed within a trial. Some potential confounding or moderators have not been measured in
the studies and could not be included in the model
 The interindividual variability necessary to estimate distribution of individually achieved serum
25(OH)D concentration was unknown and it was estimated on the basis of the mean coefﬁcient
of variation across study arms assumed to be a proxy of the interindividual variability.
 Sampling uncertainty, i.e. the uncertainty in the serum 25(OH)D measurement arising from the
sample of studies used, was not accounted for. The mean prediction has been adopted (to
calculate the percentages of individuals exceeding a certain serum 25(OH)D concentration)
instead of the upper bound of the prediction interval of the prediction.
4. Assessment of the daily vitamin D intake in infants (≤ 1 year) in
Europe
4.1. Food composition data
4.1.1. Food composition data either published or collected through a consultation
of MS by the European Commission
4.1.1.1. Composition data on fortiﬁed foods in Finland
The highest number of fortiﬁed foods notiﬁed in the Finnish marked between 2012 and 2016 is
represented by ‘milk and milk products’ (n = 197), of which 75% contained at least 1 lg/100 g of
vitamin D (overall, median content of 1 lg/100 g, which is also the value of 116 milk products, i.e.
60% of the total) (Evira, 2017). The second most frequent category are ‘special diet products’,
including, e.g. IF and FoF and processed cereals, with a median content of 2.5 lg/100 g, followed by
other fortiﬁed foods containing between 1 and 20 lg/100 g.
4.1.1.2. Composition data of IF and FoF in France
In 2012, data declared on the labels were studied for IF (n = 36) and FoF (n = 43) and young child
formulae (n = 50), covering 89% of the volume of the French market for these products (in
supermarkets and pharmacies, excluding products for special medical uses) (Oqali, 2014). Median-
labelled energy contents was 67 kcal/100 mL for IF and FoF. Median-labelled vitamin D contents were
1.0 lg/100 mL for IF and 1.10 lg/100 mL for FoF. Consumption volumes recommended on labels
were about 0.7–1 L/day for the ﬁrst 6 months and about 0.6 L/day for the second 6 months of age.
4.1.1.3. Composition data of fortiﬁed foods in the Netherlands
To assess vitamin D intake in Dutch infants, Verkaik-Kloosterman et al. (2017a) used composition
data from the Dutch database (NEVO 201141), complemented with labelled composition data from an
41 www.rivm.nl/nevo
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inventory of vitamin D fortiﬁed foods on the Dutch market and intended for children aged 0–4 years,
carried out in 2011.42 Food groups identiﬁed as voluntarily fortiﬁed were porridge and breakfast
cereals, infant cookies, dairy products43 and drinks,44 with a vitamin D content that ranged from
0.74 to 16.5 lg/100 g.
4.1.1.4. Composition data from an analytically measured data set on vitamin D
Data on vitamin D composition of foods were compiled based on EuroFIR standards (Milesevic
et al., 2018) with the aim of creating a data set on vitamin D content in foods based on analytical
data. Analytical data were mainly collected from (i) nine national databases from or outside the EU
with documented values of total vitamin D, D2, D3 and 25(OH)D (i.e. excluding estimations or
imputations), or (ii) from the literature or (iii) speciﬁcally for fortiﬁed foods, from data of
manufacturers (collected by the Nordic countries or the Netherlands). The most common analytical
method was HPLC. Most of the data were extracted from meat, fortiﬁed foods/formulations and ﬁsh
groups. Most of the data were on total vitamin D and were obtained for fortiﬁed foods, novel foods,
‘formulations’ and milk and dairy products. Data from vitamin D3 mostly come from ﬁsh, meat and
dairy groups. Data on vitamin D2 were lacking in the European data set, contrary to the US
Department of Agriculture (USDA) database (mushrooms and milk substitutes). Data on 25(OH)D3
came from meat and ﬁsh groups, eggs and dairy products. IF were not a stand-alone category but
were grouped by the authors in the category ‘fortiﬁed formulations’, including also meal replacements
and ‘functional snacks and powders’, with varying vitamin D content per 100 g.
4.1.1.5. Data on overages45 from the Netherlands and the UK
Verkaik-Kloosterman et al. (2017b) measured with HPLC the content of vitamin D in 29 fortiﬁed
foods (mainly FoF and porridge) and 15 dietary supplements available on the Dutch market and
intended for infants aged 6–12 months. For fortiﬁed foods, the results showed that the analysed
content was 50–153% of the values declared on the labels. In particular, the analysed vitamin D
content was between 50 and 127% of declared values for ‘instant baby porridge’ and between 74 and
81% for ‘ready-to-eat baby porridge’. Analysed content was 102–153% of the labelled value for FoF
and between 8 and 177% for supplements.
Allen et al. (2014) described the methodology and results of the update of the National Diet and
Nutrition Survey (NDNS) Nutrient Databank46 in 2011 for 257 of the 289 foods or supplements identiﬁed
as fortiﬁed with vitamin D (both vitamin D2 and D3). The authors mention that information received from
industry indicated that ‘overages’47 ranged between 20% and 30% for vitamin D fortiﬁed foods and 20%
and 40% for vitamin D supplements. The authors considered it appropriate to apply a standard overage
of 25% to all products. They also estimated a 50% reduction in ‘overage’ at consumption, after possible
losses of vitamin D during processing and through degradation. Thus, for this study, a ‘blanket overage’
of 12.5% was applied to the vitamin D content of all fortiﬁed foods and supplements to cover the
overages reported by the manufacturers and possible losses due to degradation and processing. When
calculating the updated vitamin D intake, by using the consumption data from the NDNS 2008–2010 and
the updated vitamin D composition data, the results showed an increase of 3% (6% considering the
overage of 12.5%) in the daily vitamin D intake (from 3.5 to 3.6 lg/day).
4.1.1.6. Conclusion on food composition data published or collected through a
consultation of MS
The Panel notes the limited published data on food fortiﬁed with vitamin D that may be consumed by
infants in different EU countries. The Panel notes in particular the content of vitamin D in fortiﬁed milk and
milk products in Finland. The Panel also notes a limited number of papers reporting on possible disparities
between labelled values and actual (analysed) contents (overages) of fortiﬁed foods and supplements.
42 Combining data from two databases (www.levensmiddelendatabank.nl, and www.innovadatabase.com), a supermarket
inventory, and searches on websites of manufacturers.
43 Fruit fromage frais, ready-to-drink milk porridge, yogurt drink.
44 Instant cacao powder and soya drink.
45 As indicated in this publication: ‘Some studies indicate that manufacturers of such products [fortiﬁed foods and dietary
supplements] may add higher amounts of micronutrients, in general, to compensate for losses during processing and shelf life
(so-called overages)’.
46 Database of nutrient composition data used to estimate nutrient intake for all foods, supplements and recipes in the NDNS.
47 As indicated in this publication: ‘the additional amount or ‘overage’ added during fortiﬁcation and supplementation above the
label value to allow for any processing losses and degradation.’
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4.1.2. Food composition data from the EFSA nutrient composition database
For a speciﬁc intake assessment, composition data for ‘vitamin D’ and for cholecalciferol (vitamin
D3) in foods and beverages were derived from the EFSA Nutrient Composition Database (Roe et al.,
2013). In case, no country-speciﬁc data were available for certain food codes, national data compilers
who provided the database to EFSA borrowed compatible data from other countries and/or from
similar foods. Regarding harmonisation of provided data, all food entries in this database are classiﬁed
according to the food classiﬁcation and description system FoodEx2 (EFSA, 2011a).
Data on vitamin D, originating from 12 countries48 and covering 3,027 records related to 394
different FoodEx2 codes, were available after data cleaning (Section 4.4.1.2). While fortiﬁcation was
among the facet descriptors of this database, information on whether a given food code was fortiﬁed
with vitamin D was generally not available. The method used by national data compilers to obtain the
composition data on vitamin D3 or ‘vitamin D’ provided to EFSA for all these food records were mostly
(about 2/3) not known. For the remaining food records, depending on the country, vitamin D was
analytically measured (in 6 of 12 countries) mostly via HPLC, or obtained via different calculation
procedures (at recipe or ingredient level) or by imputations. Three countries stated that total vitamin D
content was calculated for some food records as the sum of vitamin D3 and 25(OH)D3
49 (applying a
factor of 5–25(OH)D3), and possibly vitamin D2.
4.1.3. Food composition data from Mintel Global New Products Database (GNPD)
For the intake assessment, EFSA gathered data on the levels of vitamin D in fortiﬁed foods from
the Mintel Global New Products Database (GNPD). This is an online database, which monitors product
introductions in markets of consumer packaged goods worldwide. Mintel GNPD started covering the
food markets of the European Union in 1996, currently presenting data from 20 of its 28 member
states and Norway. At the time of the search, it contained information on over 2 million food and
beverage products, of which more than 900,000 are or have been available on the European food
market. In particular, Mintel GNPD shows the ingredient list, the labelled table of nutrient information
and pictures of the packages of the products.
For the purpose of this scientiﬁc opinion, EFSA searched Mintel GNPD, in particular:
 to check the frequency of the presence of ‘vitamin D’/D2/D3 in the ingredient list, thus
identifying products fortiﬁed with vitamin D within the EU’s food products,
 and to check the labelled content of this vitamin D.
4.1.4. Composition data for foods for infants with regulated vitamin D content
Commission Directive 2006/141/EC4 (Section 1.1) set the range (minimum and maximum values)
for vitamin D content in IF and FoF to 1–2.5 and 1–3 lg vitamin D/100 kcal, respectively. For both
types of formulae, the energy content should range between 60 and 70 kcal/100 mL. Commission
Delegated Regulation (EU) 2016/1273, which will repeal Directive 2006/141/EC from 2020
(Section 1.1), revises these values and set the same vitamin D levels for IF and FoF, in the range 2–
3 lg/100 kcal. According to these regulatory texts, IF are the only processed foodstuff which wholly
satisﬁes the nutritional requirements of infants during the ﬁrst months of life until the introduction of
appropriate complementary feeding (while FoF are intended for infants when appropriate
complementary feeding is introduced).
Commission Directive 2006/125/EC50 prescribes that ‘baby foods’ cannot be fortiﬁed with
vitamin D. ‘Cereals with an added high-protein food which are or have to be reconstituted with water
or other protein-free liquid’ have to be mandatorily fortiﬁed at levels ranging between 1 and 3 lg/
100 kcal (content in food ready for use). ‘Simple cereals which are or have to be reconstituted with
milk or other appropriate nutritious liquids’, ‘pastas which are to be used after cooking in boiling water
or other appropriate liquids’, ‘rusks and biscuits which are to be used either directly or after
pulverisation, with the addition of water, milk or other suitable liquids’, can be fortiﬁed to a maximum
of 3 lg/100 kcal (content in food ready for use). For these last three food categories, no minimum
content for vitamin D is speciﬁed.
48 Germany, Denmark, Finland, France, UK, Iceland, Italy, the Netherlands, Portugal, Serbia, Sweden, Slovenia.
49 Denmark, Finland and the UK.
50 Commission Directive 2006/125/EC of 5 December 2006 on processed cereal-based foods and baby foods for infants and
young children. OJ L 339, 6.12.2006, p. 16.
UL of vitamin D for infants
www.efsa.europa.eu/efsajournal 53 EFSA Journal 2018;16(8):5365
4.2. Food consumption and vitamin D intake or modelling data
4.2.1. Vitamin D intake or modelling data, either published or collected through
a consultation of Member States by the European Commission
4.2.1.1. Intake of vitamin D in infants: previous assessments by EFSA
In its opinion on nutrient requirements and dietary intakes of infants and young children in the EU,
EFSA indicated that ‘in 18 of the 23 countries from which information was available to EFSA, vitamin D
supplementation, mainly in the form of drops or tablets, but also cod liver oil in Nordic countries, is
recommended on a national level. The duration of supplementation, however, varies and ranges from
the ﬁrst year of life to 18 years’ (EFSA NDA Panel, 2013).
The opinion on the essential composition of IF and FoF (EFSA NDA Panel, 2014a) indicated that
‘mean/median vitamin D intakes of formula-fed infants below six months of age are reported to be
around 9–10 lg/day in infants (Noble and Emmett, 2006; Fantino and Gourmet, 2008; Lennox et al.,
2013) and 3.5 lg/day in breastfed infants (Lennox et al., 2013). For infants aged 6 to < 12 months,
mean/median vitamin D intakes were observed to be in the range 3.6–10.4 lg/day (Noble and
Emmett, 2001; de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008; Marriott et al., 2008;
Thorsdottir et al., 2008; Lennox et al., 2013)’.
4.2.1.2. Intake modelling and intake data from the Netherlands
Verkaik-Kloosterman et al. (2017a) aimed to evaluate the risk of excessive vitamin D intake in
children aged 0–19 months, considering food fortiﬁcation and supplementation in the Netherlands, and
assuming a 100% compliance with vitamin D supplementation of 10 lg/day.
For infants aged 0–6 months, as no Dutch consumption data were available, the habitual
vitamin D intake (assuming no complementary food) was modelled considering daily energy
requirement, an energy content of 65 kcal/100 mL of formula, and the vitamin D content of IF
reported in 2011 (1.8 lg/100 kcal).
 From formulae only, median-estimated vitamin D intake in infants 0–6 months ranged from 6.4
(girls aged 0–1 month) to 11.7 lg/day (boys aged 5–6 months) and the P97.5 ranged from
7.9 to 14.7 lg/day for these age/sex groups.
 Assuming a 100% compliance with vitamin D supplementation of 10 lg/day, the median-
estimated total vitamin D intake (formulae and supplements) ranged from 16.4 to 21.7 lg/day
and the P97.5 ranged from 17.9 to 24.7 lg/day. Thus, none of these estimated values were
exceeding the UL of 25 lg/day (EFSA NDA Panel, 2012a).
For infants 7–12 months, Verkaik-Kloosterman et al. (2017a) used consumption data from the
VoedingsstoffenInnameOnderzoek (VIO) cross-sectional study conducted in a nationally representative
population of healthy term, non-breastfed, infants with a birth weight of at least 2.5 kg.
 Median-estimated vitamin D intake from food was 10.9 lg/day at 7 months and 5.7 lg/day at
12 months, respectively, and 95th percentile (P95) ranged from 13.5 to 16.7 lg/day.
 Assuming a 100% compliance with vitamin D supplementation of 10 lg/day, median total
vitamin D intake (from food including supplements) ranged between 15.4 and 21.1 lg/day at
12 and 7 months, respectively, and P95 ranged from 23 to 26.5 lg/day (P99: 27–29 lg/day).
The authors concluded that 4–11% of infants in the age range 7–11 months are at risk of
exceeding the UL of 25 lg/day (EFSA NDA Panel, 2012a). The authors report of some
overages51 and the probable lower compliance with vitamin D supplementation.
At the age 10–11 months, median and P95 estimated vitamin D intake from foods from another
(non-nationally representative) study (Eat Complete study) (De Jong-Rubingh and Bausch-Goldbohm,
2015) presented by the Member State do not exceed the UL of 25 lg/day (5.3 and 13.1 lg/day).
51 See Section 4.1.1.5.
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4.2.1.3. Intake modelling from Ireland
The Food Safety Authority of Ireland52 modelled the intake of vitamin D from formulae and
supplements in infants, growing at 0.4th, 50th and 99.6th centiles on the WHO growth curve. This
choice of high percentile (P99.6) was to account for the fact that, at birth, infants in Ireland are
heavier than in other countries and tend to be heavier than WHO growth standards,53 and thus to
ensure that 95% of infants in Ireland would be covered. Most infants in Ireland are formula-fed.
The model considered a daily intake of formula of 150 mL/kg body weight for ages 1–6 months,
progressively decreasing until 12 months of age to account for introduction of complementary feeding,
and the maximum vitamin D content of 3 lg/100 kcal and an energy content of 65 kcal/100 mL in
formula. Supplementation with 5 lg/day vitamin D recommended for this age54 was also considered.
Modelled vitamin D intake from formula only and for boys aged 3–6 months at P99.6 was at or
above the UL of 25 lg/day (EFSA NDA Panel, 2012a). Modelled total vitamin D intake (from formula
and supplements) at P99.6 was higher than the UL for ages 2, 3, 4, 5, 6 and 7 months, and at P50 for
ages 5 and 6 months. Data for girls were reported as being similar. The lower and higher bound
(20%, +50%) of the tolerance55 around a labelled vitamin D content of supplements of 5 lg was
also considered in the modelling. Thus, the highest modelled P99.6 of total vitamin D intake was
obtained at 6 months: 38 lg/day for a P99.6 of body weight of 10.5 kg.
4.2.1.4. Intake data from Belgium
A cross-sectional study in Belgium (VITADEK study) (Moyersoen et al., 2017, 2018) aimed at
assessing the intake of fat soluble vitamins from the consumption of foods (mandatorily or voluntarily
fortiﬁed56 or not fortiﬁed) and dietary supplements, in particular in infants (0–11 months, n = 455).
The national vitamin D supplementation is 10 lg/day for the age 0–10 years, although varying in the
Flemish (10–15 lg/day) and French-speaking (15–30 lg/day) parts of Belgium.
The P95 of estimated vitamin D intake were higher for formula-fed infants than for breastfed
infants. The P95 of estimated intake from food excluding vitamin D provided by supplements remained
below 14 lg/day at all ages in formula-fed infants thus below the UL of 25 lg/day (EFSA NDA Panel,
2012a). When considering vitamin D supplementation, the P95 of estimated total vitamin D intake
were at or above 25 lg/day for infants 0–12 months and all subpopulations considered. The
proportion of infants with total vitamin D intake above the UL was 6% (0–6 months) and 17%
(7–12 months) in breastfed infants and 17% (0–6 months) and 26% (7–12 months) in formula-fed
infants. Supplements represented 92% and 87% of total vitamin intake in breastfed infants aged
0–6 months and 7–11 months, respectively, and 53% and 56% in formula-fed infants aged
0–6 months and 7–11 months, respectively.
4.2.1.5. Intake data from Denmark
In the Danish National survey conducted in 2006–2007 (Trolle et al., 2013), for infants, estimated
vitamin D intake from foods was reported (mean and different percentiles) for males and females, for
the following age ranges: 6–7 months, 8–9 months, 10–11 months.57 The highest P95 estimated
intake of vitamin D (from foods) was found between 6 and 9 months (11–12 lg/day). According to
the authors, this highest intake in this age range was a result of the intake of IF and FoF and
‘synthetic porridge’. When considering the additional contribution from vitamin D supplementation,
52 Approaches for modelling range of micronutrient intakes for infants consuming infant formula in Ireland (2017). M. A. T. Flynn
and O. C. Lyons, Public Health Nutrition, Food Safety Authority of Ireland. (unpublished)
53 http://www.who.int/childgrowth/standards/en/
54 Food Safety Authority of Ireland (2007). Recommendations for a National Policy on Vitamin D Supplementation for Infants in
Ireland, 46 pp.
55 European Commission. Guidance document for competent authorities for the control of compliance with EU legislation on:
Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food
information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and of
the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/EC,
Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC and
Commission Regulation (EC) No 608/2004 and Council Directive 90/496/EEC of 24 September 1990 on nutrition labelling of
foodstuffs and Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the
laws of the Member States relating to food supplements with regard to the setting of tolerances for nutrient values declared on a
label. 2012.
56 For this age group, voluntarily fortiﬁed foods were milk-based cereals and cooking fats.
57 157 males (6–7 months), 159 females (6–7 months), 153 males (8–9 months), 136 females (8–9 months), 114 males
(10–11 months), 107 females (10–11 months).
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which at the time of the survey (2006) was 10 lg/day for all infants between 14 days and 1 year as
recommended by national policy, the authors indicate that no infant exceeded the UL of 25 lg/day
(EFSA NDA Panel, 2012a). The authors report that supplements contribute to the total vitamin D
intake for around 60–70% (all age groups), and that most of the infants received (not always daily)
supplementation as drops.
4.2.1.6. Intake data from the UK
Within a UK nationally representative sample of children aged 4–18 months (n = 2,246) (Lennox
et al., 2013), estimated the P95 of vitamin D intake from food only was 8.2–9.6 lg/day in breastfed
infants and 14.8–15.6 lg/day in non-breastfed infants. Estimated P95 of total vitamin D intake (from
foods including supplements) was always below the UL of 25 lg/day (EFSA NDA Panel, 2012a), and in
the range of 9.6–15.7 lg/day in breastfed infants and 15.7–17.1 lg/day in non-breastfed infants.
Percentage contribution of food sources (without supplements) to vitamin D intake is reported only
for non-breastfed infants. IF and FoF were the highest contributors to vitamin D intake in non-
breastfed infants (72–85% depending on age considered). They were followed by ‘commercial infant
foods’ (9%–12%), particularly ‘cereal-based foods and dishes’ (6%–7%).
4.2.1.7. Intake data from Finland
Healthy infants in Helsinki were recruited for a RCT (ongoing at the time of the publication) of
vitamin D supplementation (10 or 30 lg/day, VIDI study) from age 2 weeks to 2 years, and vitamin D
intake from a cross-sectional analysis of these subjects at age 1 year are presented (Hauta-Alus et al.,
2017). The authors indicate that, since 2010, vitamin D3 fortiﬁcation in Finland is 1 lg/100 mL of ﬂuid
dairy product and 20 lg/100 g of dietary fats.
Mean (SD, range) estimated vitamin D intake in partially breastfed and non-breastfed infants was
3.8 (3.0, 0–30.7) and 7.5 (3.2, 0.6–28.3) lg/day, respectively.
Among all infants, 95% consumed ‘mass-produced baby foods’. Porridges (milk-based or ‘mass-
produced baby food’) and ‘infant formulae’ were the top contributors to vitamin D intake in both
breastfed (25 and 11%, respectively) and non-breastfed (19 and 31%, respectively) infants. Other
major contributors to vitamin D intake were ﬁsh-based dishes particularly in breastfed infants (24%)
and milk particularly in non-breastfed infants (17% for skimmed milk, 12% for low-fat milk).
Contribution of meat dishes and dietary fats is also described.
4.2.1.8. Conclusion on vitamin D intake or modelling data, either published or collected
through a consultation of Member States by the European Commission
From these data, the Panel notes that ‘high’ percentiles (e.g. P95) of estimated vitamin D intake
from foods without supplements in infants were generally below the UL of 25 lg/day (EFSA NDA
Panel, 2012a). However, ‘high’ percentiles (e.g. P95) of estimated vitamin D intake from foods
including supplements in infants may be beyond the UL.
4.2.2. Individual food consumption of infants in the EU available to EFSA
To estimate dietary intake of vitamin D, EFSA used food consumption data from the EFSA
Comprehensive Food Consumption Database (EFSA, 2011b).58 This database provides a detailed
compilation of existing information on food consumption in the EU, nationally representative (or
regionally representative as for the Finnish survey), and classiﬁed according to the food classiﬁcation
and description system FoodEx2. Consumption data were collected at individual level using single or
repeated 24- or 48-hour dietary recalls or dietary records covering from 3–7 days.
For infants aged below 4 months, at the time this assessment was undertaken, food
consumption data were only available from one survey carried out in Bulgaria, and thus were not used
for the intake assessment. The methodology applied by EFSA for the intake assessment in this age
group is described in Section 4.3.1.
For infants aged 4 to less than 12 months, the intake assessment included food consumption
data from dietary surveys on subjects with at least two reporting days from six countries: Bulgaria,
Denmark, Finland, Germany, the UK and Italy, covering in total 3,375 individuals (Table 1). Infants of
different ages participated in these surveys. In particular, the Finnish survey included relatively young
infants compared to the other surveys, since the age of all subjects was rounded to 0.5 or 1 years by
58 http://www.efsa.europa.eu/en/food-consumption/comprehensive-database
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the authors of the survey and all subjects at 1 year were considered as ‘toddlers’ (children aged
1–< 3 years) in the EFSA Comprehensive Food Consumption database. Considering the very few
infants from the Italian survey, limited conclusions can be drawn from it.
The identiﬁcation of these two age categories (below and above 4 months of age) in the population
targeted in this opinion also accounts for the additional vitamin D intake in relation to the introduction
of complementary feeding (EFSA NDA Panel, 2009).59 (Table 8)
Table 8 shows the number of formula consumers in each survey, deﬁned as individuals who have
consumed infant or FoF at least once over the reporting days. Thus, the term ‘formula consumers’ in
this scientiﬁc opinion and related Annex B should not be considered as synonymous to ‘non-breast-fed
infants’ (e.g. some infants may have consumed formula and breast milk). Previous intake assessments
for scientiﬁc opinions on DRVs showed that most infants in these surveys were partially breastfed, with
a proportion of breastfed infants of 58% in the Finnish survey, 40% in the German survey, 44% in the
Italian survey, 21% in the UK survey. Overall surveys on infants included in this assessment, this
proportion is 33%. In the Finnish survey, breast milk intake was not taken into consideration in the
intake estimates as no information on the breastfeeding events was reported. The Panel notes the
limitations in the methods used for assessing breast milk consumption in infants60 and related
uncertainties in the vitamin D intake estimates for infants. However, considering the low vitamin D
content of breast milk, this was not considered by the Panel to be a major source of uncertainty.
From these surveys on infants undertaken between 2001 and 2011, limited information was
available on consumption of dietary supplements containing vitamin D:
 Consumer percentages per country: vitamin supplements (any vitamin) reported to be
consumed in Finland, UK and Italy; the percentage of consumers was 90% in the Finnish
survey but only 6% in the UK survey and 19% in the Italian survey, which, however, reported
only on three consumers;
 names of the vitamin supplements consumed, without composition data.
As noted by EFSA NDA Panel (2016), the ESPGHAN Committee on Nutrition recommends a daily
oral supplementation of 10 lg vitamin D for all infants during the ﬁrst year of life starting from birth
onwards (Braegger et al., 2013) (Section 1.6). However, there are different national supplementation
policies for vitamin D in infants in the EU (Section 1.1), and compliance with these policies may also
Table 8: Surveys in infants for which individual data were available to EFSA
Country Survey
Number of
subjects
Number of
formula
consumers
Dietary
assessment
Age (years)
min max
Bulgaria NUTRICHILD 2007 510 220 2-d 24-h recall 0.42 0.92
Denmark IAT 2006_07 826 598 7-d weighted DR 0.44 0.99
Finland DIPP_2001_2009 500 303 3-d weighted DR 0.5 0.5
Germany VELS 2001 159 110 6-d DR 0.4 0.99
Italy INRAN_SCAI_2005_2006 11 6 3-d DR 0.4 0.9
UK DNSIYC_2011 1,369 1,188 4-d weighted DR 0.39 0.99
DIPP: Type 1 Diabetes Prediction and Prevention survey; DR: dietary record; IAT: survey on Infants And Toddlers; INRAN–SCAI:
Istituto Nazionale di Ricerca per gli Alimenti e la Nutrizione – Studio sui Consumi Alimentari in Italia; min: minimum; max:
maximum; VELS: Verzehrsstudie zur Ermittlung der Lebensmittelaufnahme von S€auglingen und Kleinkindern f€ur die Absch€atzung
eines akuten Toxizit€atsrisikos durch R€uckst€ande von Pﬂanzenschutzmitteln; UK: United Kingdom.
59 In this scientiﬁc opinion of 2009 on the appropriate age for introduction of complementary feeding of infants, ’the
Panel concludes that the introduction of complementary food into the diet of healthy term infants in the EU between the age
of 4 and 6 months is safe and does not pose a risk for adverse health effects’. At the time the present scientiﬁc opinion was
drafted, this opinion on appropriate age for introduction of complementary feeding was under revision (EFSA-Q-2016-00482).
60 For example, for the German study, the total amount of breast milk was calculated based on the observations by Paul et al.
(1988) on breast milk consumption during one eating occasion at different age groups: the amount of breast milk consumed
on one eating occasion was set to 135 g/eating occasion for infants between 6 and 7 months of age and to 100 g/eating
occasion for infants between 8 and 12 months of age (Kersting and Clausen, 2003). For the UK survey, the amount of breast
milk consumed was either directly quantiﬁed by the mother (expressed breast milk) or extrapolated from the duration of each
breastfeeding event.
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vary between countries. In addition, no information was available in these six surveys on vitamin D
intake of infants through consumption of vitamin D-containing medications. In this context, and
considering the background of the mandate for this scientiﬁc opinion (Section 1.1) related to the
change in regulatory content of vitamin D in IF, the Panel did not make any assumption, in its
intake assessment, regarding vitamin D supplementation.
However, as an indication, EFSA undertook a search in the Mintel GNPD Database over the last
5 years (thus on products available after the latest survey considered) and for all EU countries included
in the Database. Overall countries with data on vitamin D supplements (19 countries, 151 products),
data on vitamin D supplements61 for infants aged < 1 year were available from 12 countries and
46 products in ﬁve different formats (capsules, drops, tablets, chewing pastilles or powder). Out of
these products (44 of them containing vitamin D3, the rest unspeciﬁed), 33 provided an intake of
10 lg/day, with different conditions of use and formats (mostly drops or twist-off capsules). The
remaining products, according to the different conditions of use, provided for a vitamin D amount
between 1.75 and 15 lg/day (Appendix Q). The Panel notes that, although some information on
composition of the products was available in the Mintel GNPD, it showed that there was variability in
the additional amount of vitamin D from supplements (1.75–15 lg/day). This database does not
provide information on food consumption, in particular on supplement consumption.
The Panel decided to perform the intake assessment separately for infants below and above
4 months of age, to account for the additional vitamin D amount in relation to the introduction of
complementary feeding (Section 1.6). For the intake assessment for infants aged from 4 to less than
12 months, food consumption data from nationally or regionally representative dietary surveys on
infants were available from six countries. For the reasons described above, the Panel did not make
any assumption in its intake assessment regarding vitamin D supplementation.
4.3. Intake calculations for infants aged 0–< 4 months (formula
consumers) undertaken by EFSA
4.3.1. Approach for the calculations (formula consumers aged 0–< 4 months)
For the assessment of the intake of vitamin D for infants aged less than 4 months, the Panel used the
default value for high formula consumption proposed by the EFSA Scientiﬁc Committee et al. (2017b)
(Section 2). In this Guidance Document, assuming that in non-breastfed infants, formula is the only
source of nutrition for the ﬁrst 16 weeks of life, the default value of 260 mL/kg body weight per day
among infants aged about 1 month is deﬁned as the highest relative consumption on a body weight basis
for the whole period of the ﬁrst 16 weeks. This value is also in line with data on formula consumption
among formula consumers (i.e. not the full study population) in the Bulgarian survey (Section 4.2.2).
The Panel also used for these calculations the P95 of formula consumption in infants aged about
4 months, based on the same Guidance Document and derived from the same study, i.e. 195 mL/kg
body weight per day at 4 months.
As the Panel sets an UL based on an intake on a daily basis (and not relative to body weight), the
Panel multiplied the default value by reference body weights. For these calculations, median body
weights of boys and girls were used. The choice of the median body weights was based on the need
to make calculations for a reference/standard situation. The Panel considered that the choice of a
higher percentile (e.g. P95) would have been reﬂecting an extreme scenario and therefore
overconservative. The Panel assumes that the high consumption of formula expressed in mL per kg
body weight per day may be observed among the heaviest infants but also the lightest who may be
experiencing catch-up growth.
Median body weights used for the calculations came from two sources:
 median weights for ages 1 and 4 months of male and female infants according to the WHO
Growth Standards (WHO Multicentre Growth Reference Study Group, 2006). These were
created from longitudinal primary growth data and related information from 8,440 healthy
breastfed infants and young children from diverse ethnic backgrounds and cultural settings
(Brazil, Ghana, India, Norway, Oman and USA). The Panel notes that only one European
country (Norway) was considered in this data set; however, the WHO Growth Standards are
widely used in EU countries.
61 This covers only products available in supermarkets (e.g. not drops or tablets with vitamin D for infants available in pharmacy
under a medical prescription).
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 median measured body weights of EU male and female infants according to van Buuren et al.
(2012). This external scientiﬁc report was provided to EFSA and compiles anthropometry data
for infants and children (0–18 years) from the 27 EU Member States at the time of the report.
For the calculations, median body weights at age 4–5 weeks (as a proxy for age 1 month) and
age 18 weeks (as a proxy for age 4 months) were considered.
Calculations were performed with the maximal content of vitamin D allowed both in the Directive
2006/141/EC and Commission Delegated Regulation (EU) 2016/127 (2.5 and 3 lg/100 kcal,
respectively), and an energy content from IF between 60 and 70 kcal/100 mL, as provided by both
legislative texts. Although possible ‘overage’ has been reported, e.g. in formulae (Section 4.1.1.5), the
Panel did not make assumptions regarding possible ‘overage’ in these calculations. The Panel also
did not make assumptions on intake provided by vitamin D supplementation (Section 4.2.2).
4.3.2. Results of the calculations (formula consumers aged 0–< 4 months)
Results are provided in Table 9. Estimated intakes of vitamin D above the present UL of 25 lg/day
for infants (EFSA NDA Panel, 2012a) are indicated in bold and italics.
Considering the maximal regulated vitamin D in IF in Commission Delegated Regulation (EU) 2016/127
(3 lg vitamin D/100 kcal), the Panel notes that, depending on the reference body weight, ‘high’
formula consumption, age of the infants (about 1 or 4 months) and energy content of formulae (without
considering additional intake due to supplementation and without considering possible overages62):
 some of these calculated ‘high’ vitamin D intake are below the UL of 25 lg/day set in 2012,
 others are above this UL of 25 lg/day and remain below 30 lg/day.
Considering the maximal regulated vitamin D content in IF in Directive 2006/141/EC (2.5 lg
vitamin D/100 kcal), the Panel notes that all estimated vitamin D intakes indicated in Table 9 were
below the UL of 25 lg/day set in 2012 (without considering additional intake due to supplementation
and without considering possible overages).
Table 9: Calculation for intake assessment of infants aged less than 4 months
Age
Reference body
weight (kg)
Absolute volume
of formulae
consumed
(mL/day)
Calculated vitamin D
intake according
to Directive
2006/141/EC
Calculated vitamin D
intake according
to Delegated
Regulation (EU)
2016/127
min–max (lg/day)(c) min–max (lg/day)(d)
Boys Girls Boys Girls Boys Girls Boys Girls
Default value at 1 mo=260 mL/kg body weight per day(e)
1 mo 4.5(a) 4.2(a) 1,170 1,092 18–21 16–19 21–25 20–23
4 wk 4.2(b) 4(b) 1,092 1,040 16–19 16–18 20–23 19–22
5 wk 4.4(b) 4.2(b) 1,144 1,092 17–20 16–19 21–24 20–23
Default value at 4 mo=195 mL/kg body weight per day(e)
4 mo 7(a) 6.4(a) 1,365 1,248 21–24 19–22 25–29 23–26
18 wk 6.6(b) 6.2(b) 1,287 1,209 19–23 18–21 23–27 22–25
(a): Median reference weight according to WHO Growth Standards (WHO Multicentre Growth Reference Study Group, 2006).
(b): Median weight according to the report from (van Buuren et al., 2012).
(c): Range of maximal values of vitamin D content in infant formulae calculated as 2.5 lg/100 mL 9 60–70 kcal = 1.5–1.75 lg/
100 mL
(d): Range of maximal values of vitamin D content in infant formulae calculated as 3 lg/100 mL 9 60–70 kcal = 1.8–2.1 lg/
100 mL
(e): Default values according to EFSA Scientiﬁc Committee et al. (2017b).
62 See Sections 4.1.1.5 and 4.3.1.
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4.4. Intake assessment for infants aged 4–< 12 months undertaken by
EFSA
4.4.1. Approach for the intake assessment (age 4–< 12 months)
4.4.1.1. Selection of data on natural vitamin D content in foods
Among foods that naturally contain vitamin D (i.e. that are not fortiﬁed with this vitamin), sources
of vitamin D3 include animal foods (e.g. ﬁsh, offal, meat, egg yolks) (Section 1.5), for which vitamin D
content may differ according to factors including the vitamin D content of the animal feed (EFSA NDA
Panel, 2016). For potential natural sources of vitamin D2, i.e. higher fungi, the content may depend on
whether or not mushrooms have been cultivated in the dark or whether yeast has been exposed to UV
(Kristensen et al., 2012; EFSA NDA Panel, 2014b).
In this intake assessment, the effect of cooking practices (baking, steaming, etc.) was not taken
into account. For milk or fermented milk products, skimmed, semiskimmed or whole milk were not
considered separately (vitamin D content was averaged for unfortiﬁed milk, see Section 4.4.1.3).
Similarly, for meat and meat products, the different meat cuts for a given animal (e.g. collar, shoulder,
leg, ﬁllet) were not considered separately.
4.4.1.2. Selection of data on fortiﬁed foods: outlier analysis and data cleaning
As information on the level of fortiﬁcation of foods was generally not available from the EFSA
Nutrient Composition Database (Section 4.1.2), EFSA performed an outlier analysis of its data set to
identify any value which deviated from the others for a given food code. The objective was to
discriminate values that were due to variability in their natural vitamin D content from values due to
fortiﬁcation. In addition, possible misclassiﬁcations of food codes in a given food group were corrected
and/or the records deleted.
EFSA performed the outlier analysis on food categories for which a more than 10-fold difference
between the minimum and the maximum values of vitamin D content was identiﬁed in the EFSA
Nutrient Composition Database, with more than 10 eating occasions in the EFSA Comprehensive Food
Consumption Database.
 When no outliers were identiﬁed for a given food code, the mean content of vitamin D was
taken as a unique value.
 Whenever outliers were identiﬁed for a given food code, highest and lowest values were
compared with published data, national food composition databases available online as well as
with data from the Mintel Database and recipes available on the Internet (for composite foods,
e.g. biscuits). If not part of the natural variability according to this search, the highest vitamin
D contents were assumed to be due to vitamin D fortiﬁcation. A few foods (e.g. avocado, meat
burger) showing implausible vitamin D content (as provided to EFSA by some national
databases) were excluded.
As additional check speciﬁcally to discriminate foods with natural content of vitamin D from foods
fortiﬁed with vitamin D, EFSA performed searches in Mintel GNPD to identify foods containing vitamin D as
an ingredient, marketed in the EU in the last 5 years (2012–2017). This search showed a high variability in
fortiﬁcation practices within the EU, with regard to the number of foods identiﬁed with vitamin D as an
ingredient per country63 or the frequency of such foods within each Mintel food category per country.64
As a result of the outlier analysis and the reality check in Mintel, 58 food categories for which food
consumption data were available for infants in the EFSA Comprehensive Food Consumption Database,
and which could contain vitamin D according to the EFSA Nutrient Composition Database, were
considered for this assessment of vitamin D intake. For 14 of them, the possibility of fortiﬁcation with
vitamin D was taken into account. For each food category, for the fortiﬁed and non-fortiﬁed versions
when applicable, an average content of vitamin D was estimated (Section 4.4.1.3).
Within the 58 food categories which could contain vitamin D, in case of ‘zero’ values for some
foods, only values considered plausible and part of the natural variability were included in the
63 For example, over all food categories followed in the Mintel GNPD database, over the past 5 years, nine products were
identiﬁed in Slovakia with vitamin D in the ingredient list, and about 430 in the UK (search in September 2017).
64 For example, the percentage of butter fortiﬁed with vitamin D was calculated by EFSA to be 1.2% overall Europe from the
data available in Mintel, but the analysis by country showed that e.g. 23.7% of butter in Norway was fortiﬁed with vitamin D
(search in September 2017).
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calculations (e.g. non-fortiﬁed breakfast cereals). The ‘zero’ values considered as not plausible were
excluded from the calculations (e.g. zero vitamin D in whole cow milk) or reclassiﬁed accordingly.
For some food codes of animal origin, identiﬁed discrepancies in vitamin D content between
countries that provided data to EFSA may have been due to the use by some national food
composition databases of a factor of 5 to convert 25(OH)D present in animal foods into total vitamin D
(EFSA NDA Panel, 2016) (Section 4.1.2). In such cases, corrections were applied by EFSA to convert
all values to vitamin D3.
Dilution/conversion factors were used based on a previous report65 that deﬁned them on the basis
of information from the Mintel GNPD database, which conﬁrmed the usual factors used in other risk
assessment areas.
 For IF and FoF reported in the Consumption Database as powder, a conversion factor of 8 was
used to convert all forms into liquid.
 For processed cereal-based foods for infants, as the regulated vitamin D contents are
expressed for the reconstituted forms (i.e. forms ready for use, see Section 4.1.4), different
factors were used to convert all consumption data into values for these forms. A conversion
factor of 4 was used for ‘simple cereals which have to be reconstituted with milk or other
appropriate nutritious liquids’.66 A factor of 7 was instead used for ‘cereals with an added high
protein food which have to be reconstituted with water or other protein-free liquid’.67
4.4.1.3. Selection of values for vitamin D content in non-fortiﬁed and fortiﬁed foods
For its intake assessment, the Panel considered the vitamin D content of the following fortiﬁed foods:
 The regulated contents of IF and FoF and processed cereals-based foods for infants and young
children (Section 4.1.4). As the regulated vitamin D contents were expressed per 100 kcal of
foods ready for use, EFSA collected data on the speciﬁc energy content of each speciﬁc food
category among processed cereals-based foods for infants (Directive 2006/125/EC50) in the
Mintel GNPD Database. EFSA used the median energy content to convert the regulated vitamin D
contents into values per 100 g or mL (Table 10). For IF and FoF, the minimal and maximal
regulated contents were considered (thus, no distribution of vitamin D content in formulae
between these two extremes was considered) (Table 10).
 For fortiﬁed milk, the Panel chose the vitamin D content of 1 lg/100 mL, as the maximum
content present in the EU market, in Finland (Table 11).
 For the remaining foods consumed by infants, the mean vitamin D content as indicated in
the EFSA Nutrient Composition Database was considered (Section 4.1.2). For the remaining 11
food categories possibly fortiﬁed, EFSA used the mean vitamin D content (Table 11) as
indicated in this EFSA Database for the fortiﬁed and non-fortiﬁed versions after data cleaning
(Section 4.4.1.4).
Although ‘overage’ in fortiﬁed foods (or dietary supplements) has been reported (Section 4.1.1.5),
EFSA did not make any assumptions regarding possible overage for this intake assessment.
Table 10: Vitamin D content considered for three mandatorily fortiﬁed food categories for infants
Food category Mean content (lg/100 g or 100 mL)
‘Old’ regulation
(Directive
2006/141/EC)
‘New’ regulation
(Del. Reg.(EU)
2016/127)
Directive
2006/125/EC
Min Max Min Max Min Max
Infant formulae 0.60 1.75 1.20 2.10
Follow-on formulae 0.60 2.10 1.20 2.10
Cereals with an added
high-protein food reconstituted
0.81 2.43
65 EFSA internal report on the harmonization of dilution factors to be used in the assessment of dietary exposure. Available at:
https://zenodo.org/record/1256085#.WxTweC5uaUm
66 As ‘the most frequent reconstitution indication presented by manufacturers is 1 part of cereals to 4 parts of water’.
67 As, in the range of dilution factors (5–10) provided by the producers, more than half of the products presenting indications of
lower dilutions ratios.
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An additional reality check speciﬁcally on the vitamin D content of the fortiﬁed versions of the food
categories in Table 11 was conducted by EFSA in the Mintel GNPD Database. This search was done
over the last 5 years and for ﬁve of the countries that provided infant food consumption data from
dietary surveys (Italy, Denmark, Finland, UK, Germany, Table 8).68 This reality check (Table 12)
conﬁrmed that the mean values of vitamin D content taken into account in the intake assessment for
the foods considered to be fortiﬁed were equal or below the most frequent values reported for these
fortiﬁed foods available on the market according to Mintel (no overestimation). As the available data
on intake of vitamin D in infants collected from the literature and Members States showed that the
main contributors to vitamin D intake were food supplements followed by mandatorily fortiﬁed foods
(e.g. formulae) (Section 4.2.1), further reﬁnements on the composition data for voluntarily fortiﬁed
foods were not deemed necessary for this assessment.
4.4.1.4. Proposed intake scenarios for infants aged 4–< 12 months
The intake of vitamin D from food (without dietary supplements) was calculated at the individual
level by multiplying the average daily consumption for each food or food groups with the
Table 11: Vitamin D content considered for 11 food categories considering or not fortiﬁcation
Food category
Mean content (lg/100 g or 100 mL)
Non-fortiﬁed Fortiﬁed
Biscuits, rusks and cookies for children 2.80 10.00
Biscuits 0.40 2.20
Cheese 0.29 2.10
Margarines and similar 0.28 5.97
Milk and dairy powders 0.20 2.10
Dairy dessert and similar 0.15 0.44
Milk 0.14 1.00
Fermented milk products 0.07 0.27
Breakfast cereals 0.00 2.08
Dairy imitates 0.00 1.04
Simple cereals for infants or children, reconstituted 0.00 2.43
Table 12: Comparison of the vitamin D content of fortiﬁed food categories in EFSA Nutrient
Composition Database and in Mintel GNPD database
Food category fortiﬁed
with vitamin D
Vitamin D content
(from EFSA’s data)(a)
Vitamin D content
(fromMintel GNPD)
Number of
products in
Mintel GNPD
mean
(lg/100 mL or /100 g)
mode
(lg/100 mL or /100 g)
Dairy imitates 1 0.75 241
Cheese 2.10 6.25 29
Margarines and similar 5.97 7.5 191
Milk and dairy powders 2.10 2 (as prepared/
reconstituted)
7
Dairy dessert and similar 0.44 0.75 138
Milk 1.00 1 26
Fermented milk products 0.27 0.75 272
Breakfast cereals 2.08 4.2 281
Biscuits 2.2 1.5 34
Biscuits and rusks for infants 10 10 5
GNPD: Global New Products Database.
(a): EFSA Nutrient Composition Database (Roe et al., 2013). Date of searches: December 2017–February 2018.
68 At the time of this assessment, the Bulgarian market was not followed in Mintel GNPD.
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corresponding vitamin D content, summing up the respective intakes throughout the diet. In principle,
inaccuracies in this matching of food consumption and food composition data may lead to
uncertainties (either under or overestimation); however, these were assumed to be limited. No
assumptions were made about the consumption of dietary supplements or medications containing
vitamin D by infants (Section 4.2.2).
In the context of the present mandate, EFSA estimated distributions of vitamin D intake from food
(P5, P95, median and mean) in two subgroups: formula consumers and non-formula consumers.
Formula consumers were deﬁned as those consuming formula at least once during the day (Section
4.2.2). EFSA considered different scenarios to estimate vitamin D intake from food (without
considering dietary supplements) in infants aged 4–< 12 months. Summary results for formula
consumers are discussed in the core text of this opinion, while detailed results for formula and non-
formula consumers are available in Annex B (Excel® ﬁle).
Two main scenarios were deﬁned: ‘fortiﬁed’ and ‘non-fortiﬁed’ with vitamin D. Further detailed
scenarios were deﬁned based on the minimal and maximal vitamin D content of infant and FoF, which
are the main source of vitamin D in infants, according to the two regulatory texts for these food
categories (Table 10).
Scenarios 1–4 (‘non-fortiﬁed’ scenarios) consider all foods at their natural vitamin D content
(including zero) and the three food categories mandatorily fortiﬁed with vitamin D (Table 10): infant
and FoF and cereals with an added high protein food reconstituted with water or other protein-free
liquid (a subcategory of processed cereal-based foods for infants and young children).
Scenarios 5–8 (‘fortiﬁed’ scenarios) consider the 11 food categories (Table 11) with a vitamin D
content considered to be due to fortiﬁcation and the three food categories mandatorily fortiﬁed with
vitamin D.
The different scenarios take into account IF and FoF fortiﬁed at the minimum (scenarios 1 and 3, 5
and 7) or the maximum (scenarios 2 and 4, 6 and 8) regulated vitamin D content, from both
regulatory texts (Directive 2006/141/EC and Commission Delegated Regulation (EU) 2016/127)
(Sections 1.1 and 4.1.4). They also take into account processed cereals-based foods for infants and
young children at their minimum (scenarios 1 and 3) and/or maximum (scenarios 6 and 8) regulated
values (Directive 2006/125/EC) (Section 4.1.4).
Depending on the scenario, for the 11 food categories listed in Table 4, the vitamin D content
which is considered natural, or the content after fortiﬁcation, was used for the calculations for the
‘non-fortiﬁed’ or ‘fortiﬁed’ scenarios, respectively. For example:
 in scenarios 1–4, whenever biscuit consumption was reported at individual level, it was
assumed that all foods from the category ‘biscuit’ were non-fortiﬁed. Thus, the average vitamin
D content of the ‘non-fortiﬁed version’ observed in the EFSA Nutrient Composition Database for
this food category (i.e. 0.4 lg/100 g) was used.
 On the contrary, in scenarios 5–8, whenever biscuit consumption was reported at individual
level, it was assumed that all foods from the category ‘biscuit’ were fortiﬁed at the average
level of 2.2 lg/100 g.
Detailed results on estimated vitamin D intake (P5, P95, median and mean) for each scenario are
available in Annex B (Excel® ﬁle), and summary results are discussed in Section 4.4.2.
From this approach, major points need to be highlighted:
 In the ‘fortiﬁed scenarios’ (scenarios 5–8), no assumption was made on the proportion of foods
within each of the 11 food categories that may be voluntarily fortiﬁed.
 Consumption of none, one or up to all of the 11 food categories that can be voluntarily fortiﬁed
may have been reported at individual level. This means that, for example, if for a given
individual, eating occasions were reported for all of these 11 food categories, all were
considered as non-fortiﬁed (scenarios 1–4) or as fortiﬁed (scenarios 5–8) at the level indicated
in Table 11.
 This means that, while the food consumption data are representative of the country in which
the survey was made (e.g. Bulgaria, UK, Denmark), the composition data used in the fortiﬁed
scenarios were not meant to reﬂect the fortiﬁcation practices of this speciﬁc country. The
scenarios were rather deﬁned as describing ‘extreme’ situations that may occur on the EU
market regarding voluntarily fortiﬁed foods, taking into account different possible food patterns
in infants and the two ‘extremes’ in the range of the vitamin D content in mandatorily fortiﬁed
foods.
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4.4.2. Results of the intake assessment for infants aged 4–< 12 months
Among formula consumers, across the eight scenarios and the six surveys considered by EFSA for
its intake assessment, the mean contribution of IF or FoF to vitamin D intake from food (without
dietary supplements) was variable and detailed results are reported in Annex B (Excel® ﬁle). The mean
contribution of IF and FoF (combined) across scenarios and countries ranged from 31% to 97%.
This is in line with available data published or collected from Member States (Section 4.2.1) indicating
that the main contributors to vitamin D intake from food (without dietary supplements) were the
mandatorily fortiﬁed foods (including processed cereal-based foods).
As previously mentioned (Section 4.4.1.4), the eight scenarios were deﬁned as describing situations
that may occur on the EU market regarding voluntarily fortiﬁed foods, taking into account different
possible food patterns in infants and the two extremes in the range of the vitamin D content in
mandatorily fortiﬁed foods (they were not meant to reﬂect the fortiﬁcation practices of speciﬁc
countries). Observed food patterns were not available for infants in nationally representative surveys
from all EU Member States and food fortiﬁcation practices vary substantially from one country to the
other. The Panel notes that this should be born in mind when discussing estimated intakes
of vitamin D in different scenarios.
Tables 13 and 14 report estimated intake of vitamin D (mean, and P95, i.e. ‘high consumers’ for
vitamin D) in formula consumers, for the scenarios based on Commission Delegated Regulation (EU)
2016/127. Detailed results for these scenarios and this regulatory text as well as results for scenarios
based on Directive 2006/141/EC and results for non-formula consumers are available in Annex B
(Excel® ﬁle). The Panel notes that estimated vitamin D intakes from food (without dietary
supplements) are much lower in non-formula consumers than in formula consumers (discussed below):
estimated mean intakes in non-formula consumers across surveys and scenarios were all below the AI
for infants of 10 lg/day and even estimated intakes at P95 of non-formula consumers were at or
below the AI (EFSA NDA Panel, 2016).
Annex B and Tables 13–14 indicate (in red in Annex B, and in italics in the Tables) estimated
intakes below the AI for infants of 10 lg/day. Intakes close to the UL of 25 lg/day for infants set in
2012 (EFSA NDA Panel, 2012a) were also identiﬁed (in bold and italics in the Tables). This information
is provided for the reader in order to help interpret the magnitude and distribution of the estimated
intakes in the different scenarios. The reader of Annex B is also kindly invited to take into
account national food consumption patterns, national food fortiﬁcations practices and
national supplementation policies to estimate vitamin D intakes in his/her own country.
Table 13: Mean vitamin D intake from food (without dietary supplements) of infants 4–12 months,
formula consumers only, under Commission Delegated Regulation (EU) 2016/127, in four
scenarios (S)
Country
Survey (food
consumption data)
N of
subjects
Mean
vitamin D intake (lg/day)
‘non-fortiﬁed’
scenarios(a)
‘fortiﬁed’
scenarios(b)
Min Max Min Max
S3 S4 S7 S8
Bulgaria NUTRICHILD 220 7.1 11.3 9.6 13.9
Germany VELS 110 4.5 7.1 7.2 9.8
Denmark IAT 2006_07 598 5.3 8.5 6.9 10.1
Finland DIPP_2001_2009 303 5.6 9.5 6.2 10.2
UK DNSIYC_2011 1,188 7.2 11.8 9.1 13.8
Italy INRAN_SCAI_2005_06 6 5.1 8.7 6.5 10
DIPP: Type 1 Diabetes Prediction and Prevention survey; DR: dietary record; IAT: survey on Infants And Toddlers; INRAN-SCAI:
Istituto Nazionale di Ricerca per gli Alimenti e la Nutrizione – Studio sui Consumi Alimentari in Italia; min: minimum; max:
maximum; VELS: Verzehrsstudie zur Ermittlung der Lebensmittelaufnahme von S€auglingen und Kleinkindern f€ur die Absch€atzung
eines akuten Toxizit€atsrisikos durch R€uckst€ande von Pﬂ anzenschutzmitteln; UK: United Kingdom.
(a): Minimum (S3) and maximum (S4) vitamin D regulated content in formulae, no voluntarily fortiﬁed foods considered.
(b): Minimum (S7) and maximum (S8) vitamin D regulated content in formulae, mandatory and voluntarily fortiﬁed foods
considered.
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Scenarios 3 and 4 represent, respectively, the estimates for the scenarios with the minimum (2 lg/
100 kcal) and the maximum (3 lg/100 kcal) regulated content of vitamin D in infant and FoF
according to the Commission Delegated Regulation (EU) 2016/127 that will come into force in 2020
(further called ‘new’ regulation).
For comparison purposes, scenarios 7 and 8 represent the ‘worst-case’ scenarios with, respectively,
the minimum and the maximum vitamin D regulated content set according to the proposed values in
Commission Delegated Regulation (EU) 2016/127 that will come into force in 2020.
The Panel notes that, for formula consumers, the mean intakes are mostly below the AI for the
‘non-fortiﬁed’ scenarios (3 and 4) and around the AI for the fortiﬁed scenarios (7 and 8). The P95
intake for the ‘non-fortiﬁed’ scenarios is around the AI considering the minimum vitamin D regulated
content, whilst P95 intakes for scenarios 7 and 8 are above the AI but below 25 lg/day.
Considering the range of vitamin D intake coming from formula consumption with composition
according to Commission Delegated Regulation (EU) 2016/127, depending on the food patterns of
formula consumers observed in a speciﬁc country, the Panel notes that:
 High consumers (P95 of vitamin D intake) may consume approximately between about 10 and
25 lg/day vitamin D from foods in countries with high frequency of food fortiﬁcation
(scenarios 7–8)
 High consumers (P95 of vitamin D intake) may consume approximately between about 8 and
20 lg/day vitamin D from foods in countries with low frequency of food fortiﬁcation
(scenarios 3–4)
Assuming all formulae contain vitamin D at the maximum regulated content, the impact of
voluntary food fortiﬁcation at current vitamin D content is shown by comparing scenarios 4 and 8.
Depending on the food patterns and the age of the infants, the Panel notes that the impact of food
fortiﬁcation may contribute up to around 5 lg/day extra at P95.
In comparison, the difference in estimated intakes at P95 between the ‘old’ (Directive 2006/141/EC)
(scenario 6) and ‘new’ regulation (Commission Delegated Regulation (EU) 2016/127) (scenario 8) is
smaller (e.g. around 3 lg at P95) (Annex B).
The Panel also notes that although the consumption of IF or FoF has a large impact on vitamin
D intake, the additional impact of changing from the ‘old’ to the ‘new’ maximum vitamin D content is
Table 14: P95 vitamin D intake from food (without dietary supplements) of infants 4–12 months,
formula consumers only, under Commission Delegated Regulation (EU) 2016/127, in four
scenarios (S)
Country
Survey
(food consumption
data)
N of
subjects
P95 vitamin D intake (lg/day)
“non-fortiﬁed”
scenarios(a)
“fortiﬁed”
scenarios(b)
Min Max Min Max
S3 S4 S7 S8
Bulgaria NUTRICHILD 220 12.1 19.9 16.7 24.6
Germany VELS 110 8.2 13.2 12.9 16.9
Denmark IAT 2006_07 598 9.7 16.4 11.2 17.7
Finland DIPP_2001_2009 303 10.3 17.9 10.4 18.1
UK DNSIYC_2011 1,188 11.2 18.8 13.5 20.5
Italy INRAN_SCAI_2005_06 6 * * * *
DIPP: Type 1 Diabetes Prediction and Prevention survey; DR: dietary record; IAT: survey on Infants And Toddlers; INRAN-SCAI:
Istituto Nazionale di Ricerca per gli Alimenti e la Nutrizione – Studio sui Consumi Alimentari in Italia; min: minimum; max:
maximum; VELS: Verzehrsstudie zur Ermittlung der Lebensmittelaufnahme von S€auglingen und Kleinkindern f€ur die Absch€atzung
eines akuten Toxizit€atsrisikos durch R€uckst€ande von Pﬂanzenschutzmitteln; UK: United Kingdom.
*: 95th percentile intakes calculated from fewer than 60 subjects require cautious interpretation as the results may not be
statistically robust (EFSA, 2011b) and, therefore, for these dietary surveys, the 95th percentile estimates are not presented in
the intake results.
(a): Minimum (S3) and maximum (S4) vitamin D regulated content in formulae, no voluntarily fortiﬁed foods considered.
(b): Minimum (S7) and maximum (S8) vitamin D regulated content in formulae, mandatory and voluntarily fortiﬁed foods
considered.
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relatively small. There is little difference between the highest estimated intake at the mean or P95 for
the ‘old’ and ‘new’ scenarios (Annex B), i.e. comparing:
 Scenarios 2 and 4 among the ‘non-fortiﬁed scenarios’ (highest mean of about 11 vs. about
12 lg/day, and highest P95 about 17 vs. about 20 lg/day, respectively)
 Scenarios 6 and 8 among the ‘fortiﬁed scenarios’ (highest mean of about 13 vs. about
14 lg/day, and highest P95 about 22 vs. about 25 lg/day, respectively).
5. Derivation of a Tolerable Upper Intake Level for vitamin D for
infants
Based on the proposed mechanism of toxicity (Section 1.9) and previous assessments by EFSA and
other bodies (Sections 1.4 and 1.10), the Panel focussed on the following four adverse health
outcomes: hypercalciuria, hypercalcaemia, ectopic calciﬁcation, e.g. nephrocalcinosis, and abnormal
growth patterns. The adverse outcomes associated with ‘high’ daily vitamin D intake in infants were
examined by the Panel in trials and prospective observational studies obtained through a systematic
literature review (Section 3). Hypercalciuria is considered as the earliest sign of excessive vitamin D
intake (Section 1.9).
5.1. Hypercalciuria
Two prospective observational studies and three RCTs were available, which measured urinary Ca/Cr
ratios in healthy infants supplemented with vitamin D up to 40 lg/day for a period of 6 weeks up to
11 months (Section 3.3.2). These studies showed inconsistent results with considerable discrepancies in
the rate of hypercalciuria (from 3–6% to 39%). There was no dose–response relationship between
urinary Ca/Cr ratios and the administered dose of vitamin D in any of these studies (Appendix M).
The Panel notes the methodological limitations of these studies in relation to design that the
deﬁnition of hypercalciuria based on the value of urinary Ca/Cr ratio varied between studies and that
urinary Ca/Cr ratios were assessed in single spot urine samples which limit their ability to provide
reliable information on the total amount of calcium excreted with the urine.
The Panel considers that available data on the relationship between vitamin D intake and the
risk of hypercalciuria cannot be used for deriving the UL of vitamin D for infants.
5.2. Hypercalcaemia
Sixteen papers (each covering one or several studies) measured serum calcium and/or reported on
hypercalcaemia in healthy infants supplemented with vitamin D up to 50 lg/day for up to 11 months
(Section 3.3.3). This number includes the few papers used in the former EFSA Opinion (EFSA NDA
Panel, 2012a), and two additional papers published after the end of the literature search (Section 3.1).
These studies analysed either serum total calcium or ionised calcium. Three of the studies (four
papers) reported cases of hypercalcaemia deﬁned as ‘high’ serum calcium concentration. Among them,
one RCT reported suspected hypercalcaemia based on ionised calcium in a few infants in each of the
study groups supplemented with vitamin D doses from 10 to 40 lg/day. Clinical symptoms suggestive
of hypercalcaemia were not observed in any of these studies, and there was no indication of an
association between the dose of vitamin D and risk of hypercalcaemia. This absence of a dose–
response relationship was also obvious from forest plots of mean serum total calcium and
supplemental intake of vitamin D (up to 50 lg/day) in study arms at different time points, in infants
below and above 6 months of age (Figure 2).
The Panel notes that the deﬁnition of hypercalcaemia varied between studies, and often only single
measurements of serum calcium were reported which may not provide an indication of the risk of
sustained elevated serum calcium. The Panel also notes that in case reports, clinical symptoms
suggestive of hypercalcaemia have been associated with vitamin D intakes of 44 lg/day and above
(Section 3.4).
The Panel considers that available data on the relationship between vitamin D intake and the risk of
hypercalcaemia do not allow conclusions to be drawn for deriving the UL of vitamin D for infants.
5.3. Ectopic calciﬁcation (e.g. nephrocalcinosis)
The risk of developing nephrocalcinosis as a result of vitamin D3 supplementation with 12.5 lg/day
for 2 months was considered in one study in healthy infants (Section 3.3.4). This study did not ﬁnd
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any cases of nephrocalcinosis, but the Panel notes that the dose of vitamin D was well below the
current UL (close to the AI of 10 lg/day (EFSA NDA Panel, 2016)). In another study on healthy infants
supplemented with doses up to 40 lg/day of vitamin D3 for 11 months, additional safety procedures
(electrocardiogram or renal ultrasound) in those with ‘suspected’ hypercalcaemia or ‘suspected’
hypercalciuria did not reveal any abnormalities in secondary analysis (Sections 3.3.2 and 3.3.3).
The Panel notes the scarcity of data on ectopic calciﬁcation in relation to vitamin D intake and
considers that the available data cannot be used for deriving the UL of vitamin D for infants.
5.4. Abnormal growth patterns
Eleven papers (some of them on studies of small scale) investigated growth and/or anthropometric
parameters at speciﬁc ages (rather than increments over time which would better represent growth) in
healthy infants supplemented with vitamin D up to 40 lg/day for up to 11 months (Section 3.3.5).
Since the previous Opinion (EFSA NDA Panel, 2012a), which described the results from earlier studies
that did not provide consistent results, three additional RCTs reported on growth of infants
supplemented with vitamin D (up to 40 lg/day) as secondary outcomes. The forest plots (Appendix P)
provided no evidence of a dose–response relationship between daily vitamin D supplemental intake
over the range of doses tested (i.e. up to 40 lg/day) and absolute mean values of attained length and
weight at different time points. The Panel notes that growth was not a primary endpoint of the
investigation in most of the studies.
The Panel considers that the available data on the relationship between vitamin D intake and the
risk of abnormal growth patterns cannot be used for deriving the UL of vitamin D for infants.
5.5. Conclusion on daily vitamin D intake and adverse health outcomes
The Panel notes the absence, for ethical reasons, of data on the systematic administration of
deﬁned vitamin D doses above 50 lg/day to healthy infants.
The Panel concludes that the available data on adverse health outcomes (hypercalciuria,
hypercalcaemia, nephrocalcinosis, abnormal growth patterns) cannot be used alone for deriving the
UL of vitamin D for infants.
5.6. Serum 25(OH)D concentration
The level of daily vitamin D intake or serum 25(OH)D concentration that is associated with the
occurrence of adverse health outcomes could not be determined by the Panel on the basis of the
available data. In consideration of the uncertainties associated with the available evidence from studies
on daily vitamin D intake and various adverse health outcomes in infants (Section 5.5), the Panel could
not deﬁne a NOAEL for vitamin D intake. However, the Panel notes the proposed mechanisms by
which sustained elevated serum 25(OH)D concentrations could lead to adverse health outcomes
(Section 1.9). For reasons described in Section 3.3.6, the Panel considers that a serum 25(OH)D
concentration of 200 nmol/L or below is unlikely to pose a risk of adverse health outcomes
(hypercalciuria, hypercalcaemia, nephrocalcinosis, abnormal growth) in infants. This should not be
regarded as a cut-off for toxicity but as a conservative value from which a UL could be derived.
Thus, the Panel derives the UL of vitamin D for infants based on the dose–response relationship of
daily supplemental intake of vitamin D and serum 25(OH)D concentrations that are unlikely to pose a
risk of adverse health outcomes. The Panel recognises, however, that serum 25(OH)D
concentration is not an adverse health outcome per se but can be considered as a
surrogate endpoint.
Hence, the Panel used an approach for the derivation of the UL for vitamin D in infants similar to
that used for setting AIs for vitamin D (EFSA NDA Panel, 2016), i.e. the assessment of the dose–
response relationship between daily vitamin D intake and achieved serum 25(OH)D concentrations,
based on aggregated data (meta-regression). In this opinion, only supplemental vitamin D doses could
be considered (instead of the total vitamin D intake, for setting AIs for vitamin D), the correlated
structure in the data (several arms within one study and repeated measurements at different time
points within one arm) was accounted for and, in order to be as protective as possible, varying values
for the covariates were considered (and not e.g. their mean values).
This choice of approach by the Panel is in line with the guidance of EFSA’s Scientiﬁc Committee on
Benchmark Dose Modelling (BMD), that recommends using a dose–response modelling approach to
establish the reference point (point of departure), in order to set health-based guidance values (EFSA
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Scientiﬁc Committee et al., 2017a). The Panel chose to select serum 25(OH)D concentrations as a
reference point. For selection of the model, the Akaike information criterion was applied (Section 3.5
and Annex A).
From the systematic literature review undertaken by EFSA, six trials in healthy infants (corresponding
to 17 arms, and 58 time points) with limited risk of bias were included in a quantitative meta-analytical
synthesis, in order to characterise the dose–response relationship between daily supplemental intake of
vitamin D (between 5 and 50 lg/day) and mean achieved serum 25(OH)D concentrations in each study
arm (Sections 3.1 and 3.5 and Annex A). This model was stratiﬁed by baseline serum 25(OH)D
concentrations (10–30, 30–60, 60–100 nmol/L) and age groups (< 6 months, ≥ 6 months) and the
duration of vitamin D supplementation was set at 3–6 months. From this model, an empirical distribution
of mean achieved serum 25(OH)D concentrations was generated from a large number of simulations.
From this, a distribution of serum 25(OH)D concentrations that may be achieved by individuals was then
simulated, and the Panel estimated, for different vitamin D intakes, the percentage of infants possibly
reaching a concentration above 200 nmol/L as a numerical threshold.
In this approach, models based on original or ln-transformed scales were derived: the ln-
transformed model is the one better meeting the assumptions of normality and homoscedasticity,
whereas the model in the original scale better ﬁts linearity, and both models (both scales)
considered together give a sense of the uncertainty associated with the several choices performed
at the methodological level and their inﬂuence on the results.
As a result of the analysis, the percentages of infants exceeding the serum 25(OH)D concentration
of 200 nmol/L increase with increasing supplemental vitamin D intakes. This percentage is higher with
increasing baseline serum 25(OH)D concentrations and decreases with age.
5.6.1. Infants aged up to 6 months
Based on the results of the prediction model in original scale (Table 6), 25 lg/day can be identiﬁed
as the daily intake of vitamin D at which, depending on the baseline serum 25(OH)D concentration,
0–4% of individuals aged < 6 months would exceed serum 25(OH)D concentrations of 200 nmol/L.
The results of the ln-transformed scale, up to a vitamin D supplemental dose of 25 lg/day, are
consistent with the results in the original scale. The Panel notes that predictions from the model for
the age 0–6 months support the UL of 25 lg/day set by SCF (2003) and retained by EFSA NDA
Panel (2012a).
For infants aged up to 6 months, the Panel concludes that the available body of evidence supports
keeping the previous UL of 25 lg/day.
5.6.2. Infants aged 6 to less than 12 months
The Panel notes that, in the prediction model, at a given intake of vitamin D, infants older than
6 months achieve lower serum 25(OH)D concentrations than infants younger than 6 months, which
may be explained by the increase in body mass (Tables 6 and 7). The Panel also notes that the UL set
for children aged 1–10 years is 50 lg/day (EFSA NDA Panel, 2012a).
Based on the results of the prediction model (original scale) (Table 7), for infants aged between 6
and 12 months of age, the predicted percentage of individuals exceeding serum 25(OH)D
concentrations of 200 nmol/L would be 0–1% at supplemental vitamin D intake of up to 25 lg/day,
0–2% at intakes of up to 30 lg/day and 0–4% at intakes of up to 35 lg/day. For the ln-transformed
scale, these percentages of individuals exceeding serum 25(OH)D concentrations of 200 nmol/L range
from 0 to around 2% for doses up to 35 lg/day. Thus, for infants aged 6 to less than 12 months, the
Panel considers that evidence from the predictions supports a UL for vitamin D of 35 lg/day.
5.6.3. General comments on the model
Acknowledging the heterogeneity in the body of evidence and the uncertainties in the modelling,
this dose–response analysis offers the opportunity to identify the level of vitamin D intake from
supplements associated with the minimum percentage of infants with ‘high’ 25(OH)D concentrations in
serum (Section 3.5 and Annex A).
In this model, only supplemental vitamin D intake is considered because data on the vitamin D
intake from the other foods of the diet were not available in most of the studies. Therefore, the infants
exceeding the serum 25(OH)D concentration of 200 nmol/L are likely to have total vitamin D intakes
somewhat beyond the intakes provided by supplements.
UL of vitamin D for infants
www.efsa.europa.eu/efsajournal 68 EFSA Journal 2018;16(8):5365
The derived UL for vitamin D in infants is based on studies using supplemental vitamin D rather than
formula fortiﬁed with speciﬁc amounts of vitamin D. It is unknown whether vitamin D from formula will
have different absorption and bioavailability from vitamin D provided as a supplement as there are only
limited data on the effect of the food matrix on vitamin D absorption (EFSA NDA Panel, 2016).
5.6.4. Case reports
Case reports describe adverse health outcomes (mentioned above) associated with the
administration to one or a few infants of repeated mg doses of vitamin D as well as with chronic daily
administration of vitamin doses of about 4.5–20 times the AI of 10 lg/day for this age (EFSA NDA
Panel, 2016) (Section 3.4). The Panel notes that adverse health outcomes reported in these case
reports were associated with elevated serum 25(OH)D and reduced PTH concentrations. As these
reports either cannot be converted into daily doses or are based on incidental ﬁndings, the
Panel concludes that they are not suitable to deﬁne a LOAEL for vitamin D in infants.
6. Characterisation of the risk
The characterisation of the risk of an intake above the UL for vitamin D is presented separately for
infants aged up to 6 months and infants aged 6 to less than 12 months.
The characterisation of the risk is derived from the intake assessment, which was conducted
separately for infants aged up to 4 months, and for those aged 4 to less than 12 months, to account
for the additional vitamin D intake in relation to the introduction of complementary feeding
(Section 4.2.2). For reasons previously described (Sections 4.1.1.5 and 4.2.2), the Panel did not make
assumption in its intake assessment regarding vitamin D supplementation or possible overages from
fortiﬁed foods or supplements.
6.1. Characterisation of the risk for infants < 6 months of age
For exclusively breastfed infants, no risk of exceeding the UL is expected because of the low
vitamin D content in breast milk (ranging from 0.25 to 2.0 lg/L, (EFSA NDA Panel, 2016)).
For infants exclusively fed with formula, the calculations are based on default ‘high’ IF
consumptions of 260 and 195 mL/kg body weight per day at about 1 and 4 months, respectively
(EFSA Scientiﬁc Committee et al., 2017b), on the 50th percentile of reference body weights (WHO
Multicentre Growth Reference Study Group, 2006; van Buuren et al., 2012), and the maximum
regulated vitamin D content in IF of 2.5 lg/100 kcal (Directive 2006/141/EC) or 3 lg/100 kcal
(Commission Delegated Regulation (EU) 2016/127).
 The daily vitamin D intake from IF alone, containing the maximal regulated vitamin D content
of 3 lg/100 kcal, may exceed the UL of 25 lg/day at age about 4 months in some infants,
depending on the energy content of formulae which may vary between 60 and 70 kcal/100 mL
(Section 4.3.2, Table 9). The precise percentage of such infants could not be determined from
the available data. Estimated vitamin D intakes from IF alone would remain below 30 lg/day.
 The daily vitamin D intake from IF alone, containing the maximal regulated vitamin D content
of 2.5 lg/100 kcal, will not exceed the UL of 25 lg/day (Section 4.3.2, Table 9). The margin
between the calculated intakes via formulae and the UL varies between 1 and 9 lg/day,
depending on the reference body weight, ‘high’ formula consumption, age (about 1 or
4 months) and energy content considered.
6.2. Characterisation of the risk for infants ≥ 6 months of age
The intake assessment for infants aged 4 to less than 12 months was conducted separately for
consumers and non-consumers of IF and FoF (Section 4.4). The intake assessment was done:
 using food consumption data of infants from six surveys, most of them nationally
representative of EU countries, conducted between 2001 and 2011 and for which the individual
data were available to EFSA in 2017;
 and considering eight intake scenarios. These were deﬁned based on the minimum or
maximum amount of vitamin D in IF and FoF according to the two regulatory texts (Directive
2006/141/EC and Commission Delegated Regulation (EU) 2016/127) and based on the
composition of foods fortiﬁed or not with vitamin D, coming from the EFSA Nutrient
Composition Database and from the Mintel GNPD.
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The scenarios were assumed to describe situations that may occur on the EU market taking into
account voluntarily fortiﬁed foods, different possible food patterns in infants, but excluding the
contribution from supplements (for the reasons explained in Section 4.2.2), and considering the two
extremes in the range of the vitamin D content in mandatorily fortiﬁed foods. They were not meant to
reﬂect the fortiﬁcation practices of the six EU countries that provided food consumption data.
For the characterisation of the risk of an intake above the UL for vitamin D, means and P95 of
estimated vitamin D intake from European populations were used (Tables 13 and 14).
 For infants consuming neither formulae nor fortiﬁed foods and for those not consuming
formulae but consuming fortiﬁed foods, the estimated means and P95 of vitamin D intake are
below or at the AI of 10 lg/day.
 For infants consuming IF or FoF containing the maximum regulated amount of vitamin D (i.e.
3 lg/100 kcal) but not consuming fortiﬁed foods, the estimated means and P95 of vitamin D
intake range from about 7 to 12 lg/day and from about 13 to 20 lg/day, respectively. The
margin between the estimated P95 of vitamin D intake in formula consumers and the UL of
35 lg/day varies between about 15 and 22 lg/day.
 With the additional intake of fortiﬁed foods, the estimated means and P95 vitamin D intake
range from about 10 to 14 lg/day and from about 17 to 24.6 lg/day, respectively. The margin
between the estimated P95 of vitamin D intake and the UL of 35 lg/day varies between about
10 and 18 lg/day.
The Panel concludes that data from various European infant populations indicate that for infants
aged 6 to less than 12 months, vitamin D intake in high consumers of formulae and fortiﬁed foods is
below the UL of 35 lg/day.
7. Conclusions
7.1. Conclusion regarding the UL for vitamin D in infants
The Panel concludes that the UL for infants < 6 months of age is set at 25 lg/day and the UL for
infants ≥ 6 months of age is set at 35 lg/day (Section 5).
The Panel concludes on the UL for vitamin D from data mainly on vitamin D3 (Annex A), as the
dose–response analysis to predict the percentage of individuals that would have serum 25(OH)D
concentrations above 200 nmol/L included studies that used supplementation with vitamin D3.
However, the updated UL of 25 and 35 lg/day applies both to vitamin D2 and D3.
7.2. Conclusion regarding the maximal regulated vitamin D content in
infant formulae (infants below 4 months)
The use of a maximum vitamin D content of 3 lg/100 kcal in IF as per Commission Delegated
Regulation (EU) 2016/127 may lead some infants aged at about 4 months to consume amounts of
vitamin D above the UL of 25 lg/day from formulae alone (without considering additional intake due
to supplementation and without considering possible overages) (Sections 4.1.1.5, 4.3.1, 4.3.2 and
6.1). The precise percentage of such infants could not be determined from the available data.
The use of a maximum vitamin D content of 2.5 lg/100 kcal in IF in Directive 2006/141/EC does
not result in intakes of vitamin D above the UL of 25 lg/day from formulae alone (without considering
additional intake due to supplementation and without considering possible overages). The margin
between the calculated intakes via formulae and the UL varies between 1 and 9 lg/day
(Sections 4.1.1.5, 4.3.1 and 4.3.2).
7.3. Conclusion regarding infants aged 4–12 months
For infants aged 4 to less than 12 months and consuming IF or FoF containing the maximum
amount of vitamin D (i.e. 3 lg/100 kcal as per Commission Delegated Regulation (EU) 2016/127) but
not consuming fortiﬁed foods or supplements (Sections 4.2.2, 4.4.2 and Annex B):
 the margin between the estimated P95 of vitamin D intake in formula consumers and the UL of
35 lg/day (i.e. for infants 6–12 months) varies between about 15 and 22 lg/day (scenario 4).
 the margin calculated with the UL of 25 lg/day (i.e. for infants 4–6 months) varies between
about 5 and 12 lg/day (scenario 4).
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With the additional intake of fortiﬁed complementary foods (scenarios in Section 4.4.2 and
Annex B):
 the margin between the estimated P95 of vitamin D intake in formula consumers and the UL of
35 lg/day (i.e. for infants 6–12 months) varies between about 10 and 18 lg/day (scenario 8).
 the margin calculated with the UL of 25 lg/day (i.e. for infants 4–6 months) varies between
about 0.4 and 8 lg/day (scenario 8).
For infants aged 4 to less than 12 months and consuming IF or FoF containing the maximum
amount of vitamin D (i.e. 2.5 or 3 lg/100 kcal, respectively, as per Directive 2006/141/EC) but not
consuming fortiﬁed foods or supplements (Sections 4.2.2, 4.4.2 and Annex B):
 the margin between the estimated P95 of vitamin D intake in formula consumers and the UL of
35 lg/day (i.e. for infants 6–12 months) varies between about 18 and 22 lg/day (scenario 2).
 the margin calculated with the UL of 25 lg/day (i.e. for infants 4–6 months), varies between
about 8 and 12 lg/day (scenario 2).
With the additional intake of fortiﬁed complementary foods (scenarios in Section 4.4.2 and
Annex B):
 the margin between the estimated P95 of vitamin D intake in formula consumers and the UL of
35 lg/day (i.e. for infants 6–12 months) varies between about 13 and 20 lg/day (scenario 6).
 the margin calculated with the UL of 25 lg/day (i.e. for infants 4–6 months), varies between
about 3 and 10 lg/day (scenario 6).
Observed food patterns were not available for infants in nationally representative surveys from all
EU Member States and food fortiﬁcation practices vary substantially from one country to the other. The
Panel notes that this should be born in mind when discussing estimated intakes of vitamin D in
different scenarios. The margin between the estimated P95 of vitamin D intake in formula consumers
and the UL in the various deﬁned scenarios of food consumption could be considered as an indication
of the possible additional impact of supplementation. This indication should be considered bearing in
mind the regulatory compositional requirements of formulae and in the speciﬁc context of national
supplementation policies and compliance with these policies.
8. Recommendations for research
• Consumption surveys providing information on dietary (including fortiﬁed foods) and
supplemental vitamin D intake of infants and compliance with vitamin D supplementation
policies in different countries. Intake data modelling of contribution of foods, including fortiﬁed
foods and supplements, to vitamin D intake of infants, and their impact on the intake of the
low and high consumers (to minimise both the risk of vitamin D deﬁciency and the risk of
exceeding the UL);
• Studies on infants that compare the effect of vitamin D2 and D3 on serum 25(OH)D
concentrations;
• Studies on infants providing information on the normal range of physiological values of serum
and urinary calcium;
• Longitudinal studies with regular, reliable and standardised measurements of calcium in serum
and urine, serum 25(OH)D and PTH concentrations and ectopic calciﬁcation in relation to total
vitamin D intake (foods including supplements); information may also be obtained by revisiting
previously generated datasets;
• Studies on the functional role of the C3-epimer of 25(OH)D;
• Studies providing information on the dose–response relationship between vitamin D intake and
serum concentration of 25(OH)D and vitamin D metabolites;
• Studies to better characterise the inﬂuence of various factors on serum 25(OH)D concentration
(in particular in infants), e.g.: vitamin D frequency of consumption, baseline serum 25(OH)D
concentration, sun exposure, season, body mass (or age) and body fat, maternal
characteristics during pregnancy and lactation, in particular maternal supplementation with
vitamin D.
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1,25(OH)2D 1,25-dihydroxy-vitamin D
25(OH)D 25-hydroxy-vitamin D
AI adequate intake
BMD Benchmark Dose Modelling
BMI body mass index
BSA body surface area
CI conﬁdence interval
CLIA automated chemiluminiscence immunoassay
COT UK Committee on toxicity of chemical in food, consumer products and the environment
CPBA competitive protein-binding assay
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DBP vitamin D-binding protein
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ELISA enzyme-linked immunosorbent assay
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ESPGHAN European Society for Paediatric Gastroenterology, Hepatology and Nutrition
FFQ food frequency questionnaire
FGF ﬁbroblast growth factor
FoF follow-on formula
FoodEx2 EFSA food classiﬁcation and description system (revision 2)
GNPD Global New Products Database
HPLC high-performance liquid chromatography
IF infant formula
IIH idiopathic infantile hypercalcaemia
IOM US Institute of Medicine
IU international unit
LC–MS/MS liquid chromatography-tandem mass spectrometry
LOAEL lowest observed adverse effect level
MS member state
NDA Panel on Dietetic Products, Nutrition and Allergies
NDNS National Diet and Nutrition Survey
NEVO Nederlands Voedingsstoffenbestand
NIST US National Institute of Standards and Technology
NOAEL no observed adverse effect level
NRCT non-randomised controlled trial
NRNCT non-randomised non-controlled trial
NTP National Toxicology Program
OHAT Ofﬁce of Health Assessment and Translation
OR odds ratio
P95 95th percentile
PROSP prospective cohort study
PTH parathyroid hormone
RCT randomised controlled trial
RIA radioimmunoassay
RNCT randomised non-controlled trial
RoB risk of bias
RIA radioimmunoassay
SACN Scientiﬁc Advisory Committee on Nutrition
SCF Scientiﬁc Committee on Food
SD standard deviation
SLC solute carrier
UF uncertainty factor
UL tolerable upper intake level
USDA US Department of Agriculture
UV ultraviolet
VDSP Vitamin D Standardization Program
VDR vitamin D receptor
VIDI vitamin D intervention
VIO VoedingsstoffenInnameOnderzoek (Nutrient Intake Study)
VITADEK study on the intake of vitamin A, D, E and K
Vitamin D2 ergocalciferol
Vitamin D3 cholecalciferol
WHO World Health Organization
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Appendix A – Systematic literature search for hazard characterisation:
mapping of results of the literature search by languages (e.g. in Embase)
Date: June 2017
Language Embase
English 4450
French 162
German 161
Spanish 81
Polish 59
Italian 42
Russian 27
Turkish 22
Czech 21
Japanese 20
Chinese 19
Dutch 19
Hungarian 11
Portuguese 9
Swedish 8
Danish 7
Croatian 6
Norwegian 6
Bulgarian 5
‘Unknown’ 5
Persian 4
Ukrainian 4
Romanian 3
Serbian 3
Slovak 3
Arabic 2
Finnish 2
Icelandic 2
Afrikaans 1
Catalan 1
Estonian 1
Greek 1
Korean 1
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Appendix B – Systematic literature search for hazard characterisation:
initial eligibility criteria related to study characteristics/populations
NB: Criteria described below are those as initially selected by the Panel. A few of these criteria have
later been adapted by the Panel (Section 3)
Study populations
(at the time of the
intake of vitamin D)
In 1) Studies on healthy full-term infants (from birth to < 12 months). In case of
a study on a mixed population, e.g. a study on infants (i.e. > 12 months) and
young children (1–3 years), for which the results would not be reported
separately), the study may be included, in case it respects the other eligibility
criteria.
2) Studies on full-term infants with vitamin D deﬁciency rickets under
treatment.
3) Studies on an undistinguishable mix of full and preterm infants, or studies on
infants with no clear/explicit information on whether the infants were born at
term or not, may be considered as well.
Out 1) Studies and study arms explicitly restricted to preterm infants (deﬁned
as born before the 37th week of gestation). It was considered that
extrapolating from premature/preterm infants, which is a heterogeneous group,
to full-term infants was not possible.
2) Trials or prospective studies restricted to infants with (a) disease(s)69
(apart from full-term infants with vitamin D deﬁciency rickets under treatment)
are excluded. This criterion does not apply to retrospective cohort studies,
case–control studies or case reports on the outcomes of interest. Retrospective
studies undertaken only on people with a disease should be excluded. In case
of a study on a mixed population (e.g. infants with vitamin D deﬁciency
rickets with or without additional diseases, for which the results would
not be reported separately), the study may be included, in case it respects the
other eligibility criteria.
3) Studies investigating the association between dietary or supplemental
vitamin D intake of pregnant or breastfeeding women on (adverse)
health outcomes in their offspring.
4) Studies investigating very low birth weight infants.
Studies on low birth weight infants (deﬁned as weighing less than 2.5 kg or
also called small for gestational age infants) will not be excluded, as healthy
full-term low birth weight infants could still be fed with standard infant formula
or breastfed and could even receive higher amount of formulae. However, very
low birth weight infants (deﬁned as infants weighing less than 1.5 kg) are often
(very) preterm or born at term but with adverse health outcomes and/or fed
parenterally or enterally via a tube and/or fed with a preterm formula. Thus,
studies on these infants will be excluded from this assessment, because the
results that cannot be extrapolated to the general population of healthy infants
born at term
Study designs In 1) Randomised controlled trials, which assessed the effect of different
levels of intake of vitamin D on the selected adverse health outcomes and
endpoints
In view of the variety of adverse health outcomes considered, no minimal
duration for the study will be requested
2) non-controlled randomised trials (e.g. comparing the same dose of
vitamin D2 and vitamin D3), non-randomised controlled trials, non-
randomised non-controlled trials
69 In particular, studies on ‘idiopathic infantile hypercalcaemia’ should be excluded.
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3) Observational studies (retrospective and prospective cohort
studies, case–control), excluding cross-sectional studies.
For case–control and retrospective cohort studies, the case individuals would
need to present at least one of the adverse health outcomes identiﬁed
In view of the different adverse health outcomes considered, which could occur
within different time frames, no limits on the follow-up will be requested (e.g. a
study reporting outcomes in childhood or adulthood after vitamin D
consumption in infancy would be considered).
Special attention will be paid to:
– the consideration of main confounding factors
– the quality of the study design (e.g. was the body weight measured, was the
sun exposure assessed, was the time of the year reported, was the dose
analytically checked?)
Out 1) Cross-sectional observational studies
This study type provides only summary information on intake/dose of
supplementation and its association with frequency of occurrence of adverse
effects
2) Preclinical studies (animals, in vitro, in silico data)
3) Case reports: Case reports will not be considered for further screening,
data extraction, appraisal and dose–response analysis, as referring to acute/
short-term consumption of vitamin D and due to the high risk of bias. However,
reports on case individuals presenting at least one of the adverse health
outcomes identiﬁed may be considered qualitatively in the scientiﬁc opinion, but
separately from the other considered study designs, and in case of clear
identiﬁcation of the ingested dose of vitamin D and the adverse health outcome
observed in infants under clinical care. Thus, data from case reports may be
used as supporting evidence. For this, they will be ﬂagged to go to a speciﬁc
category in order to allow an easy retrieval
Intervention (study
designs 1 or 2) or
exposure (study
design 3)
In For trials, oral vitamin D consumption, alone or with a concomitant intake
of other nutrient(s) (e.g. vitamin D + calcium). Trials should consider dose(s) of
vitamin D above 10 lg/day (value set for the adequate intake for infants
(EFSA NDA Panel, 2016)).
In view of the low content of vitamin D in breast milk, and the often limited
content of vitamin D in some foods (e.g. fruits and vegetables), studies that do
not assess the vitamin D intake from sources other than the intervention will
not be excluded (e.g. a study on vitamin D supplementation in breastfed
infants with no information on vitamin D in breast milk would not be excluded)
Out 1) Interventions with parenteral administration of vitamin D
2) Interventions using only doses of vitamin D of 10 lg/day or less.
3) Although no requirement on frequency of vitamin D oral consumption will be
applied to the search or during the title/abstract screening, changes in serum
or urinary calcium concentrations or serum 25(OH)D concentrations after
weekly, monthly or single large doses of vitamin D cannot be directly compared
with those occurring after daily or weekly consumption. Thus, while trials on
daily doses may be considered for further quantitative analysis, as for case
reports mentioned above, trials (or arms of trials) on weekly, monthly
doses, bolus doses or ‘stoss’ therapy will be ﬂagged to go to a speciﬁc
category in order to allow an easy retrieval
Outcomes of interest In Above-mentioned health outcomes
– hypercalciuria: number of cases or percentage of cases, data on urinary
calcium concentrations, data or urinary ratios of calcium/creatinine
– hypercalcaemia: number of cases or percentage of cases, data on serum
calcium concentrations, ionised calcium concentrations
– ectopic calciﬁcation in particular nephrocalcinosis: number of cases or % of
cases of nephrocalcinosis
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– failure to thrive: weight, length/height, head circumference longitudinally
reported
– ‘high’ serum 25(OH)D concentration
Out Any other health outcomes or endpoints
In particular, studies only on cord blood would not be relevant (unless
measurements of serum/plasma 25(OH)D concentration later during infancy are
also available), as 25(OH)D concentration in cord blood would rather be
indicative of maternal vitamin D status and the provision of vitamin D to the
foetus by the mother
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Appendix C – Systematic literature search for hazard characterisation: search strategies
Final number of hits for each database (bold) are given before the removal of duplicates.
1) Pubmed
Date of the search 19/6/2017
Limits: items published in English, French or German
Search Query Hits
#24 Search #22 AND #23 3,304
#23 Search English[Language] OR French[Language] OR German[Language] 24,243,150
#22 Search #20 NOT #21 3,551
#21 Search “Editorial” [Publication Type] OR “Letter” [Publication Type] 1,381,109
#20 Search #18 NOT #19 3,585
#19 Search (rat[ti] OR rats[ti] OR mouse[ti] OR mice[ti] OR murine[ti] OR rodent[ti] OR rodents[ti] OR hamster[ti] OR hamsters[ti] OR pig[ti] OR pigs
[ti] OR porcine[ti] OR rabbit[ti] OR rabbits[ti] OR animal[ti] OR animals[ti] OR dogs[ti] OR dog[ti] OR cats[ti] OR bovine[ti] OR sheep[ti] OR ovine
[ti] OR monkey[ti] OR monkeys[ti]) NOT medline[sb]
96,381
#18 Search #16 NOT #17 3,595
#17 Search “animals”[MeSH Terms] NOT “humans”[MeSH Terms] 4,338,097
#16 Search #15 AND #2 3,750
#15 Search #13 OR #14 18,602
#14 Search “Vitamin D/adverse effects”[Mesh:noexp] OR “Vitamin D/complications”[Mesh:noexp] OR “Vitamin D/toxicity”[Mesh:noexp] OR “Vitamin D/
poisoning”[Mesh:noexp] OR “Cholecalciferol/adverse effects”[Mesh:noexp] OR “Cholecalciferol/complications”[Mesh:noexp] OR “Cholecalciferol/
toxicity”[Mesh:noexp] OR “Cholecalciferol/poisoning”[Mesh:noexp] OR “Ergocalciferols/adverse effects”[Mesh:noexp] OR “Ergocalciferols/
complications”[Mesh:noexp] OR “Ergocalciferols/toxicity”[Mesh:noexp] OR “Ergocalciferols/poisoning”[Mesh:noexp]
1,846
#13 Search #12 AND #5 17,413
#12 Search #11 OR #10 OR #9 OR #8 OR #7 OR #6 5,552,060
#11 Search (((((“Hydroxycholecalciferols”[Mesh] OR “25-Hydroxyvitamin D 2”[Mesh] OR hydroxycholecalciferol*[tiab] OR hydroxycolecalciferol*[tiab]
OR hydroxyergocalciferol*[tiab] OR “hydroxyvitamin d”[tiab] OR “hydroxyvitamins d”[tiab] OR “hydroxyvitamin d3”[tiab] OR “hydroxyvitamins
d3”[tiab] OR “hydroxivitamin d”[tiab] OR “hydroxivitamins d”[tiab] OR “hydroxivitamin d3”[tiab] OR “hydroxivitamins d3”[tiab] OR calcifediol[tiab]
OR 25ohd[tiab] OR “25 ohd”[tiab] OR “25 oh d”[tiab] OR “25ohd3”[tiab] OR “25 ohd3”[tiab] OR “25 oh d3”[tiab] OR “25 oh d 3”[tiab] OR
calcidiol[tiab]) AND (serum[tiab] OR plasma[tiab] OR blood[tiab]))) OR (“Hydroxycholecalciferols/blood”[Mesh] OR “25-Hydroxyvitamin D 2/
blood”[Mesh]))) AND (((concentration*[tiab] OR elevat*[tiab] OR high[tiab] OR higher[tiab] OR increas*[tiab])))
14,786
#10 Search “Hypercalcaemia”[Mesh] OR “Calcium/blood”[Mesh] OR Hypercalcaemia[tiab] OR hypercalciema[tiab] OR hypercalcaemia[tiab] OR
calcemia[tiab] OR ((blood[tiab] OR serum[tiab] OR plasma[tiab]) AND calcium[tiab]) OR “Hypercalciuria”[Mesh] OR “Calcium/urine”[Mesh] OR
hypercalciuria[tiab] OR hypercalcinuria[tiab] OR calciuria[tiab] OR (urinary[tiab] AND calcium[tiab]) OR calcium ratio[tiab] OR calcium homeostasis
[tiab] OR (calcium[tiab] AND homoeostasis[tiab])
124,450
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Search Query Hits
#9 Search “Urolithiasis”[Mesh] OR ((urinary[tiab] OR kidney*[tiab] OR renal[tiab] OR bladder[tiab] OR vesical[tiab] OR ureter*[tiab]) AND (calcu*
[tiab] OR stone*[tiab] OR lithias*[tiab])) OR nephrolith*[tiab] OR urolith*[tiab] OR cystolith*[tiab]
78,590
#8 Search “Nephrocalcinosis”[Mesh] OR nephrocalcinos*[tiab] OR ((kidney*[tiab] OR renal[tiab] OR tubulus[tiab] OR tubular[tiab] OR nephric[tiab])
AND (calcinosis[tiab] OR calcinoses[tiab] OR calciﬁcation[tiab] OR calciﬁed[tiab])) OR ectopic calciﬁcation*[tiab] OR abnormal calciﬁcation*[tiab]
OR acute calciﬁcation*[tiab] OR ectopic calcinos*[tiab]
10,013
#7 Search “Drug-Related Side Effects and Adverse Reactions”[Mesh] OR “Toxicity Tests”[Mesh] OR “Poisoning”[Mesh:noexp] OR “Substance-Related
Disorders”[Mesh:noexp] OR “Drug Overdose”[Mesh] OR “No-Observed-Adverse-Effect Level”[Mesh] OR “Dose-Response Relationship,
Drug”[Mesh] OR ((adverse[tiab] OR side[tiab] OR undesirable[tiab] OR unwanted[tiab]) AND (effect[tiab] OR effects[tiab] OR reaction*[tiab] OR
event[tiab] OR events[tiab] OR outcome*[tiab])) OR complication*[tiab] OR upper intake*[tiab] OR upper limit*[tiab] OR intake limit*[tiab] OR
noael[tiab] OR noel[tiab] OR no observed effect*[tiab] OR toxic*[tiab] OR intoxic*[tiab] OR poison*[tiab] OR excess*[tiab] OR risk[tiab] OR risks
[tiab] OR hypervitaminos*[tiab] OR hyper vitaminos*[tiab] OR supervitaminos*[tiab] OR “super vitaminosis”[tiab] OR “super vitaminoses”[tiab]
OR “dose response”[tiab] OR “dose effect”[tiab] OR “dosage effect”[tiab] OR “dosage response”[tiab] OR “dose activity”[tiab] OR “dosage
activity”[tiab]
4,048,172
#6 Search ((“Body Weight”[Mesh] OR “Growth and Development”[Mesh:NoExp] OR “Growth”[Mesh] OR “Body Height”[Mesh] OR “Body Mass
Index”[Mesh] OR growth[tiab] OR weight[tiab] OR “body size”[tiab] OR “body mass”[tiab] OR BMI[tiab] OR length[tiab] OR height[tiab] OR
“head circumference”[tiab] OR development*[tiab]) AND (retard*[tiab] OR disorder*[tiab] OR reduc*[tiab] OR trajector*[tiab] OR disturb*[tiab]
OR curve*[tiab] OR limit*[tiab] OR negative[tiab] OR adverse[tiab] OR rate[tiab] OR factor affect*[tiab] OR factors affect*[tiab] OR factor
inﬂuenc*[tiab] OR factors inﬂuenc*[tiab] OR factor alter*[tiab] OR factors alter*[tiab] OR factor chang*[tiab] OR factors chang*[tiab] OR failure
[tiab] OR abnormal*[tiab])) OR “Growth Disorders”[Mesh] OR “Body Weight Changes”[Mesh] OR “Failure to Thrive”[Mesh] OR “failure to
thrive”[tiab]
1,922,815
#5 Search #3 AND #4 24,263
#4 Search “Dietary Supplements”[Mesh:NoExp] OR “Food, Fortiﬁed”[Mesh] OR “Infant Food”[Mesh] OR “Milk”[Mesh] OR intake*[tiab] OR consum*
[tiab] OR supplement*[tiab] OR diet[tiab] OR diets[tiab] OR dieta*[tiab] OR diete*[tiab] OR food*[tiab] OR administrat*[tiab] OR intervention
[tiab] OR fortif*[tiab] OR milk[tiab] OR formula*[tiab] OR high dose[tiab] OR higher dose[tiab] OR high dosage[tiab] OR higher dosage[tiab] OR
overdos*[tiab] OR over dosage*[tiab] OR over dose[tiab]
2,696,723
#3 Search “Vitamin D”[Mesh:NoExp] OR “Cholecalciferol”[Mesh:NoExp] OR “Ergocalciferols”[Mesh:NoExp] OR “vitamin d”[tiab] OR “vit d”[tiab] OR
vitd[tiab] OR “vitamin d2”[tiab] OR “vit d2”[tiab] OR vitd2[tiab] OR “vitamin d3”[tiab] OR “vit d3”[tiab] OR vitd3[tiab] OR ergocalciferol*[tiab] OR
calciferol*[tiab] OR cholecalciferol*[tiab] OR colecalciferol*[tiab] OR calciol[tiab]
64,610
#2 Search “Infant”[Mesh] OR “Pediatrics”[Mesh:NoExp] OR “Neonatology”[Mesh] OR infan*[tiab] OR newborn*[tiab] OR “new born”[tiab] OR “new
borns”[tiab] OR perinat*[tiab ] OR neonat*[tiab] OR baby[tiab] OR babies[tiab] OR toddler*[tiab] OR preschoolchild*[tiab] OR boy[tiab] OR boys
[tiab] OR girl[tiab] OR girls[tiab] OR child[tiab] OR children[tiab] OR childhood[tiab] OR kid[tiab] OR kids[tiab] OR pediatric*[tiab] OR paediatric*
[tiab] OR “month old”[tiab] OR “months old”[tiab]
2,290,689
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2) Embase
Date of the search 20/6/2017
Limits: items published in English, French or German
Search Query Hits
#22 #19 NOT #20 AND ([english]/lim OR [french]/lim OR [german]/lim) 4,688
#21 #19 NOT #20 5,085
#20 [conference abstract]/lim OR [editorial]/lim OR [letter]/lim OR ‘conference review’/it 4,127,436
#19 #15 NOT #18 6,779
#18 #16 NOT #17 5,248,835
#17 ‘human’/exp OR ‘human experiment’/de 18,295,966
#16 ‘animal’/exp OR ‘animal experiment’/exp 23,543,619
#15 #1 AND #14 7,079
#14 #12 OR #13 33,627
#13 ‘vitamin d intoxication’/exp OR ‘vitamin d’/dd_ae,dd_to OR ‘ergocalciferol’/dd_ae,dd_to OR ‘colecalciferol’/dd_ae,dd_to 3,065
#12 #4 AND #11 31,975
#11 #5 OR #6 OR #7 OR #8 OR #9 OR #10 6,731,707
#10 ‘Hypercalcaemia’/exp OR ‘calcium blood level’/exp OR ‘calcium homeostasis’/exp OR Hypercalcaemia:ab,ti OR hypercalciema:ab,ti OR
hypercalcaemia:ab,ti OR calcemia:ab,ti OR ((blood OR serum OR plasma) NEAR/3 calcium):ab,ti OR ‘hypercalciuria’/exp OR ‘calcium urine level’/
exp OR hypercalciuria:ab,ti OR hypercalcinuria:ab,ti OR calciuria:ab,ti OR (urinary NEAR/3 calcium):ab,ti OR ‘calcium ratio’:ab,ti OR ‘calcium
homeostasis’:ti,ab OR ‘calcium homoeostasis’:ti,ab
94,693
#9 ‘hydroxycolecalciferol’/exp OR ‘25 hydroxyvitamin d’/exp OR ‘calcifediol’/exp OR hydroxycholecalciferol*:ab,ti OR hydroxycolecalciferol*:ab,ti OR
hydroxyergocalciferol*:ab,ti OR ‘hydroxyvitamin d’:ab,ti OR ‘hydroxyvitamins d’:ab,ti OR ‘hydroxyvitamin d3’:ab,ti OR ‘hydroxyvitamins d3’:ab,ti OR
‘hydroxivitamin d’:ab,ti OR ‘hydroxivitamins d’:ab,ti OR ‘hydroxivitamin d3’:ab,ti OR ‘hydroxivitamins d3’:ab,ti OR calcifediol:ab,ti OR 25ohd:ab,ti
OR ‘25 ohd’:ab,ti OR ‘25 oh d’:ab,ti OR ‘25ohd3’:ab,ti OR ‘25 ohd3’:ab,ti OR ‘25 oh d3’:ab,ti OR ‘25 oh d 3’:ab,ti OR calcidiol:ab,ti AND (serum:ti,
ab OR plasma:ti,ab OR blood:ti,ab OR ‘blood level’/de OR ‘vitamin blood level’/exp) AND (concentration*:ti,ab OR elevat*:ti,ab OR high*:ti,ab OR
increas*:ti,ab OR level*:ti,ab)
21,352
#8 ‘urolithiasis’/exp OR ((urinary OR ‘urinary tract’ OR kidney* OR renal OR bladder OR vesical OR ureter*) NEAR/3 (calcul* OR stone* OR lithias*)):
ti,ab OR nephrolith*:ti,ab OR urolith*:ti,ab OR cystolith*:ti,ab
72,056
#7 ‘kidney calciﬁcation’/exp OR ((kidney* OR renal OR tubulus OR tubular OR nephric) NEAR/3 (calcinosis OR calcinoses OR calciﬁcation OR
calciﬁed)):ti,ab OR nephrocalcinos*:ti,ab OR ((ectopic OR abnormal OR acute) NEXT/3 calciﬁcation*):ti,ab OR (ectopic NEXT/3 calcinos*):ti,ab
8,171
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Search Query Hits
#6 ‘growth disorder’/de OR ‘failure to thrive’/exp OR ‘growth retardation’/exp OR ‘growth, development and aging disorders’/de OR ‘body weight
disorder’/exp OR ((growth OR weight OR ‘body size’ OR height OR ‘body mass’ OR bmi OR length OR ‘head circumference’ OR development*)
NEAR/7 (retard* OR disorder* OR disturb* OR trajector* OR curve* OR reduc* OR limit* OR negative OR adverse OR rate OR failure OR
abnormal*)):ti,ab OR (growth:ti,ab OR weight:ti,ab OR ‘body size’:ti,ab OR height:ti,ab OR ‘body mass’:ti,ab OR bmi:ti,ab AND (factor* NEAR/3
(affect* OR inﬂuenc* OR alter* OR chang*)):ti,ab) OR ‘failure to thrive’:ti,ab OR (‘body growth’/exp OR ‘body weight’/exp OR ‘body size’/exp OR
‘body height’/exp OR ‘body mass’/exp AND (retard*:ti,ab OR disorder*:ti,ab OR disturb*:ti,ab OR trajector*:ti,ab OR curve*:ti,ab OR reduc*:ti,ab
OR limit*:ti,ab OR negative:ti,ab OR adverse:ti,ab OR rate:ti,ab OR failure:ti,ab OR abnormal*:ti,ab))
1,251,502
#5 ‘drug overdose’/exp OR ‘drug safety’/exp OR ‘adverse drug reaction’/de OR ‘complication’/de OR ‘hypervitaminosis’/de OR ‘no-observed-adverse-
effect level’/exp OR ‘intoxication’/de OR ‘toxicity’/exp OR ‘risk’/de OR ‘dose response’/exp OR ((adverse OR side OR undesirable OR unwanted)
NEAR/3 (effect* OR reaction* OR event OR events OR outcome*)):ti,ab OR complication*:ti,ab OR ((upper OR intake) NEAR/3 limit*):ti,ab OR
‘upper intake’:ti,ab OR noael:ti,ab OR noel:ti,ab OR ‘no observed effect level’:ti,ab OR ‘no observed effect levels’:ti,ab OR toxic*:ti,ab OR intoxic*:
ti,ab OR poison*:ti,ab OR excess*:ti,ab OR safety:ti,ab OR risk:ti,ab OR risks:ti,ab OR hypervitaminos*:ti,ab OR ‘hyper vitaminosis’:ab,ti OR ‘hyper
vitaminoses’:ti,ab OR supervitaminos*:ti,ab OR ‘super vitaminosis’:ti,ab OR ‘super vitaminoses’:ti,ab OR ‘dose response’:ti,ab OR ‘dose effect’:ti,ab
OR ‘dosage effect’:ti,ab OR ‘dosage response’:ti,ab OR ‘dose activity’:ti,ab OR ‘dosage activity’:ti,ab
5,839,586
#4 #2 AND #3 46,331
#3 ‘vitamin intake’/exp OR ‘vitamin supplementation’/exp OR ‘dietary supplement’/exp OR ‘baby food’/exp OR ‘milk’/exp OR intake*:ti,ab OR
consum*:ti,ab OR supplement*:ti,ab OR diet*:ti,ab OR food*:ti,ab OR administrat*:ti,ab OR intervention:ti,ab OR fortif*:ti,ab OR milk:ti,ab OR
formula*:ti,ab OR (high* NEAR/3 (dose OR dosage)):ti,ab OR overdos*:ti,ab OR ‘over dosage’:ti,ab OR ‘over dose’:ti,ab
3,668,797
#2 ‘vitamin d’/de OR ‘ergocalciferol’/exp OR ‘colecalciferol’/exp OR ‘vitamin d’:ab,ti OR ‘vit d’:ab,ti OR vitd:ab,ti OR ‘vitamin d2’:ab,ti OR ‘vit d2’:ab,ti
OR vitd2:ab,ti OR ‘vitamin d3’:ab,ti OR ‘vit d3’:ab,ti OR vitd3:ab,ti OR ergocalciferol*:ab,ti OR calciferol*:ab,ti OR cholecalciferol*:ab,ti OR
colecalciferol*:ab,ti OR calciol:ab,ti
113,962
#1 ‘infant’/exp OR ‘toddler’/exp OR ‘neonatology’/exp OR ‘pediatrics’/de OR infan*:ab,ti OR newborn*:ab,ti OR ‘new born’:ab,ti OR ‘new borns’:ab,ti
OR perinat*:ab,ti OR neonat*:ab,ti OR baby:ab,ti OR babies:ab,ti OR toddler*:ab,ti OR preschoolchild*:ab,ti OR boy:ab,ti OR boys:ab,ti OR girl:
ab,ti OR girls:ab,ti OR child:ab,ti OR children:ti,ab OR childhood:ti,ab OR kid:ab,ti OR kids:ab,ti OR pediatric*:ab,ti OR paediatric*:ab,ti OR ‘month
old’:ti,ab OR ‘months old’:ti,ab
2,907,454
3) Cochrane Library
Date of the search 20/6/2017
ID Search Hits
#1 [mh infant] or [mh ^paediatrics] or [mh neonatology] or infan*:ti,ab,kw or newborn*:ti,ab,kw or “new born”:ti,ab,kw or “new borns”:ti,ab,kw or
perinat*:ti,ab,kw or neonat*:ti,ab,kw or baby:ti,ab,kw or babies:ti,ab,kw or toddler*:ti,ab,kw or preschoolchild*:ti,ab,kw or boy:ti,ab,kw or boys:ti,ab,
kw or girl:ti,ab,kw or girls:ti,ab,kw or child:ti,ab,kw or children:ti,ab,kw or childhood:ti,ab,kw or kid:ti,ab,kw or kids:ti,ab,kw or pediatric*:ti,ab,kw or
paediatric*:ti,ab,kw or “month old”:ti,ab,kw or “months old”:ti,ab,kw
134,248
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ID Search Hits
#2 [mh ^”Vitamin D”] or [mh ^Cholecalciferol] or [mh ^Ergocalciferols] or “vitamin d”:ti,ab,kw or “vit d”:ti,ab,kw or vitd:ti,ab,kw or “vitamin d2”:ti,ab,kw
or “vit d2”:ti,ab,kw or vitd2:ti,ab,kw or “vitamin d3”:ti,ab,kw or “vit d3”:ti,ab,kw or vitd3:ti,ab,kw or ergocalciferol*:ti,ab,kw or calciferol*:ti,ab,kw or
cholecalciferol*:ti,ab,kw or colecalciferol*:ti,ab,kw or calciol:ti,ab,kw (Word variations have been searched)
6,704
#3 (([mh “Body Weight”] or [mh ^”Growth and Development”] or [mh Growth] or [mh “Body Height”] or [mh “Body Mass Index”] or growth:ti,ab,kw or
weight:ti,ab,kw or “body size”:ti,ab,kw or “body mass”:ti,ab,kw or BMI:ti,ab,kw or length:ti,ab,kw or height:ti,ab,kw or “head circumference”:ti,ab,kw or
development*:ti,ab,kw) and (retard*:ti,ab,kw or disorder:ti,ab,kw or reduc*:ti,ab,kw or limit*:ti,ab,kw or negative:ti,ab,kw or adverse:ti,ab,kw or rate:ti,
ab,kw or failure:ti,ab,kw or abnormal*:ti,ab,kw or (factor*:ti,ab,kw near/3 (affect*:ti,ab,kw or inﬂuenc*:ti,ab,kw or alter*:ti,ab,kw or chang:ti,ab,kw))))
or [mh “Growth Disorders”] or [mh “Body Weight Changes”] or “failure to thrive”:ti,ab,kw or [mh “Failure to thrive”]
116,445
#4 [mh “Drug-Related Side Effects and Adverse Reactions”] or [mh “Toxicity Tests”] or [mh ^Poisoning] or [mh ^”Substance-Related Disorders”] or [mh
“Drug Overdose”] or [mh “No-Observed-Adverse-Effect Level”] or [mh “Dose-Response Relationship, Drug”] or ((adverse:ti,ab,kw or side:ti,ab,kw or
undesirable:ti,ab,kw or unwanted:ti,ab,kw) near/3 (effect:ti,ab,kw or effects:ti,ab,kw or reaction*:ti,ab,kw or event:ti,ab,kw or events:ti,ab,kw or
outcome*:ti,ab,kw)) or complication*:ti,ab,kw or upper intake*:ti,ab,kw or upper limit*:ti,ab,kw or intake limit*:ti,ab,kw or noael:ti,ab,kw or noel:ti,ab,
kw or no observed effect*:ti,ab,kw or toxic*:ti,ab,kw or intoxic*:ti,ab,kw or poison*:ti,ab,kw or excess*:ti,ab,kw or risk:ti,ab,kw or risks:ti,ab,kw or
hypervitaminos*:ti,ab,kw or hyper vitaminos*:ti,ab,kw or supervitaminos*:ti,ab,kw or “super vitaminosis”:ti,ab,kw or “super vitaminoses”:ti,ab,kw or
“dose response”:ti,ab,kw or “dose effect”:ti,ab,kw or “dosage effect”:ti,ab,kw or “dosage response”:ti,ab,kw or “dose activity”:ti,ab,kw or “dosage
activity”:ti,ab,kw
403,722
#5 [mh Nephrocalcinosis] or nephrocalcinos*:ti,ab,kw or ((kidney*:ti,ab,kw or renal:ti,ab,kw or tubulus:ti,ab,kw or tubular:ti,ab,kw or nephric:ti,ab,kw)
near/3 (calcinosis:ti,ab,kw or calcinoses:ti,ab,kw or calciﬁcation:ti,ab,kw or calciﬁed:ti,ab,kw)) or ((ectopic:ti,ab,kw or abnormal:ti,ab,kw or acute:ti,ab,
kw) near/2 calciﬁcation*:ti,ab,kw) or (ectopic:ti,ab,kw near/3 calcinos*:ti,ab,kw)
97
#6 [mh Hypercalcaemia] or [mh Calcium/BL] or Hypercalcaemia:ti,ab,kw or hypercalciema:ti,ab,kw or hypercalcaemia:ti,ab,kw or calcemia:ti,ab,kw or
((blood:ti,ab,kw or serum:ti,ab,kw or plasma:ti,ab,kw) and calcium:ti,ab,kw) or [mh Hypercalciuria] or [mh Calcium/UR] or hypercalciuria:ti,ab,kw or
hypercalcinuria:ti,ab,kw or calciuria:ti,ab,kw or (urinary:ti,ab,kw near/3 calcium:ti,ab,kw) or “calcium ratio”:ti,ab,kw or “calcium homeostasis”:ti,ab,kw or
(calcium:ti,ab,kw near/3 homoeostasis:ti,ab,kw)
13,420
#7 ((([mh Hydroxycholecalciferols] or [mh “25-Hydroxyvitamin D 2”] or hydroxycholecalciferol*:ti,ab,kw or hydroxycolecalciferol*:ti,ab,kw or
hydroxyergocalciferol*:ti,ab,kw or “hydroxyvitamin d”:ti,ab,kw or “hydroxyvitamins d”:ti,ab,kw or “hydroxyvitamin d3”:ti,ab,kw or “hydroxyvitamins d3”:
ti,ab,kw or “hydroxivitamin d”:ti,ab,kw or “hydroxivitamins d”:ti,ab,kw or “hydroxivitamin d3”:ti,ab,kw or “hydroxivitamins d3”:ti,ab,kw or calcifediol:ti,
ab,kw or 25ohd:ti,ab,kw or “25 ohd”:ti,ab,kw or “25 oh d”:ti,ab,kw or “25ohd3”:ti,ab,kw or “25 ohd3”:ti,ab,kw or “25 oh d3”:ti,ab,kw or “25 oh d 3”:ti,
ab,kw or calcidiol:ti,ab,kw) and (serum:ti,ab,kw or plasma:ti,ab,kw or blood:ti,ab,kw)) or ([mh Hydroxycholecalciferols/BL] or [mh “25-Hydroxyvitamin D
2”/BL])) and (concentration*:ti,ab,kw or elevat*:ti,ab,kw or high:ti,ab,kw or higher:ti,ab,kw or increas*:ti,ab,kw)
2,360
#8 [mh Urolithiasis] or ((urinary:ti,ab,kw or kidney*:ti,ab,kw or renal:ti,ab,kw or bladder:ti,ab,kw or vesical:ti,ab,kw or ureter*:ti,ab,kw) near/3 (calcu*:ti,
ab,kw or stone*:ti,ab,kw or lithias*:ti,ab,kw)) or nephrolith*:ti,ab,kw or urolith*:ti,ab,kw or cystolith*:ti,ab,kw
2,649
#9 #8 or #7 or #6 or #5 or #4 or #3 456,639
#10 #9 and #2 5,156
#11 [mh ^”Vitamin D”/AE,CO,TO,PO] or [mh ^Cholecalciferol/AE,CO,TO,PO] or [mh ^Ergocalciferols/AE,CO,TO,PO] 160
#12 #10 or #11 5,168
#13 #12 and #1 829
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ID Search Hits
#14 [mh ^”Dietary Supplements”] or [mh “Food, Fortiﬁed”] or [mh milk] or [mh “Infant Food”] or intake*:ti,ab,kw or consum*:ti,ab,kw or supplement*:ti,
ab,kw or diet*:ti,ab,kw or food*:ti,ab,kw or administrat*:ti,ab,kw or intervention:ti,ab,kw or fortif*:ti,ab,kw or milk:ti,ab,kw or formula*:ti,ab,kw or
(high* near/3 (dose or dosage)):ti,ab,kw or overdos*:ti,ab,kw or (over near/1 dosage*):ti,ab,kw or “over dose”:ti,ab,kw
397,557
#15 #13 and #14 718
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Appendix D – Systematic literature search for hazard characterisation:
predeﬁned list of parameters for data extraction from the included studies
For the included studies (that considered daily intake of vitamin D)
1) Data on study setting extracted for each paper:
• Study number (in case of several studies in the same paper)
• Study design:
 Type of design For trials: if compliance was assessed (yes/no) Duration (for trials) or length of follow-up (for observational studies) Latitude (keeping one decimal after the comma). If not available, city/region, country
code. If not reported in the paper, latitude was imputed at the phase of the data
analysis, based on the information on city/country.
• Study population:
 Age category when vitamin D was consumed (infants only, or mixed populations
comprising infants)
 Sex: all males, all females, mixed Health status, e.g. healthy infants, infants with vitamin D-deﬁcient rickets, infants
with hypovitaminosis D
 category of length of gestation: all full-term (either explicitly mentioned in the paper
or if inclusion criterion of the study subjects was deﬁned as at or more than
37 weeks of gestation), mixed (i.e. clearly stated or suspected/unspeciﬁed)
 Type of feeding at inclusion: all exclusively breastfed, all exclusively formula-fed,
mixed (i.e. any other cases, e.g. partially breastfed, with complementary feeding)
 Information on sample size (full study population or per group) and if information on
the characteristics/reasons of lost to follow-up was provided.
2) Data on outcomes/endpoints at different time points (including baseline) will be
extracted for each paper:
• Study number
• Study design:
 Study group Additional variables to be ﬁlled-in in case of deﬁnition of groups not only by vitamin D
intake (e.g. one group receiving vitamin D2 and another group receiving vitamin D3) Time points (0–N) or date of each time point (if reported in the paper) Age at each time point.
• Vitamin D intake:
 Source of supplemental vitamin D intake (e.g. supplements as tablets/pills, supplements
as drops, supplements (unspeciﬁed form), formula/meal/any other fortiﬁed food)
 Form of the vitamin D supplemental intake (D2, D3, D unspeciﬁed, D2+D3) Frequency of supplementation per group (daily to be extracted for further analysis;
weekly, monthly, bolus, single doses to be ﬂagged in a separate category; injections
not to be considered in this mandate)
 Duration of supplementation If the dose was analytically checked. If compliance/adherence was assessed Information on vitamin D intake (observational studies) or background vitamin D
intake (trials, i.e. apart from the vitamin D intervention dose).
• Information on calcium supplementation/intake
• Outcomes of interest at the different time points, including at birth if available) (there could
be several outcomes per study):
 Weight If using z-scores: if the WHO growth standards were used or other standards
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 Percentage of small for gestational age infants (if reported) Length/height If using z-scores: if the WHO growth standards were used or other standards Head circumference If anthropometry data were measured or reported, and if measured, if they were
repeatedly measured
 number of cases or % of cases of failure to thrive number of cases or % of cases of hypercalcaemia deﬁnition of hypercalcaemia by the authors, cut-off value in mmol/L serum total calcium concentrations; serum-ionised calcium concentrations if available number of cases or % of cases of hypercalciuria deﬁnition of hypercalciuria by the authors, cut-off value used urinary calcium concentrations; daily urinary volume duration of urinary collection (24h, spot urine, others) one or more spot urine samples number of collection days? data on urinary ratios of calcium/creatinine; urinary creatinine concentrations number of cases or % of cases of nephrocalcinosis/ectopic calciﬁcation serum 25(OH)D concentration If ‘high’ 25(OH)D was deﬁned in the paper and how; if so: number of cases or % of cases analytical method(s) for serum 25(OH)D measurement: HPLC, LC-MS/MS, CPBA,
enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), others,
unspeciﬁed)
 external quality control (yes/no): mention of the laboratory certiﬁcation by the
Vitamin D External Quality Assessment Scheme (DEQAS) and National Institute of
Standards and Technology (NIST) standard reference material.
• Additional comments whenever required.
Simpliﬁed data extraction for study types not considered for further data extraction,
appraisal and dose–response analysis, but considered qualitatively in the scientiﬁc opinion
(Section 3.4):
For case reports: information such as number of cases, age, vitamin D intake, vitamin D form (D2,
D3, both, unspeciﬁed), consumption duration, were identiﬁed.
For studies using non-daily vitamin D doses, the following information was identiﬁed:
• study type (e.g. RCT),
• if compliance was assessed (yes/no),
• study duration/follow-up,
• latitude if available otherwise city and country,
• health status of the infants (e.g. healthy, with vitamin D deﬁciency rickets, low birth weight
infants),
• sample size,
• full-term infants or not,
• mixed populations of males and females or not,
• type of feeding at inclusion,
• age,
• number of groups,
• vitamin D dose,
• form of vitamin D,
• frequency of supplementation,
• duration of supplementation,
• mode of administration (e.g. drops),
• calcium intake,
• and whether data were assessed or reported (yes/no) on urinary calcium, hypercalciuria, serum
calcium, hypercalcaemia, nephrocalcinosis, 25(OH)D concentration in serum, anthropometric
parameters, abnormal growth.
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Appendix E – Systematic literature search for hazard characterisation:
outcome of the search and screening
Records identified through database 
searching 
N = 8,710 
Embase: 4,688 
Pubmed: 3,304 
Cochrane: 718 
Sc
re
en
in
g
In
cl
u
de
d
El
ig
ib
ili
ty
Id
en
ti
fi
ca
ti
on
Additional records identified through 
other sources 
N = 0 
Records after duplicates removed 
N = 5,373 
Records screened (title and abstract) 
N = 5,373 
5,118 records excluded at 
title and abstract screening 
Full-text articles assessed for eligibility 
N = 255
230 full-text articles excluded 
during full-text screening  
Full-text articles included in 
appraisal of the risk of bias 
N = 31 
Studies included in quantitative 
analysis (serum 25(OH)D) 
N = 6  
Other studies discussed 
narratively
3 studies (2 papers) excluded 
after preliminary statistical 
analysis
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Appendix F – Appraisal of the risk of bias: tool with domain speciﬁc questions and relevant study design
Bias Domains and Questions Study designs
Randomised
controlled
trials
Non-
randomised
controlled
trials
Randomised
non-controlled
trials
Non-
randomised
non-controlled
trials
Prospective
observational
studies
Retrospective
studies
Appraisal of internal validity
The ability of a study to provide an unbiased estimate of the true value of the parameter(s) that the study is intended to estimate.
SELECTION BIAS
1. Was administered dose or exposure level adequately randomised? X X
2. Was allocation to study groups adequately concealed? X X
3. Did selection of study participants result in appropriate comparison
groups?
X X X X
CONFOUNDING BIAS
4. Did the study design or analysis account for important confounding
and modifying variables of the outcome? Were the confounding and
modifying variables measured reliably and consistently?
X X X X X X
PERFORMANCE BIAS
5. Were the research personnel and human subjects blinded to the
study group during the study considering the health-outcome ‘failure to
thrive’?
X X X X
ATTRITION / EXCLUSION BIAS
6. Were outcome data complete without attrition or exclusion from
analysis?
X X X X X
DETECTION BIAS
7. Can we be conﬁdent in the exposure characterisation? X X X X X X
8. Can we be conﬁdent in the outcome assessment considering the
outcome?
X X X X X X
SELECTIVE REPORTING BIAS
9. Were all measured outcomes reported when considering the outcome? X X X X X X
OTHER SOURCES OF BIAS
10. Are there no other potential threats to internal validity (e.g.
statistical methods were appropriate and researchers adhered to the
study protocol)?
X X X X X X
Adapted from OHAT/NTP risk of bias tool (https://ntp.niehs.nih.gov/ntp/ohat/pubs/riskofbiastool_508.pdf).
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Appendix G – Synthesis of the risk of bias by individual studies investigating hypercalciuria/urinary calcium
Gallo et al. (2013a)
Holmlund-Suila
et al. (2012)
Siafarikas
et al. (2011)
Emel
et al. (2012)(a)
Czech-Kowalska
et al. (2012)
Hoppe
et al. (1997)
TOT H
RCT NRNCT PROSP
SELECTION BIAS (randomisation)
L H L H NA H 3
SELECTION BIAS (allocation concealment)
L L H NA NA NA 1
CONFOUNDING BIAS
L L L H H H 3
PERFORMANCE BIAS (blinding)
L L H H NA NA 2
ATTRITION/EXCLUSION BIAS
L L H L L H 2
DETECTION BIAS (exposure characterisation)
L L H H H H 4
DETECTION BIAS (outcome assessment)
L L L L L L 0
SELECTIVE REPORTING BIAS
L L L L L L 0
OTHER SOURCE OF BIAS
L L H H L H 3
TOT H 0 1 5 5 2 5
TIER 1 2 3 3 2 3
H = high risk of bias.
L = low risk of bias.
NA = not applicable due to the characteristics of the study.
NA = not relevant due to the study design.
NRNCT: non-randomised non-controlled trial; NRCT: non-randomised controlled trial; PROSP: prospective cohort study; RCT: randomised controlled trial.
(a): Excluded from the statistical analysis as subjects with vitamin D deﬁciency rickets.
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Appendix H – Synthesis of the risk of bias by individual studies investigating hypercalcaemia/serum calcium
Gallo
et al.
(2013a)
Grant
et al.
(2014)
Holmlund-
Suila et al.
(2012)
Nguema-
Asseko
et al.
(2005)
Pittard
et al.
(1991)
Siafarikas
et al.
(2011)
Zeghoud
et al.
(1997)
Gordon
et al.
(2008)
Vervel
et al.
(1997)
Ziegler
et al.
(2014)
Fomon
et al.
(1966)
Emel
et al.
(2012)(a)
Pincus
et al.
(1954)
Seino
et al.
(1981)(a)
Ala-
Houhala
(1985)
Czech-
Kowalska
et al.
(2012)
Gallo
et al.
(2016)
Hazell
et al.
(2017)
TOT
H
RCT NRCT, RNCT, NRNCT PROSP
SELECTION BIAS (randomisation)
L L H H H L H L H L H H H H H NA L L 10
SELECTION BIAS (allocation concealment)
L L L H H H H H H L NA NA NA NA H NA NA NA 7
CONFOUNDING BIAS
L L L H H L H L H L H H H H H H L L 10
PERFORMANCE BIAS (blinding)
L L L H H H H H H L H H H H H NA NA NA 11
ATTRITION/EXCLUSION BIAS
L L L H L H H L H L L L L L H L L L 5
DETECTION BIAS (exposure characterisation)
L H L H H H H L H L H H H H H H L L 12
DETECTION BIAS (outcome assessment)
L L L L L L L L L L L L L L L L L L 0
SELECTIVE REPORTING BIAS
L L L L L L L L L L L L L H L L L L 1
OTHER SOURCE OF BIAS
L L L H H H H L H H H H H H L L L L 10
TOT H 0 1 1 7 6 5 7 2 7 1 5 5 5 6 6 2 0 0
TIER 1 2 2 3 3 3 3 1 3 1 3 3 3 3 3 2 1 1
H = high risk of bias.
L = low risk of bias.
NA = not applicable due to the characteristics of the study.
NA = not relevant due to the study design.
NRNCT: non-randomised non-controlled trial; PROSP: prospective cohort study; RCT: randomised controlled trial; RNCT: randomised non-controlled trial.
(a): Excluded from the statistical analysis as subjects with vitamin D deﬁciency rickets.
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Appendix I – Synthesis of the risk of bias by individual studies investigating nephrocalcinosis
Emel et al. (2012)(a) Hoppe et al. (1997) TOT H
NRNCT PROSP
SELECTION BIAS (randomisation)
H H 2
SELECTION BIAS (allocation concealment)
NA NA 0
CONFOUNDING BIAS
H H 2
PERFORMANCE BIAS (blinding)
H NA 1
ATTRITION/EXCLUSION BIAS
L H 1
DETECTION BIAS (exposure characterisation)
H H 2
DETECTION BIAS (outcome assessment)
L L 0
SELECTIVE REPORTING BIAS
L H 1
OTHER SOURCE OF BIAS
H H 2
TOT H 5 6
TIER 3 3
H = high risk of bias.
L = low risk of bias.
NA = not applicable due to the study design.
NRNCT: non-controlled non-randomised trial; PROSP: prospective cohort study.
(a): Excluded from the statistical analysis as subjects with vitamin D deﬁciency rickets.
UL of vitamin D for infants
www.efsa.europa.eu/efsajournal 99 EFSA Journal 2018;16(8):5365
Appendix J – Synthesis of the risk of bias by individual studies investigating anthropometric parameters
Gallo
et al.
(2013a)
Holmlund-
Suila
et al. (2012)
Nguema-
Asseko
et al. (2005)
Pittard
et al.
(1991)
Siafarikas
et al.
(2011)
Ziegler
et al.
(2014)
Fomon
et al.
(1966)
Czech-
Kowalska
et al.
(2012)
Gallo
et al.
(2016)
Hazell
et al.
(2017)
Hypp€onen
et al.
(2011)
TOT H
RCT NRNCT PROSP
SELECTION BIAS (randomisation)
L H H H L L H NA L L H 5
SELECTION BIAS (allocation concealment)
L L H H H L NA NA NA NA NA 3
CONFOUNDING BIAS
L L H H L L H H L L H 5
PERFORMANCE BIAS (blinding)
L L H H H L H NA NA NA NA 4
ATTRITION/EXCLUSION BIAS
L L H L H L L L L L H 3
DETECTION BIAS (exposure characterisation)
L L H H H L H H L L H 6
DETECTION BIAS (outcome assessment)
L H H L L L L H L L H 4
SELECTIVE REPORTING BIAS
L L L L L L L L L L L 0
OTHER SOURCE OF BIAS
L L H H H H H L L L H 6
TOT H 0 2 8 6 5 1 5 3 0 0 6
TIER 1 2 3 3 3 1 3 3 1 1 3
H = high risk of bias.
L = low risk of bias.
NA = not applicable due to the characteristics of the study.
NA = not relevant due to the study design.
NRNCT: non-randomised non-controlled trial; PROSP: prospective cohort study; RCT: randomised controlled trial.
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Appendix K – Synthesis of the risk of bias by individual studies investigating high serum 25(OH)D concentration
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O
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H
RCT NRCT, RNCT, NRNCT PROSP
SELECTION BIAS (randomisation)
L L H H H H L L H H L L H H H H H NA L L H 12
SELECTION BIAS (allocation concealment)
L L L H H H H H H H L NA NA NA NA H H NA NA NA NA 9
CONFOUNDING BIAS
L L L H H L L L H H L L H H H H H L L L H 10
PERFORMANCE BIAS (blinding)
L L L NA H H H H H H L H H H H H H NA NA NA NA 12
ATTRITION/EXCLUSION BIAS
L L L L H L H L H H L L L H L H H L L L L 7
DETECTION BIAS (exposure characterisation)
L H L H H H H L H H L H H H H H H H L L H 15
DETECTION BIAS (outcome assessment)
H H H H H H H H H H H H H H H H H H L L H 19
SELECTIVE REPORTING BIAS
L L L L L L L L L L L L L L H H L H L L L 3
OTHER SOURCES OF BIAS
L L L H H H H L H H H L H H H H L L L L L 11
TOT H 1 2 2 6 8 6 6 3 8 8 2 3 6 7 7 9 7 3 0 0 4
TIER 2 2 2 3 3 3 3 2 3 3 2 2 3 3 3 3 3 2 1 1 3
H = high risk of bias
L = low risk of bias
NA = not applicable due to the characteristics of the study.
NA = not relevant due to the study design.
NRCT: non-randomised controlled trial; NRNCT: non-randomised non-controlled trial; PROSP: prospective cohort study; RCT: randomised controlled trial; RNCT: randomised non-controlled trial.
(a): Excluded from the statistical analysis as subjects with vitamin D deﬁciency rickets.
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Appendix L – Assessment: summary characteristics of the studies included after the extensive literature search
Study population Diet characteristics
Biblio
graphy
Nb
Health
status
Full term
Vit D
source
-trials
Vit D form D_ wks
Method for
serum
25(OH)D
VitD dose
analytically
checked
Compliance
check
Ca-
supp
Comments on study
characteristics
(Country)
Hemisphere:
Latitude
TofFeed
Vit D dose
lg/day
L- wks
DESIGN: RCT
AGE CLASS: ALL INFANTS
Gallo et al.
(2013a)
132 Healthy Full term Drop D3 12 LC-MS,MS Yes Yes No Authors mentioned that infants grew
in an age-appropriate way over time,
with no differences over groups.
Vitamin D from other foods than
breast milk assessed using 3-d dietary
records.
(CA)
N:>= 40 & <= 50
Mixed G1:10
G2:20
G3:30
G4:40
11
Grant et al.
(2014)
200 Healthy Mixed Drop D3 7 LC-MS,MS No Yes No All mean weight at birth above 3.4 kg.
Preterm received vitamin D through
parenteral and oral nutrition. Mothers
of infants in groups 2 and 3
supplemented during pregnancy.
(NZ)
S:< 40
Mixed G1:0
G2:10
G3:20
6
Holmlund-Suila
et al. (2012)
113 Healthy Full term Drop D3 3 Other Yes Yes No Analytical method for 25(OH)D:
automated chemiluminiscence
immunoassay (CLIA).(FI)
N:>= 50
Mixed G1:10
G2:30
G3:40
3
Kunz et al.
(1982)
29 Healthy Mixed Pill NA 2 CPBA No No No Infants received formula containing
10 lg/L vitamin D.
(DE)
N:>= 50
Formula G1:25
G2:12.5
1.4
Nguema-Asseko
et al. (2005)
79 Healthy Mixed S-NA NA 7 NA No No No Vitamin D provided via Uvestero®.
Unclear if exclusively breastfed (but
assumed to). All infants born in
August.
(GA)
N:< 40
Breast G1:25
G2:0
6
Pittard et al.
(1991)
25 Healthy Full term S-NA NA 4 NA No No No Throughout the study, each neonate
was given an 84J/30 mL formula, that
contained 12.8 mmol/L of calcium, and
no added vitamin D.
(US)
N:< 40
Unclear G1:1
0G2:20
3.7
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Study population Diet characteristics
Biblio
graphy
Nb
Health
status
Full term
Vit D
source
-trials
Vit D form D_ wks
Method for
serum
25(OH)D
VitD dose
analytically
checked
Compliance
check
Ca-
supp
Comments on study
characteristics
(Country)
Hemisphere:
Latitude
TofFeed
Vit D dose
lg/day
L- wks
Siafarikas et al.
(2011)
40 Healthy Full term Pill D3 2 RIA No No No In each group, an even number of
infants born in summer and in winter
(DE)
N:>= 50
Breast G1:6.25
G2:12.5
1.4
Vervel et al.
(1997)(Study 1
and Study 2)
80 Healthy Full term Drop D2 4 CPBA No Yes No Results reported i) according to
whether the mothers were
supplemented (n = 22) or not (n = 48)
and ii) according to the dose given to
infants.
Content of vitamin D in formula
reported. Intake of formula measured
but not reported
Study 1: infants from
unsupplemented mothers Study 2:
infants from supplemented mothers
(FR)
N:>= 40 & <= 50
Formula G1:12.5
G2:25
3
Zeghoud et al.
(1997)
14 (Study 1);
36 (Study 2);
29 (Study 3)
Healthy Full term S-NA D2 4 CPBA No No No Vitamin D provided via Uvesterol
®.
Vitamin D content in formula 11 +/ 1
lg/L D3.
Study nr 1: neonates with vitamin D
deﬁciency (25(OH)D < 30 nmol/L) and
with high PTH (> 60 ng/L).
Study nr 2: neonates with 25(OH)D
< 30 nmol/L. Study nr 3: neonates
with 25(OH)D strictly > 30 nmol/L
(FR)
N:>= 40 & = 50
Formula G1:25
G2:12.5
3
Ziegler et al.
(2014)
213 Healthy Full term Drop D3 9 RIA Yes Yes No Complementary feeding possible but
not formula until 9 mo. Mean vitamin
D supplement really consumed,
according to time points:
Group 1: 5.5–6 lg/day
Group 2: 10–11 lg/day
Group 3: 14–15 lg/day
Group 4: 19–20.5 lg/day
(US)
N:< 40
Breast G1:5
G2:10
G3:15
G4:20
11
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Study population Diet characteristics
Biblio
graphy
Nb
Health
status
Full term
Vit D
source
-trials
Vit D form D_ wks
Method for
serum
25(OH)D
VitD dose
analytically
checked
Compliance
check
Ca-
supp
Comments on study
characteristics
(Country)
Hemisphere:
Latitude
TofFeed
Vit D dose
lg/day
L- wks
DESIGN: RCT
AGE CLASS: MIXED POPULATION
Gordon et al.
(2008)
26 HypovitD Mixed Drop D2,D3 2 Other Yes Yes Yes 25(OH)D measured by
chemiluminescence.
Data on arm on weekly dose (n = 14)
not extracted
(US) N:>= 40 &
<= 50
Mixed G1:50
G2:50
1.4
DESIGN: RNCT, NRCT,NRNCT
AGE CLASS: ALL INFANTS
Ala-Houhala
(1985)
47 (Study 1)
45 (Study 2)
Healthy Full term S-NA NA 5 CPBA No No No From the main study (n = 100,
including 8 in a pilot study, results not
extracted), 9 infants excluded as
mothers interrupted exclusive
breastfeeding, but unclear if they
belong to the pilot or the main study.
Half of the mothers were
supplemented during pregnancy.
Mothers of group 1 are supplemented
after delivery, while those of group 2
and 3 are not.
Study 1: infants followed in winter
Study 2: infants followed in summer
(FI)
N:>= 50
Breast G1:0
G2:10
G3:25
4.6
Fomon et al.
(1966)
NA Healthy Full term FORT NA 6 NA No No No Commercial complementary feeding
free of vitamin D was permitted. Mean
birth weight of 3.4–3.6 kg in each
group. Group 1: received formula
with 10 lg/405 mL, median vitamin D
intake is 11.25 lg/day (range 9–
14 lg/day). 13 subjects at inclusion
(11 completed 112 days and 2 were
lost to follow up before). Group 2:
received 40 lg/405 mL. Median intake
of vitamin D 45 lg/day (range 34.5–
54 lg/day).
(US)
N:>= 40 & <= 50
Mixed G1:11.25
G2:45
G3:7.5
5.6
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Study population Diet characteristics
Biblio
graphy
Nb
Health
status
Full term
Vit D
source
-trials
Vit D form D_ wks
Method for
serum
25(OH)D
VitD dose
analytically
checked
Compliance
check
Ca-
supp
Comments on study
characteristics
(Country)
Hemisphere:
Latitude
TofFeed
Vit D dose
lg/day
L- wks
Group 3: Control group of 31
breastfed infants (not exclusively
breastfed, as they receive 1 lg/
100 mL of formula). Vitamin D content
in breast milk not measured. Average
vitamin D intake of 2 lg/day from
formula and supplements consumed (5
lg/day). Authors say total vitamin D
intake in this group was about
7.5 lg/day
Holst-Gemeiner
et al. (1978)
10 Healthy Mixed Drop D3 2 RIA No No No Infants received breastmilk or formula
but no other vitamin D
supplementation. Data for the group
receiving a bolus dose not extracted
(AT) N:>= 40 &
<= 50
Mixed G1:30 1.2
Pehlivan et al.
(2003)
40 Healthy Mixed S-NA NA 4 Other No No No The paper mentions 65 infants and 40
breastfed infants. Not clear if the 40
are included in the 65 or not. Only
data for 40 breastfed infants
extracted. Supplementation started at
the start of the second week in both
groups. Baseline values not reported
(TR)
N:>= 40 & <= 50
Breast G1:10
G2:20
4
Pincus et al.
(1954)
NA Healthy Mixed FORT/S-
NA
NA 1 NA No No No All infants were breastfed but unclear
if exclusively. Group 1: no
supplement. Group 2: supplement
was an aqueous preparation. Group
3: fed with a formula not containing
vitamin D. Group 4: fed with formula
containing 10 lg/L vitamin D. Unclear
how much formula was consumed, so
real vitamin D intake is unknown.
Group 5: fed with a formula not
containing vitamin D. Infants received
vitamin D supplement in an aqueous
preparation
(US)
N:>= 40 & <= 50
Mixed G1:0
G2:15
G3:0
G4:10
G5:15
1
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Study population Diet characteristics
Biblio
graphy
Nb
Health
status
Full term
Vit D
source
-trials
Vit D form D_ wks
Method for
serum
25(OH)D
VitD dose
analytically
checked
Compliance
check
Ca-
supp
Comments on study
characteristics
(Country)
Hemisphere:
Latitude
TofFeed
Vit D dose
lg/day
L- wks
Ribot (1981) 35 Healthy Mixed S-NA NA 1 CPBA No No No Vitamin D provided via Uvesterol®.
Group1: newborns, group 2: aged
2–6 mo. Data for the group of
premature infants not extracted
(FR)
N:>= 40 & <= 50
NA G1:25
G2:25
1
DESIGN: PROSP
AGE CLASS: ALL INFANTS
Czech-Kowalska
et al. (2012)
(PL)
N:>= 50
19 (Study 1),
11 (Study 2)
Hypovit D Full term Drop D3 3 Other No Yes No No signs of rickets. Median birth
weight of 3570 g (3405;3890).
Seventeen infants (56.7%) born in
summer and 13 infants (43.3%) in
winter. Twenty-ﬁve infants (83.3%)
were regularly supplemented (1 drop
daily), while in 5 cases (4 deﬁcient and
1 insufﬁcient at T1) the
supplementation scheme was different,
i.e. 2 drops of vitamin D ingested
occasionally in a time period of 2–10
weeks. Most of the infants were
exclusively breastfed.
Mixed 2.3 Median intake at time point 1 for
the full study 14 lg/day (P25–P75
12.5–17).
Analytical method for 25OHD:
immunochemiluminescence.
Study 1: newborn infants with 25OHD
less than 27.5 nmol/L (‘deﬁcient’
group). All infants were
supplemented, but they did not
receive vitamin D supplementation at
baseline.
Time point 0, median (IQR): vitamin D
supplements (lg/day) 0 (0;0); total
vitamin D intake (lg/day) 0.5 (0.5;0.5)
Time point 1, median (IQR): vitamin D
supplements (lg/day) 17 (12.5;19);
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Study population Diet characteristics
Biblio
graphy
Nb
Health
status
Full term
Vit D
source
-trials
Vit D form D_ wks
Method for
serum
25(OH)D
VitD dose
analytically
checked
Compliance
check
Ca-
supp
Comments on study
characteristics
(Country)
Hemisphere:
Latitude
TofFeed
Vit D dose
lg/day
L- wks
total vitamin D intake (lg/day) 18
(13.5;20).
Study 2: newborn infants with 25OHD
between 27.5 and 50 nmol/L
(‘insufﬁcient’ group).
Time point 0, median (IQR): vitamin D
supplements (lg/day) 0 (0;0); total
vitamin D intake (lg/day) 0.5 (0.5;0.5)
Time point 1, median (IQR): vitamin D
supplements (lg/day) 12.5 (12.5;15);
total vitamin D intake (lg/day) 19
(13.5;20).
Both groups did not differ by maternal
vitamin D supplementation, infants’
age, gender, birth weight, season of
birth, type of feeding and vitamin D
intake. 86% of mothers reported
vitamin D supplementation during
pregnancy.
Hoppe et al.
(1997)
37 Healthy Full term S-NA D3 3 NA No No No Birth weight in term infants, mean
(SD): formula-fed 3,316 (562),
breastfed 3,047 (710) g.
Calcium content of infant feedings
(mg/100 mL)-Human milk 30-
formula A 57 – Formula B 45.
Authors indicate that serum ca and
creatinine were in the normal age-
related range (range not given).
Group 1: only formula-fed term
infants.
Group 2: only breastfed term infants.
(CH, DE)
N:>= 40 & <= 50
Mixed G1:12.5
G2:12.5
2
Pludowski et al.
(2011)
75 Healthy Full term Drop D3 7 Other No Yes No Analytical method for 25OHD:
radioreceptor method.
A subgroup from the full study group
(n = 132) of 82 infants with a
complete data set was selected,
(PL)
N:>= 50
Mixed G1:NA
G2:NA
6
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Study population Diet characteristics
Biblio
graphy
Nb
Health
status
Full term
Vit D
source
-trials
Vit D form D_ wks
Method for
serum
25(OH)D
VitD dose
analytically
checked
Compliance
check
Ca-
supp
Comments on study
characteristics
(Country)
Hemisphere:
Latitude
TofFeed
Vit D dose
lg/day
L- wks
divided into 3 subgroups according to
vitamin D supplementation scheme
reported by caregivers:
1. Regular supplementation at both 6
and 12 months (n = 43) (Group 1).
2. Supplementation scheme changed
between the 6th and the 12th month
(n = 32) i.e. regular supplementation,
then occasional, or the other way
round, or discontinued
supplementation. Group 2)
3. Occasional supplementation at both
6 and 12 months (n = 7).
Questionnaire used to collect dietary
data and data on vitamin D
supplements. Vitamin D intake from
breast milk not taken into account.
Group 1: Infants regularly
supplemented with vitamin D).
T0: Total intake (food + supplements):
29 +/ 18 lg/day. T1: Total intake
(food+supplements): 29 +/ 14 lg/
day.
Group 2: Infants with reported
changes in the supplementation
scheme. T0: Total intake
(food+supplements): 28.5 +/ 15.5
lg/day. T1: Total intake
(food+supplements): 19 +/ 14 lg/
day.
DESIGN: PROSP
AGE CLASS: MIXED POPULATION
Gallo et al.
(2016)
132 Healthy Full term Drop D3 12 LC-MS, MS Yes Yes No Same cohort as Hazell et al., 2017.
Dietary intake from other foods
assessed using three 24h recalls andMixed 0.1
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Study population Diet characteristics
Biblio
graphy
Nb
Health
status
Full term
Vit D
source
-trials
Vit D form D_ wks
Method for
serum
25(OH)D
VitD dose
analytically
checked
Compliance
check
Ca-
supp
Comments on study
characteristics
(Country)
Hemisphere:
Latitude
TofFeed
Vit D dose
lg/day
L- wks
validated FFQ for preschool children
used to assess calcium and vitamin D
(from food and supplements) intake
over the past month.
Background intake (food only) at
36 months not signiﬁcantly different
among groups, in particular for
calcium and vitamin D: calcium:
931–970 mg/day; vitamin
D: 6–7.5 lg/day
Vitamin D, total diet and supplements
(group 1,2,3,4) Tertile 1: % ≤ 9 lg/
day 40.0, 25.0, 19.0, 36.0Tertile 2: %
9–13 lg/day 16.0, 42.0, 46.0,
9.0Tertile 3: % ≥ 13 lg/day 44.0,
33.0, 35.0, 55.0. No information given
on intake between the end of the trial
and one month before the follow-up.
(CA)
N:>= 40 & <= 50
G1:10
G2:20
G3:30
G4:40
Hazell et al.
(2017)
132 Healthy Full term Drop D3 12 LC-MS,MS Yes Yes No Same cohort as Gallo et al., 2016;
follow-up of the trial Gallo et al.,
2013a; From the original 132
participants in the trial, 66% (49 boys
and 38 girls) returned for the 3-year
follow-up.
(CA) N:>= 40 &
<= 50
Mixed G1:10
G2:20
G3:30
G4:40
0.1
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Study population Diet characteristics
Biblio
graphy
Nb
Health
status
Full term
Vit D
source
-trials
Vit D form D_ wks
Method for
serum
25(OH)D
VitD dose
analytically
checked
Compliance
check
Ca-
supp
Comments on study
characteristics
(Country)
Hemisphere:
Latitude
TofFeed
Vit D dose
lg/day
L- wks
Hypp€onen et al.
(2011)
12058 Mixed Mixed Drop NA 13 NA No Yes No 200 infants identiﬁed as having rickets.
Daily dose of vitamin D calculated on
the basis of the concentration of
vitamin D in the product used and the
reported dosage (as number of
droplets) of the product. 84 children
who had received cod liver oil were
classiﬁed as having received the
recommended dose (50 lg/day).
No information on vitamin D
supplementation after the ﬁrst year.
According to contemporary
recommendations, vitamin D
supplementation of 50 lg/day was
recommended to all children up to 2 y,
which may suggest that systematic
supplementation in many cases was
restricted to the ﬁrst 2 y of life.
Subjects grouped according to
frequency of supplementation: none,
irregularly, regularly. Analysis
according to daily doses done only in
those that received supplementation
regularly
NA G1:0
G2:< 50
G3:50
G4:> 50
0.6
AT: Austria; Breast: exclusively breastfed at inclusion; CA: Canada; Ca-supp: calcium supplementation (yes/no); CBPA: competitive protein-binding assay; CH: Switzerland; CLIA: automated
chemiluminiscence immunoassay; D: Duration of vitamin D additional intake (converted into weeks and rounded); DE: Germany; FI: Finland; Formula : exclusively formula-fed at inclusion; FORT:
fortiﬁed food (formula); FR: France; GA: Gabon; L: Length of follow-up (converted into weeks and rounded); LCMS-MS: liquid chromatography-tandem mass spectrometry; N: North; Nb: number
of subjects at randomisation/inclusion; NA: type of feeding at inclusion not speciﬁed; NRCT: non-randomised controlled trial; NRNCT: non-randomised non-controlled trial; NZ: New Zealand; PL:
Poland; PROSP: prospective cohort study; RCT: randomised controlled trial; RNCT: randomised non-controlled trial; RIA: radioimmunoassay; S: South; S-NA: supplements in an unspeciﬁed form;
TofFeed: type of feeding at inclusion; TR: Turkey; US: United States; wks: weeks.
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Appendix M – Assessment: studies reporting on urinary calcium/creatinine
ratio
Design Citation Tier
Vitamin D dose Age Urinary Ca/Cr ratio
(lg/day) (weeks) unit (mean) (SD)
RCT Holmlund-Suila et al. (2012) 2 10 13 mmol/mmol 2 n.a.
30 12 mmol/mmol 1.95 n.a.
40 13 mmol/mmol 2.1 n.a.
Gallo et al. (2013a) 1 10 0 other(a) 1.9 n.a.
10 4 other(a) 1.6 n.a.
10 8 other(a) 1.7 n.a.
10 21 other(a) 1.7 n.a.
10 34 other(a) 0.9 n.a.
10 48 other(a) 0.85 n.a.
20 0 other(a) 2.2 n.a.
20 4 other(a) 2.1 n.a.
20 8 other(a) 1.85 n.a.
20 21 other(a) 1.7 n.a.
20 34 other(a) 0.8 n.a.
20 48 other(a) 0.5 n.a.
30 0 other(a) 1.9 n.a.
30 4 other(a) 2.1 n.a.
30 8 other(a) 2 n.a.
30 21 other(a) 1.6 n.a.
30 34 other(a) 0.6 n.a.
30 48 other(a) 0.85 n.a.
40 0 other(a) 1.7 n.a.
40 4 other(a) 1.9 n.a.
40 8 other(a) 2.1 n.a.
40 21 other(a) 1.6 n.a.
PROSP Hoppe et al. (1997) 3 12.5 0 mol/mol 0.1 0.41
12.5 0 mol/mol 0.22 0.48
12.5 9 mol/mol 0.27 0.87
12.5 9 mol/mol 0.36 0.6
Czech-Kowalska et al. (2012) 2 16.75(b) 0 mg/mg 0.46 0.53
16.75(b) 11 mg/mg 0.57 0.28
12.5(c) 0 mg/mg 0.39 0.27
12.5(c) 11 mg/mg 0.61 0.7
PROSP: prospective cohort study; RCT: randomised controlled trial; SD: standard deviation.
The values of urinary Ca/Cr ratio from the study by Siafarikas et al. (2011) not included as the unit was not reported in the
paper.
(a): outside of the normal range of the hospital (Section 3.3.2.2).
(b): vitamin D deﬁcient subjects (Section 3.3.2.3).
(c): vitamin D insufﬁcient subjects (Section 3.3.2.3).
UL of vitamin D for infants
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Appendix N – Assessment: studies reporting on serum total calcium (tier 3)
Design Citation
Vitamin D
dose
Age Total blood calcium
(lg/day) (weeks)
N
(subjects
included in the
measurement)
(mean) (SD)
RCT Nguema-Asseko et al. (2005) 0 13 27 2.23 0.6
0 26 28 2.32 0.2
25 13 37 2.39 0.2
25 26 24 2.45 0.2
Siafarikas et al. (2011) 6.25 0 14 2.38 2.29
6.25 6 14 2.66 2.58
12.5 0 14 2.38 2.29
12.5 6 14 2.55 2.47
Vervel et al. (1997)(a) 12.5 0 28 2.44 0.15
12.5 4 28 2.57 0.08
12.5 13 20 2.62 0.09
25 0 20 2.46 0.16
25 4 20 2.53 0.06
25 13 14 2.62 0.07
Vervel et al. (1997)(b) 12.5 0 6 2.58 0.09
12.5 4 6 2.56 0.11
12.5 13 4 2.58 0.14
25 0 16 2.51 0.07
25 4 16 2.56 0.08
25 13 14 2.58 0.07
Zeghoud et al. (1997) 12.5 0 n.a. 2.41 0.21
12.5 4 n.a. 2.58 0.49
12.5 13 n.a. 2.65 0.51
25 0 n.a. 2.41 0.21
25 4 n.a. 2.53 0.07
25 13 n.a. 2.6 0.12
12.5 0 n.a. 2.48 0.12
12.5 4 n.a. 2.58 0.49
12.5 13 n.a. 2.58 0.49
25 0 n.a. 2.48 0.12
25 4 n.a. 2.52 0.09
25 13 n.a. 2.6 0.12
12.5 0 n.a. 2.52 0.1
12.5 4 n.a. 2.58 0.49
12.5 13 n.a. 2.6 0.5
25 0 n.a. 2.62 0.1
25 4 n.a. 2.57 0.06
25 13 n.a. 2.6 0.12
RNCT, NRCT,NRNCT Ala-Houhala (1985)(c) 0 0 n.a. 2.78 0.23
0 8 n.a. 2.7 0.22
0 20 n.a. 2.7 0.22
10 0 n.a. 2.8 0.2
10 8 n.a. 2.75 0.2
10 20 n.a. 2.7 0.2
25 0 n.a. 2.8 0.13
25 8 n.a. 2.8 0.13
25 20 n.a. 2.75 0.13
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Design Citation
Vitamin D
dose
Age Total blood calcium
(lg/day) (weeks)
N
(subjects
included in the
measurement)
(mean) (SD)
Ala-Houhala (1985)(d) 0 0 n.a. 2.78 0.23
0 8 n.a. 2.7 0.22
0 20 n.a. 2.7 0.22
10 0 n.a. 2.6 0.19
10 8 n.a. 2.7 0.2
10 20 n.a. 2.7 0.2
25 0 n.a. 2.7 0.12
25 8 n.a. 2.7 0.12
25 20 n.a. 2.65 0.12
Fomon et al. (1966) 7.5 4 24 2.52 0.16
7.5 8 23 2.45 0.08
7.5 12 23 2.53 0.14
7.5 16 24 2.51 0.12
7.5 20 20 2.48 0.11
7.5 24 18 2.42 0.13
11.25 4 10 2.48 0.16
11.25 8 8 2.53 0.11
11.25 12 10 2.48 0.1
11.25 16 7 2.52 0.12
11.25 20 9 2.49 0.11
11.25 24 9 2.49 0.13
45 4 9 2.47 0.12
45 8 9 2.52 0.21
45 12 11 2.57 0.09
45 16 7 2.46 0.12
45 20 11 2.44 0.18
45 24 11 2.42 0.2
Pincus et al. (1954) 0 0 15 2.23 0.16
0 0 46 2.36 0.17
0 1 15 2.26 0.14
0 1 46 2.28 0.23
10 0 52 2.27 0.21
10 1 52 2.15 0.37
15 0 13 2.29 0.08
15 0 30 2.27 0.11
15 1 n.a. 2.22 0.09
15 1 30 2.04 0.29
n.a.: not available; NRCT: non-randomised controlled trial; NRNCT: non-randomised non-controlled trial;; RCT: randomised
controlled trial; RNCT: randomised non-controlled trial; SD: standard deviation.
(a): Study 1, infants from unsupplemented mothers
(b): Study 2, infants from supplemented mothers
(c): Study 1, infants followed in winter
(d): Study 2, infants followed in summer
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Appendix O – Assessment: studies reporting ionised calcium values
Design Citation Dose
Age Ionised blood calcium
(weeks) Units (mean) (SD)
RCT Gallo et al. (2013a)(a) 10 0 mmol/L 1.38 n.a.
10 4 mmol/L 1.37 n.a.
10 8 mmol/L 1.37 n.a.
10 21 mmol/L 1.35 n.a.
10 34 mmol/L 1.33 n.a.
10 48 mmol/L 1.32 n.a.
20 0 mmol/L 1.4 n.a.
20 4 mmol/L 1.4 n.a.
20 8 mmol/L 1.37 n.a.
20 21 mmol/L 1.35 n.a.
20 34 mmol/L 1.33 n.a.
20 48 mmol/L 1.32 n.a.
30 0 mmol/L 1.39 n.a.
30 4 mmol/L 1.37 n.a.
30 8 mmol/L 1.36 n.a.
30 21 mmol/L 1.35 n.a.
30 34 mmol/L 1.33 n.a.
30 48 mmol/L 1.32 n.a.
40 0 mmol/L 1.4 n.a.
40 4 mmol/L 1.38 n.a.
40 8 mmol/L 1.37 n.a.
40 21 mmol/L 1.35 n.a.
PROSP Hazell et al. (2017) 10 48 mmol/L 1.29 0.03
20 48 mmol/L 1.3 0.05
30 48 mmol/L 1.28 0.06
40 48 mmol/L 1.27 0.05
n.a.: not available; PROSP: prospective cohort study; RCT: randomised controlled trial; SD: standard deviation.
(a): Units as reported in the paper are nmol/L, but here assumed to be mmol/L based on Gallo et al. (2014b).
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Appendix P – Forest plot on studies reporting on mean body length (cm)
and mean body weight (g) (tiers 1–2)
Body length (cm) 
Body weight (g) 
D: vitamin D dose (µg/day). T: age of the infants in weeks (rounded). 
Values at baseline are not shown. 
Values for trials (NRCT: non-randomised controlled trial; NRNCT: non-randomised non-controlled trial; RCT: randomised 
controlled trial; RNCT: randomised non-controlled trial) and prospective observational studies (PROSP) are indicated separately. 
Gallo et al. (2016) and Hazell et al. (2017): follow-up studies of Gallo et al. (2013a). The z-scores were only reported in Gallo et 
al. (2016), were extracted for this paper, and were back-calculated to absolute values. Both z-scores and absolute values were 
reported in Hazell et al. (2017), and only the absolute values were extracted for this paper. 
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Appendix Q – Assessment: vitamin D content in 46 food supplements
targeted for infants < 1 year
Country
Format
type
Serving
size/conditions
of use
Vitamin D
(daily
dose in lg)(a)
Vitamin D
form
Belgium Liquid 2 drops/day 10 D3
Belgium Tablet 1 tablet/day 10 D3
Croatia Liquid 6 drops/day 10 D3
Denmark Liquid 5 drops/day 10 D3
Denmark Liquid 5 drops/day 10 D3
Denmark Liquid 5 drops/day 10 D3
Denmark Tablet 1 tablet/day 10 D3
Denmark Tablet 1 tablet/day 10 vit D unspeciﬁed
Denmark Tablet 1 tablet/day 10 D3
Denmark Tablet 1 tablet/day 10 D3
Germany Tablet 1 tablet/day 12.5 D3
Hungary Liquid 2 drops/day 10 D3
Ireland Capsules 1 capsule/day 5 D3
Italy Liquid 30 drops/day 10 D3
Italy Liquid 4 drops/day 10 D3
Italy Liquid 0.5 mL/day 7.5 D3
Netherlands Liquid 2 drops/day 10 D3
Netherlands Liquid 10 drops/day 10 D3
Norway Liquid 10 drops/day 10 D3
Norway Liquid 1 capsule/day 10 D3
Norway Liquid 5 drops/day 10 D3
Poland Liquid 1 capsule/day 10 D3
Poland Liquid 1 capsule/day 10 D3
Poland Capsules 1 capsule/day 10 D3
Poland Capsules 1 capsule/day 10 D3
Poland Capsules 1 capsule/day 10 D3
Poland Capsules 1 capsule/day 10 D3
Poland Liquid 1 capsule/day 10 D3
Poland Capsules 1 capsule/day 15 D3
Poland Capsules 1 capsule/day 10 D3
Poland Capsules 1 capsule/day 10 D3
Sweden Liquid 5 drops/day 10 D3
Sweden Liquid 0.14 mL/day 7.5 D3
UK Liquid 1 spray/day 10 D3
UK Liquid 1 drop/day 10 D3
UK Liquid 2.5 mL/day 1.75 vit D unspeciﬁed
UK Powder 0.5–1 sachet/day 1.13–2.5 D3
UK Liquid 0.3 mL/day 10 D3
UK Chew 1 pastille/day 5 D3
UK Liquid half teaspoon/day 7 D3
UK Liquid 4 drops/day 7.5 D3
UK Liquid 0.5 mL/day 8.5 D3
UK Liquid 0.5 mL/day 10 D3
UK Liquid 1 spray/day 7.5 D3
UK Liquid 8 drops/day 8 D3
UK Liquid 5 drops/day 10 D3
n.a.: information not available from which to calculate the vitamin D content by g/mL; UK: United Kingdom.
Date of search in Mintel GNPD database: February 2018.
(a): Based on serving size and conditions of use as indicated on the label of the products.
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Annex A – Statistical methods used to estimate the intake–response of
serum 25(OH)D concentration on daily supplemental intake of vitamin D
and to derive the percentage of infants exceeding a serum 25(OH)D
concentration
Annex A can be found in the online version of this output, under the section ‘Supporting
information’, at: https://doi.org/10.2903/j.efsa.2018.5365
Description: The annex describes in details the statistical methods used to estimate the intake–
response of serum 25(OH)D concentration on daily supplemental intake of vitamin D and to derive the
percentage of infants exceeding a serum 25(OH)D concentration. These methods and the results
obtained are described in brief in Section 3.5 of this output.
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Annex B – Results of the assessment of the daily intake of vitamin D for
infants aged 4–< 12 months and 8 intake scenarios
Annex B can be found in the online version of this output, under the section ‘Supporting
information’, at: https://doi.org/10.2903/j.efsa.2018.5365
Description: The annex is an Excel® ﬁle which presents in Tables A1–A6 the detailed data of the
characteristics of the populations, food composition and food consumption used in the eight intake
scenarios applied for the intake assessment for infants aged 4–< 12 months. The results are described
in brief in Section 4.4.2 of this output.
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